Document:

EX-10.1

 Exhibit 10.1 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 EXCLUSIVE LICENSE AGREEMENT 

BETWEEN 
 LONZA HOUSTON,
INC. 
 AND 

MASSACHUSETTS EYE AND EAR INFIRMARY AND 

THE SCHEPENS EYE RESEARCH INSTITUTE, INC. 

AND 
 TDTX, INC.

 September 9, 2019 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
		
	 ARTICLE 1 DEFINITIONS
	  	 	1	 
		
	 ARTICLE 2 GRANT OF LICENSES, RESERVED RIGHTS AND SUBLICENSING
	  	 	10	 
			
	 2.1
	  	License Grant	  	 	10	 
			
	 2.2
	  	Responsibility for Affiliates and Sublicensees	  	 	10	 
			
	 2.3
	  	No Implied Licenses	  	 	10	 
			
	 2.4
	  	Reserved Rights	  	 	11	 
			
	 2.5
	  	Sublicensing	  	 	11	 
			
	 2.6
	  	Option to License Arising Patent Rights after the Effective Date	  	 	12	 
			
	 2.7
	  	MEE’s Ophthalmology Target Option	  	 	13	 
		
	 ARTICLE 3 FINANCIAL TERMS
	  	 	14	 
			
	 3.1
	  	Equity	  	 	14	 
			
	 3.2
	  	Milestone Payments	  	 	16	 
			
	 3.3
	  	Royalties	  	 	17	 
			
	 3.4
	  	Offsets from Royalty Payments; Minimum Royalty Rates	  	 	18	 
			
	 3.5
	  	[Reserved]	  	 	18	 
			
	 3.6
	  	Payment	  	 	18	 
			
	 3.7
	  	Sublicense Income	  	 	18	 
			
	 3.8
	  	Reduction of Sublicense Income Fees Payable to Licensors [***]	  	 	19	 
			
	 3.9
	  	Patent Expenses	  	 	20	 
			
	 3.10
	  	Waiver or Deferral	  	 	20	 
			
	 3.11
	  	Form of Payments and Taxes	  	 	20	 
			
	 3.12
	  	Currency Conversion	  	 	21	 
			
	 3.13
	  	Interest	  	 	21	 
			
	 3.14
	  	Right to Offset	  	 	21	 
		
	 ARTICLE 4 ROYALTY REPORTS, PAYMENTS AND FINANCIAL RECORDS
	  	 	21	 
			
	 4.1
	  	Royalty Reports	  	 	21	 
			
	 4.2
	  	Record Keeping	  	 	22	 
		
	 ARTICLE 5 JOINT STEERING COMMITTEE
	  	 	22	 
			
	 5.1
	  	Formation and Representatives	  	 	22	 
			
	 5.2
	  	JSC Chairman	  	 	22	 
			
	 5.3
	  	Meetings by the JSC	  	 	22	 
		
	 ARTICLE 6 OPERATIONS UNDER THE LICENSE
	  	 	23	 
			
	 6.1
	  	Diligence Obligations	  	 	23	 
			
	 6.2
	  	Minimum Capital Funding	  	 	24	 
			
	 6.3
	  	Minimum Potential Revenue Stream Requirements	  	 	25	 

  
 i. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
			
	 6.4
	  	Regulatory Matters	  	 	26	 
			
	 6.5
	  	Other Government Laws	  	 	26	 
			
	 6.6
	  	Patent Marking	  	 	26	 
			
	 6.7
	  	Ongoing Communication	  	 	26	 
		
	 ARTICLE 7 TDTX-LONZA STRATEGIC
MANUFACTURING RELATIONSHIP
	  	 	26	 
			
	 7.1
	  	Manufacturing Agreements	  	 	26	 
		
	 ARTICLE 8 CONFIDENTIALITY
	  	 	26	 
			
	 8.1
	  	Non-Disclosure Obligation	  	 	26	 
			
	 8.2
	  	Government-Required Disclosure	  	 	27	 
		
	 ARTICLE 9 INTELLECTUAL PROPERTY
	  	 	27	 
			
	 9.1
	  	Ancestral Technology Patent Preparation, Filing, Prosecution and Maintenance.	  	 	27	 
			
	 9.2
	  	Election Not to File and Prosecute Patent Rights	  	 	28	 
			
	 9.3
	  	Notice	  	 	28	 
			
	 9.4
	  	Relinquishing Rights	  	 	28	 
			
	 9.5
	  	Intellectual Property Rights	  	 	28	 
		
	 ARTICLE 10 PATENT INFRINGEMENT AND ENFORCEMENT
	  	 	29	 
			
	 10.1
	  	Notice	  	 	29	 
			
	 10.2
	  	Enforcement	  	 	29	 
			
	 10.3
	  	Distribution of Amounts Paid by Third Parties	  	 	30	 
			
	 10.4
	  	Declaratory Judgment or Infringement Actions	  	 	30	 
			
	 10.5
	  	Delegation	  	 	31	 
		
	 ARTICLE 11 TERM AND TERMINATION
	  	 	31	 
			
	 11.1
	  	Term	  	 	31	 
			
	 11.2
	  	Termination by Licensors	  	 	31	 
			
	 11.3
	  	Termination by TDTx	  	 	32	 
			
	 11.4
	  	Material Breach Dispute	  	 	32	 
			
	 11.5
	  	Effect of Termination	  	 	32	 
		
	 ARTICLE 12 INDEMNIFICATION AND INSURANCE
	  	 	33	 
			
	 12.1
	  	Indemnification	  	 	33	 
			
	 12.2
	  	Insurance	  	 	35	 
			
	 12.3
	  	Disclaimer of Warranties; Limitation of Liability	  	 	35	 
			
	 12.4
	  	Acknowledgement	  	 	36	 
			
	 12.5
	  	Article Survival	  	 	36	 
		
	 ARTICLE 13 REPRESENTATIONS AND WARRANTIES
	  	 	36	 
			
	 13.1
	  	TDTx’s Representations and Warranties	  	 	36	 

  
 ii. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
			
	 13.2
	  	Lonza’s Representations and Warranties and Covenants	  	 	36	 
			
	 13.3
	  	MEE’s Representations	  	 	37	 
		
	 ARTICLE 14 NOTICES
	  	 	37	 
			
	 14.1
	  	Notices to Lonza	  	 	37	 
			
	 14.2
	  	Notices to MEE	  	 	37	 
			
	 14.3
	  	Notices to TDTx	  	 	37	 
		
	 ARTICLE 15 DISPUTE RESOLUTION
	  	 	38	 
			
	 15.1
	  	Negotiation between the Parties	  	 	38	 
			
	 15.2
	  	Arbitration	  	 	38	 
			
	 15.3
	  	Governing Law	  	 	38	 
		
	 ARTICLE 16 FORCE MAJEURE
	  	 	39	 
		
	 ARTICLE 17 ASSIGNABILITY
	  	 	39	 
		
	 ARTICLE 18 MISCELLANEOUS
	  	 	39	 
			
	 18.1
	  	MEE Policies	  	 	39	 
			
	 18.2
	  	Relationship of Parties	  	 	40	 
			
	 18.3
	  	Further Actions	  	 	40	 
			
	 18.4
	  	Use of Name; Publicity	  	 	40	 
			
	 18.5
	  	Waiver	  	 	40	 
			
	 18.6
	  	Severability	  	 	40	 
			
	 18.7
	  	Amendment	  	 	40	 
			
	 18.8
	  	Entire Agreement	  	 	40	 
			
	 18.9
	  	Parties in Interest	  	 	40	 
			
	 18.10
	  	Descriptive Headings	  	 	40	 
			
	 18.11
	  	Counterparts	  	 	41	 
			
	 18.12
	  	No Presumption	  	 	41	 
			
	 18.13
	  	Interpretation	  	 	41	 

  
 iii. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED

 BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

EXCLUSIVE LICENSE AGREEMENT 

THIS EXCLUSIVE LICENSE AGREEMENT (“Agreement”),
effective as of September 9, 2019 (“Effective Date”), is made between Lonza Houston, Inc., a Delaware corporation having a principal place of business at 14905 Kirby Drive, Houston, Texas 77047, United States,
(“Lonza”) and Massachusetts Eye and Ear Infirmary, a not-for-profit Massachusetts corporation, having its principal place of business at 243
Charles Street, Boston, MA 02114, and The Schepens Eye Research Institute, Inc., a not-for-profit Massachusetts corporation, having its principal place of business at 20
Staniford Street, Boston, MA 02114 (collectively “MEE”) (Lanza and MEE are collectively referred to herein as “Licensor(s)”), and TDTx Inc., a Delaware corporation having a principal place of business
at One Broadway, 14th Floor, Kendall Square, Cambridge, MA 02142 (“TDTx” or “Licensee”). Lonza, MEE, and TDTx shall hereinafter collectively be referred to as the “Parties” and
each, individually, as a “Party”. 
 BACKGROUND 

WHEREAS, MEE owns or Controls certain Intellectual Property related to the Ancestral Technology; and 

WHEREAS, MEE has granted certain exclusive license rights under such Intellectual Property related to the
Ancestral Technology to Lonza pursuant to that certain License, Collaboration and Commercialization Agreement between MEE and Lonza dated as of [***] (the “Original Lonza-MEE
Agreement”), as such agreement is being amended and restated concurrently with the execution of this Agreement (the “Amended and Restated Lonza-MEE Agreement”), and MEE has
retained certain rights and certain fields of use under the Intellectual Property related to the Ancestral Technology that were not granted to Lonza under the Amended and Restated Lonza-MEE Agreement; and 

WHEREAS, Licensee desires to obtain an exclusive license for all fields of use (except for the Excluded
Field of Use and the Excluded Targets, as each is defined herein) under the Licensed Intellectual Property and Licensors are willing to grant such a license to Licensee in view of the Amended and Restated
Lonza-MEE Agreement and upon the terms and conditions stated under this Agreement, without the limitations and restrictions on the scope of the licensed field of use or on the right to grant sublicenses or the
scope of any permitted sublicenses that existed under the Original Lonza-MEE Agreement, all in order to enable TDTx to have a license to, and to grant broad sublicenses within the Field of Use (except for the
Excluded Field of Use and the Excluded Targets, as each is defined herein); and 
 WHEREAS, Licensee
has represented to Licensors that it has or will have the capabilities and/or experience to develop, produce, market and sell products utilizing technology that is the subject of this Agreement and has or will have the financial capacity and the
strategic commitment to facilitate the transfer of the technology for the public interest. 
 NOW THEREFORE, Lonza, MEE and TDTx, each
intending to be legally bound, do hereby agree as follows. 
 ARTICLE 1 

DEFINITIONS 
 The
capitalized terms used herein shall have the meanings set forth below in this Article 1 unless otherwise expressly defined in this Agreement. 

1.1 “Affiliate” means any company, corporation or other business entity that is controlled by, controlling, or
under common control of a Party, for so long as such control exists. For this purpose “control” means direct or indirect beneficial ownership of at least fifty percent (50%) interest in the voting stock (or the equivalent) of the company,
corporation or other business or having the right to direct, appoint or remove a majority of members of its board of directors (or their equivalents) or having the power to control the general management of the company, corporation or other
business, by law or contract; provided, however, that a business entity whose primary business is the investment in other companies shall not be deemed to “control” a Party. 

  
 1. 

 1.2 “Ancestral Technology” means all compositions, methods,
processes, tools, protocols, technical information and other technology related to and including the identified [***] and [***] sequences and any variants and all [***] created or identified from such technology, in each case solely to the extent
that such technology is disclosed in PCT application [***] and/or [***] 
 1.3 “Ancestral Technology Intellectual
Property” means the Ancestral Technology Know How and Ancestral Technology Patent Rights. 
 1.4 “Ancestral
Technology Know-How” means any Know-How that satisfies all of the following criteria, (a)-(d): (a) relates to the Ancestral Technology or the SRA Ancestral
Technology or the Licensed Products; (b) is necessary or useful for the exercise of the rights granted under Section 2.1 in the Field of Use in the Territory; (c) is described in Schedule E hereto; and (d) is Controlled by MEE or
Lonza as of the Effective Date or was generated under the SRA and is documented in writing on or within [***] of the Effective Date. For clarity, if any of the aforementioned Know-How is jointly owned by MEE
or Lonza and a Third Party such that MEE or Lonza does not Control all rights, title and interests therein, then Ancestral Technology Know-How includes only MEE or Lonza’s interest in such Know-How. The Ancestral Technology Know-How is limited to the Know-How that is described in Schedule E hereto as of the Effective Date,
or as may be updated within [***] of the Effective Date in accordance with Section 2.4.3. 
 1.5 “Ancestral
Technology Patent Rights” means (a) the United States provisional patent application [***], any conversion, continuation, continuation-in-part,
divisions, substitutions or foreign counterparts thereof, any patents issuing thereon, and any reissues, reexaminations, supplemental protection certificates or extensions thereof, including without limitation, the patents and patent applications
set forth in Schedule A (which Schedule A will be updated from time to time on an as needed basis) and (b) any other Patent Rights (including the Arising Patent Rights) Rights) which (i) claim or Cover the Ancestral Technology or the SRA
Ancestral Technology, (ii) are Controlled by Lonza (or by TDTx pursuant to the provisions of Section 2.6) at any time during the Term as the result of Lonza or its Affiliates (or TDTx pursuant to the provisions of Section 2.6) having
acquired or exercised rights in any Intellectual Property that is subject to a license, sublicense, or other agreement between Lonza and/or its Affiliates and MEE, in each case pursuant to the exercise of the option rights of Lonza under the SRA,
and (iii) are included in the license granted to TDTx under Section 2.1 on or after the Effective Date pursuant to the provisions of Section 2.6, wherein each of the conditions of subparts (i), (ii) and (iii) of this sentence are
met. 
 1.6 “Arising Patent Rights” shall mean any Patent Rights in any patentable invention generated under
the SRA, including the [***] Patent Rights and other patent applications arising under the SRA, each as set forth in Schedule A, which is Controlled by MEE or Lonza and is disclosed and claimed in a patent application, and all continuations,
divisions, and reissues based thereof, and any corresponding foreign patent applications and any patents, or other equivalent patents issuing, granted or registered thereon. 

  
 2. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.7 “Available Target” shall mean, for the purposes of either
(a) the exercise by an Existing Third Party Licensee/Sublicensee of any Unnamed Option, or (b) the exercise by MEE of its Ophthalmology Target Option in connection with a specific transgene or biological target, that, at the time that the
Existing Third Party Licensee/Sublicensee notifies MEE or Lonza that it wishes to specify such transgene or biological target or MEE notifies TDTx via the JSC that it desires to exercise its Ophthalmology Target Option with respect to such transgene
or biological target, such transgene or biological target is available for licensing. Unless TDTx can reasonably demonstrate to the JSC that either: (i) TDTx or its Affiliate or Sublicensee is already in bona fide, good faith term sheet
discussions with a Third Party wherein such term sheet either names or describes such biological target or transgene or otherwise includes such biological target or transgene (without naming or describing it) within the scope of the proposed
licensed field, subfield or indication(s) included under the term sheet, or for which TDTx or its Affiliate or Sublicensee has a final term sheet with a Third Party, in each case at the time in which the Existing Third Party Licensee/Sublicensee or
MEE requests to name or obtain license rights to such biological target or transgene; or (ii) TDTx or its Affiliate or Sublicensee is actively progressing or actively planning to progress such biological target or transgene in research,
development or commercial activities or is actively progressing or actively planning to progress financing activities involving such biological target or transgene (whether or not specifically named if otherwise described or included within the
relevant field, subfield or indication); or (iii) TDTx or its Affiliate or Sublicensee has already executed a binding definitive commercial license or sublicense agreement or asset purchase agreement (or other similar agreement for the transfer
or disposition of rights) with a Third Party with respect to such biological target or transgene which names, describes or otherwise includes such biological target or transgene (without naming or describing it) within the scope of the licensed
field, subfield or indication(s) included under such license or sublicense or other agreement. For clarity, if TDTx can reasonably demonstrate to the JSC that any of the conditions as described in subparts (i), (ii) or (iii) above are met at
the time that such transgene or biological target is requested, the transgene or biological target shall not be considered to be an Available Target. 

1.8 “Clinical Study” means a clinical study in human subjects that has been approved by a Regulatory Authority
and applicable institutional review board or ethics committee, and is designed to measure the safety and/or efficacy of a Licensed Product. Clinical Studies shall include, but not be limited to, Phase I Studies, Phase II Studies, Phase III Studies
and any clinical studies required to be conducted by any Regulatory Authorities following receipt of Regulatory Approval. 
 1.9
“Collaboration Partner” means a Sublicensee with whom TDTx or its Affiliate has entered into a contractual relationship, to collaborate in the performance of any research, development and/or commercial activities, such as
[***]. In no event may any entity whose role in the partnership is a Competing Contract Manufacturer be deemed to be a Collaboration Partner for the purposes of this Agreement nor shall any entity which merely receives a sublicense under the
Licensed Intellectual Property without such contractual relationship having any of the elements of a collaboration as described in this paragraph. 

1.10 “Combination Product” means any biopharmaceutical product that consists of a component that is a Licensed
Product and [***]. If a Licensed Product is sold as part of a Combination Product in a country in the Territory, Net Sales for the Licensed Product included in such Combination Product in such country shall be calculated as follows: 

(a) If the Licensed Product is sold separately in such country and the other active ingredient(s) or product(s) in the Combination
Product are sold separately in such country, Net Sales for the Licensed Product shall be calculated by multiplying actual Net Sales of such Combination Product in such country by the fraction A/(A+B), where A is the invoice price of the Licensed
Product when sold separately in such country and B is the total invoice price of the other active ingredient(s) or product(s) in the Combination Product when sold separately in such country; 

(b) If the Licensed Product is sold separately in such country but the other active ingredient(s) or product(s) in the Combination
Product are not sold separately in such country, Net Sales for the Licensed Product shall be calculated by multiplying actual Net Sales of such Combination Product in such country by the fraction A/D, where A is the invoice price of the Licensed
Product when sold separately in such country and D is the invoice price of the Combination Product in such country; 
 (c) If the
Licensed Product is not sold separately in such country but the other active ingredient(s) or product(s) in the Combinations Product are sold separately in such country, Net Sales for the Licensed Product shall calculated by multiplying actual Net
Sales of such Combination Product by the fraction 1 – (B/D), where B is the invoice price of the other active ingredient(s) or product(s) in the Combination Product when sold separately in such country and D is the invoice price of the
Combination Product in such country; or 

  
 3. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (d) If neither the Licensed Product nor the other active ingredient(s) or product(s)
in the Combination Product are sold separately in such country, the Parties shall [***]. 
 1.11 “Commercially Reasonable
Efforts” means the level of efforts and resources (including the promptness with which such efforts and resources would be applied) consistent with the efforts and resources normally used by a similarly situated (i.e., in terms of size,
stage and resources) biopharmaceutical, biotech or pharmaceutical (as applicable) company in the exercise of commercially reasonable business discretion relating to the research, development, manufacture, or commercialization of a biopharmaceutical
product with similar product characteristics that is of similar market potential at a similar stage of development or commercialization, taking into account issues such as efficacy, safety, product profile, anticipated or approved labeling, present
and future risk-adjusted market potential, competitive market conditions, the proprietary position of the drug substance or product, the regulatory factors and structure involved, and other key technical, legal, scientific, medical or commercial
factors, and the risk-adjusted potential profitability of the product. 
 1.12 “Competing Contract
Manufacturer” shall mean any Third Party listed in Schedule G, which may be amended from time-to-time to remove any Third Party listed that both Lonza and
TDTx agree is no longer a Competing Contract Manufacturer, as such criteria is defined below in both (i) and (ii), or any other Third Party provider of
fee-for-service contract manufacturing services that Lonza proposes to add to Schedule G after the Effective Date which Lonza can demonstrate by credible evidence in
writing, that, at the time that Lonza proposes to add the Third Party to the list in Schedule G, which shall be at least [***] prior to the time of the proposed assignment of this Agreement by TDTx under Article 17: (i) [***], and (ii) [***], such
that in all cases both (i) and (ii) are met. 
 1.13 “Compulsory License” means a compulsory license
under the Licensed Intellectual Property obtained by a Third Party through the order, decree, or grant of a competent governmental body or court, authorizing such Third Party to develop, make, have made, use, sell, offer to sell, import or otherwise
exploit a Licensed Product or a product equivalent to a Licensed Product in the Field of Use in any country in the Territory. 
 1.14
”Confidential Information” means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulas,
instructions, skills, techniques, procedures, specifications, data, results and other material, pre-clinical and Clinical Study results, manufacturing procedures, test procedures and purification and isolation
techniques, and any tangible embodiments of any of the foregoing, and any scientific, manufacturing, marketing and business plans, any financial and personnel matters relating to a Party or its present or future products, sales, suppliers,
customers, employees, investors or business, furnished by one Party (the “Disclosing Party”) to the other Party (the “Receiving Party”) on or after the Effective Date. Without limiting the foregoing,
the terms of this Agreement will be deemed “Confidential Information” of both Parties and will be subject to the terms and conditions set forth in Article 7, and all records and reports delivered by TDTx to Licensors
hereunder shall be the Confidential Information of TDTx. 
 1.15 “Contract Year” shall mean each calendar
year period during the Term; provided, however, that the first such Contract Year shall commence on the Effective Date and end one year thereafter with the last such Contract Year ending on the final day of the Term.
“Contract Year One” shall mean the first such year; “Contract Year Two” shall mean the second such year, and so on,
year-by-year. 
 1.16
“Control” or “Controlled” means, with respect to rights in any Intellectual Property, that a Party owns or has a license or sublicense to such rights and has the right and ability to grant an exclusive
license. or sublicense thereto as provided for in this Agreement, without violating the terms of any agreement or other arrangement with any Third Party, and without payment of any additional consideration to such Third Party. 

1.17 “Cover”, “Covering” or “Covered” means, with respect to a
Licensed Product, that the manufacture, use or sale of the Licensed Product would, but for a license granted in this Agreement, infringe a Valid Claim of the Ancestral Technology Patent Rights in the country in which the manufacture, use or sale
occurs. 

  
 4. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.18 “Excluded Field of Use” shall mean (i) the
treatment, palliation, prevention or diagnosis of any retinal disease, disorder or condition in humans in the Ultra-Rare Field [***], or (ii) the treatment, diagnosis, prevention and palliation of any and all balance disorders or diseases
pertaining to the inner ear and/or any and all hearing diseases or disorders, including hearing disorders of the inner ear. For clarity with respect to (ii), in the case of any disorders or diseases affecting balance, hearing or the inner ear which
also affect other sensory perceptions, organs or tissues, the Excluded Field of Use will only include such disorders or diseases to the extent pertaining to balance, hearing or the inner ear. 

1.19 “Excluded Targets” shall mean only those certain specific transgenes or targets for which Lonza or MEE has
already licensed such transgenes or targets under a commercial license agreement or provided exclusive rights under an Existing Option Agreement with respect to such transgenes or targets prior to or within [***] of the Effective Date of this
Agreement under an Existing Third Party License/Sublicense Agreement. At the request of TDTx, Lonza or MEE (as applicable) will use good faith reasonable efforts to obtain consent from the applicable Third Party to disclose, under appropriate
written confidentiality obligations, the identity of the relevant Excluded Target(s) under the relevant Existing Third Party License/Sublicense Agreement via an employee representative to be designated by Lonza or MEE as the authorized discloser
(“Gatekeeper”) of such confidential information regarding the identity of the transgenes or targets that are Excluded Target(s) hereunder. 

1.20 “Existing Third Party Licensee/Sublicensee” means, separately and collectively, each of the Third Parties
who have entered into Existing Third Party License/Sublicense Agreements. 
 1.21 “Existing Third Party License/Sublicense
Agreements” means those certain license or sublicense agreements as listed on Schedule F as of the Effective Date, in which either MEE or Lonza provides a commercial license or commercial sublicense rights to an Existing Third Party
Licensee/Sublicensee for the use of the Ancestral Technology (or a subset thereof) in connection specifically with and limited to use for one or more specified Excluded Targets or rights under an Existing Option Agreement, in the form that such
agreements exist as of the Effective Date or as agreed between the Parties related to advanced negotiations between Lonza and a Third Party for such a binding definitive sublicense agreement prior to the Effective Date but which are anticipated to
be executed within [***] after the Effective Date, or for any mutually-agreed extension beyond such [***] period that is mutually agreed in writing by each of MEE, Lonza and TDTx, such extension not to exceed [***] beyond the expiration of the [***]
period. For clarity, any such binding definitive sublicense agreements that are executed within such [***] period shall be deemed included under this definition. Also for clarity, the Existing Third Party License/Sublicense Agreements do not include
any research evaluation agreements that provide rights of use or licenses solely for limited internal research or evaluation purposes only and which do not provide any license rights or option rights for any development or commercial use (each such
agreement, a “Research Evaluation Agreement”). 
 1.22 “Existing Option Agreements”
means those certain option agreements listed on Schedule F as of the Effective Date in which either MEE or Lonza provides options to acquire commercial sublicense rights to an Existing Third Party Licensee/Sublicensee for the use of one or more
specified (or to be specified after the Effective Date of this Agreement pursuant to existing option rights that were granted as of the Effective Date of this Agreement, each an “Unnamed Option”) transgenes or biological
targets meets the definition of Available Target(s). 
 1.23 “Field of Use” means the use of a Licensed
Product in any and all fields of use, but excluding only the Excluded Field of Use and the Excluded Targets; provided, however, that the Excluded Targets shall be excluded only for the limited field(s) that are/were specifically
licensed under the applicable Existing Third Party License/Sublicense Agreement. 

  
 5. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.24 “First Commercial Sale” means the initial transfer of a
Licensed Product in a country [***] by or on behalf of TDTx, an Affiliate or Sublicensee for cash or non-cash consideration to which a fair market value can be assigned for purposes of determining Net Sales.

 1.25 “Initiation” means, with respect to a Clinical Study, the date on which a Clinical Study opens for
patient accrual at one clinical centre with all then-applicable required Regulatory Approvals and institutional approvals. 
 1.26
“Intellectual Property” means all intellectual property and forms of protection directed thereto worldwide arising under statutory or common law, and whether or not perfected, including, without limitation, the following:

 (a) Patent Rights; 

(b) all works of authorship including copyrights, copyright applications, copyright registrations, mask works, mask work applications,
and mask work registrations, including, but not limited to, any software, software code, source code, and user interfaces and rights associated therewith; 

(c) trademarks, including any logos, designs, variations or translations thereof all rights associated therewith; 

(d) all rights relating to the protection of trade secrets and Confidential Information; and 

(e) all Know-How. 

1.27 “Know-How” means any technical and other information which is not
generally available to the public, including ideas, concepts, trade secrets, inventions (whether or not patentable), discoveries, know-how, data, formulae, specifications, compositions, sequences, methods,
processes, procedures and tests and other protocols, results of experimentation and testing, fermentation and purification or process development techniques and assay protocols. 

1.28 “Licensed Intellectual Property” means, collectively, (a) the Ancestral Technology Patent, Rights,
(b) the Ancestral Technology Know-How, (c) if, when, and solely to the extent that either Lonza and/or TDTx validly exercises the option under the SRA pursuant to the provisions of Section 2.6,
the Arising Patent Rights, and [***]. 
 1.29 “Licensed Product” means any product within the Field of Use,
which product is either (i) Covered by a Valid Claim within the Ancestral Technology Patent Rights, or (ii) a variant of a naturally occurring AAV serotype that was made through the use of a method recited in a Valid Claim within the [***]
Patent Rights to identify or design such product. 
 1.30 ”Licensed Transgene” means, solely for the purpose
of defining the scope of rights granted under the Existing Third Party License/Sublicense Agreements and the Excluded Targets, the [***]. For the purposes of this definition, [***]. 

1.31 “[***] Patent Rights” means the Patent Rights as listed in [***] of Schedule A claiming the [***] method
[***] for the identification and design of novel AAV vector compositions of matter. 
 1.32 “Lonza Intellectual
Property” means any Intellectual Property of which Lonza is the owner and which is or was discovered, invented or developed by or on behalf of Lonza prior to or during the course of, but completely separate and independent from, this
Agreement but in all cases excludes the Ancestral Technology Know-How and Ancestral Technology Patent Rights and the SRA Ancestral Technology. 

  
 6. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.33 “Major Market” shall mean [***]. 

1.34 “M&A Transaction” means any transaction or agreement or series of transactions or agreements wherein
TDTx or any of its Affiliates is acquired or undergoes a merger, consolidation or other business combination with a Third Party or otherwise undergoes a change of control, or wherein TDTx sells or transfers all or substantially all of its business
or assets pertaining to this Agreement or to any Licensed Product to a Third Party purchaser or transferee. 
 1.35 “MEE
Intellectual Property” means any Intellectual Property of which MEE is the owner and which is or was discovered, invented or developed by or on behalf of MEE prior to or during the course of, but completely separate and independent
from, this Agreement. 
 1.36 “Minimum Potential Revenue Stream Requirements” has the meaning as defined in
Section 6.3.1 of this Agreement. 
 1.37 “Net Sales” means all revenues recorded by or on behalf of TDTx
or its Affiliates or Sublicensees from sales of Licensed Products in the Field of Use in the Territory to independent or unaffiliated Third Party purchasers of such Licensed Products. The permitted deductions booked on an accrual basis by TDTx, its
Affiliates and/or its Sublicenses under their respective accounting standards to calculate the recorded net sales from gross sales are as follows: 

(a) discounts actually granted, including without limitation, quantity, trade, cash and other discounts, rebates and charge-backs
(excluding inventory management fees, discounts or credits), and, solely in the case of [***]; 
 (b) amounts refunded or credits
allowed for Licensed Products or other goods returned or not accepted by customers, including in connection with recalls (regardless of the Party requesting the recall); 

(c) packaging, freight, transportation and [***] charges related to the sale, transportation, delivery or return of Licensed Products;

 (d) taxes, tariffs, customs duties, surcharges and other governmental or non-governmental
payer’s charges and chargebacks actually incurred and paid by TDTx, its Affiliates or its Sublicensees hereunder in connection with the sale, use, exportation, importation or delivery of Licensed Products or other goods to customers; 

(e) retroactive price reductions, chargebacks and rebates made to [***]; 

(f) [***]. 
 Subject to
the qualification stated below, upon any sale or other disposal of Licensed Products by or on behalf of TDTx, its Affiliates or its Sublicensees hereunder other than a bona fide arm’s length transaction exclusively for money at market value or
upon any use of the Licensed Product for purposes which do not result in a disposal of such Licensed Product in consideration of sales revenue customary in the country of use, such sale, other disposal or use shall be deemed to constitute a sale at
the greater of the actual consideration for such sale or other disposal or the then-current [***] average selling price in the country in which such sale, other disposal or use occurs. 

Net Sales includes the fair market value of any non-cash consideration from sale of Licensed Products
received by TDTx, its Affiliates or Sublicenses. Net Sales shall exclude sales or transfers of Licensed Products [***]. 
 Licensed Products
are considered “sold” when billed, invoiced, or payment is received, whichever occurs first. 

  
 7. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.38 “Patent Rights” means: (a) an issued or granted
patent, including any extension, supplemental protection certificate, registration, confirmation, reissue, reexamination or renewal thereof; (b) a pending patent application, including any continuation, divisional, continuation-in-part, substitute or provisional application thereof; and (c) all counterparts or foreign equivalents of any of the foregoing issued by or filed in any
country or other fiction. 
 1.39 “Person” means any natural person, corporation, firm, business trust, joint
venture, association, organization, company, partnership or other business entity, or any government or agency or political subdivision thereof. 

1.40 “Phase I Study” means a study of a Licensed Product in humans, the principal purpose of which is a
determination of safety, tolerability or pharmacokinetics in healthy individuals or patients in the target patient population prescribed by the relevant Regulatory Authority, from time to time, pursuant to applicable law or otherwise, including the
trials referred to in 21 C.F.R. §312.21(a), as amended. 
 1.41 “Phase I/II Study” means a Clinical
Study of a Licensed Product in humans that combines a Phase I Study and a Phase II Study into a single protocol to determine the maximum tolerable dose of the Licensed Product and to further evaluate safety and/or efficacy of such product. 

1.42 “Phase II Study” means a study of a Licensed Product in humans, the principal purpose of which is a
determination of safety and efficacy in the target patient population, which is prospectively designed to generate sufficient data that may permit commencement of a Pivotal Trial, or a similar Clinical Study prescribed by the relevant Regulatory
Authority, from time to time, pursuant to applicable law or otherwise, including the trials referred to in 21 C.F.R. §312.21(b), as amended. 

1.43 “Phase III Study” means a study of a Licensed Product in humans of the efficacy and safety of such
product, which is prospectively designed to demonstrate statistically whether such product is effective and safe for use in a particular indication in a manner sufficient (alone or together with one or more other such studies) to file an application
for Regulatory Approval for the product, as further defined in 21 C.F.R. § 312.21(c) (or the equivalent thereof outside the United States). 

1.44 “Pivotal Trial” means a Clinical Study intended to provide the basis for Regulatory Approval. For clarity,
a Pivotal Trial shall include a Phase III Study, a Phase I/II Study or a later Clinical Study where the evidence from such Clinical Study is intended to be used as the basis for Regulatory Approval. 

1.45 “Potential Revenue Stream” shall mean the total of all fees and payments potentially payable under each
Sublicense Agreement executed between TDTx and a Third Party in a Contract Year, which includes, without limitation [***], but excludes [***]. 

1.46 “Regulatory Approval” means any and all approvals (including any pricing and/or reimbursement approvals),
licenses, registrations or authorizations of any Regulatory Authority that are necessary at the relevant stage of development or commercialization for the development, marketing and sale of a Licensed Product in a country or group of countries. 

1.47 “Regulatory Authority” means any applicable supra-national, federal, national, regional, state,
provincial, or local regulatory agencies, departments, bureaus, commissions, councils, or other government entities, including the U.S. Food and Drug Administration or any successor entity thereto (“FDA”) and the European
Medicines Agency or any successor entity thereto (“EMA”), regulating or otherwise exercising authority with respect to the development, manufacture or commercialization of any Licensed Product in the Territory. 

1.48 “Royalty Term” means, on a Licensed
Product-by-Licensed Product and country-by-country basis, the period from and after the
First Commercial Sale of such Licensed Product in such country until the later to occur of (a) the last to expire Valid Claim of the Ancestral Technology Patent Rights which Covers such Licensed Product in such country and (b) ten (10)
years after the First Commercial Sale of such Licensed Product in such country. 

  
 8. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.49 “Sponsored Research Agreement” or
“SRA” shall mean the sponsored research agreement executed between Lonza and MEE with an effective date of [***], covering Lonza’s funding for the further research, development and optimization of the Ancestral
Technology at MEE under the supervision of [***] as set forth under the Research Plan of the SRA. 
 1.50 “SRA Ancestral
Technology” shall mean, collectively, any and all sequences, compositions, methods, tools, protocols or technology, and any and all viral vectors, sequences or compositions identified or created from such methods, tools, protocols or
technology, in each case solely to the extent identified, developed, generated or otherwise included or described in materials, sequences or compositions generated during and in the i performance of the SRA. 

1.51 “Sublicense” or “Sublicense Agreement” means any agreement in which a Sublicensee
receives a sublicense from TDTx or any of its Affiliates granting it commercial license rights or an option to acquire commercial license rights under the Licensed Intellectual Property or any subset thereof to discover, research, develop and/or
commercialize Licensed Products. For clarity, any M&A Transaction shall not be considered to be a Sublicense or Sublicense Agreement under this Agreement. 

1.52 “Sublicensee” means any Person which receives a Sublicense or enters into a Sublicense Agreement under
some or all of the rights granted to TDTx under this Agreement. 
 1.53 “TDTx Intellectual Property” means
any Intellectual Property (other than the Licensed Intellectual Property, MEE Intellectual Property or any Lonza Intellectual Property) owned or Controlled by TDTx, whether prior to, on or after the Effective Date. 

1.54 “Territory” means worldwide. 

1.55 “Third Party” means any Person other than Lonza, MEE, TDTx or any of their respective Affiliates. 

1.56 “Third Party License Agreement” means any agreement entered into by TDTx, or by any of its Affiliates or
by any Sublicensee with a Third Party, as applicable depending upon whether TDTx, its Affiliate or Sublicensee is the entity that will be paying royalties on Net Sales of the relevant Licensed Product(s), or any amendment or supplement thereto, in
each case after the Effective Date, whereby royalties, fees or other payments are to be made by TDTx, its Affiliates or any Sublicensee (as applicable) to such Third Party in connection with the grant of license rights under Intellectual Property
that Covers or claims either the composition of matter, manufacture or the method of treatment or use of any vector or Licensed Product or Licensed Transgene or Licensed Transgene regulatory element for the relevant Licensed Product in the Field of
Use that is Controlled by such Third Party, which rights TDTx or its Affiliates or Sublicensee, as applicable, reasonably determine are necessary to develop, manufacture, have made, import, export, use, sell, offer for sale or otherwise
commercialize the Licensed Product in the Field of Use. 
 1.57 “Ultra-Rare Field” means the Ultra-Rare Field
as such term is defined in the Amended and Restated Lonza-MEE Agreement. 
 1.58
“Valid Claim” means (a) a claim of an issued and unexpired patent, which claim has not been revoked or held unenforceable, unpatentable or invalid by an unappealed or unappealable decision of a court or other
governmental agency of competent jurisdiction and that has not been finally abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise,
or (b) a claim of a patent application that is being prosecuted in good faith and has been pending less than [***] from the date of filing of the earliest patent application from which such patent application claims priority, which claim has
not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken. For clarity, in the event that any pending claim of a patent application that does not meet the criteria under
subpart (b) of this Section 1.59 subsequently becomes an issued claim that would qualify under subpart (a) of this Section 1.59, such claim, once it issues, shall thereafter be considered a Valid Claim under this definition. 

  
 9. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 2 

GRANT OF LICENSES, RESERVED RIGHTS AND SUBLICENSING 

2.1 License Grant. Subject to all of the applicable terms and conditions of this Agreement, Licensors hereby grant to TDTx an
exclusive, non-transferable (except as expressly permitted in Article 17 (“Non-Assignability”), sublicensable (through multiple tiers) right and
license, under all of Licensors’ rights (both separately and collectively) in and to the Licensed Intellectual Property (provided, however, that the Arising Patent Rights are included within the license granted under this
Section 2.1 only pursuant to the exercise of an option to such Arising Patent Rights in accordance with the provisions of Section 2.6), to discover, research, develop, make, have made, manufacture, use, sell, offer to sell, import, export,
market, promote, distribute, register and otherwise commercially exploit Licensed Products, in the Field of Use within the Territory. For clarity, pursuant to the Amended and Restated Lonza-MEE Agreement, the
license granted to TDTx under this Section 2.1 shall not be subject to any of the restrictions, obligations or limitations with respect to the scope of the licensed Field of Use that were applicable to Lonza under the Original Lonza-MEE Agreement, and shall be subject only to the terms and conditions of this Agreement. 

Notwithstanding the above license grant, solely with respect to any manufacturing process subject matter disclosed in [***], Licensors hereby
grant to TDTx a non-exclusive, non-transferable (except as expressly permitted in Article 17
(“Non-Assignability”), nonsublicensable right and license, under the manufacturing process subject matter included in [***] and applications related therefrom to discover, research,
develop, make, manufacture, use, sell, offer to sell, import, export, market, promote, distribute, register and otherwise commercially exploit Licensed Products, in the Field of Use within the Territory. For clarity, TDTx shall have the exclusive
right and license (with the right to sublicense) as described in the preceding paragraph to all non-manufacturing process subject matter, including any composition of matter, disclosed in [***] and
applications related therefrom. 
 2.2 Responsibility for Affiliates and Sublicensees. TDTx shall have the right to grant
sublicenses to its Affiliates and to its Sublicensees to cause the performance by any of its Affiliates and/or Sublicensees of some or all of TDTx’s obligations hereunder. Until such time that [***], the right of TDTx [***]. TDTx shall be
responsible and liable for any and all acts or omissions of its Affiliates or Sublicensees in connection with the exercise by such Affiliates or Sublicensees of any sublicense rights granted hereunder and their performance of any of TDTx’s
obligations hereunder. If Licensors have a claim arising under this Agreement against an Affiliate or Sublicensee, Licensors may seek a remedy directly against TDTx and may, but is not required to, seek a remedy against the Affiliate or Sublicensee.
Any termination of the Agreement under Article 11 as to TDTx also constitutes termination as to any of its Affiliates. For clarity, pursuant to the Amended and Restated Lonza-MEE Agreement, the right to grant
sublicenses as granted to TDTx under this Section 2.2 shall not be subject to any of the restrictions, obligations or limitations with respect to the scope of permitted sublicenses within the licensed Field of Use that were applicable to Lonza
under the Original Lonza-MEE Agreement, and shall be subject only to the terms and conditions of this Agreement. 

2.3 No Implied Licenses. This Agreement confers no license or rights by implication, estoppel or otherwise under any patent
applications or patents owned in whole or in part by Lanza or MEE other than the Ancestral Technology Patent Rights and the Arising Patent Rights. For the avoidance of doubt, neither TDTx, its Affiliates nor any Sublicensee shall use or practice the
Licensed Intellectual Property with respect to any Excluded Target or any Excluded Field of Use, unless and until any such rights revert back to either of the Licensors under the applicable Existing Third Party License/Sublicense Agreement, wherein
such reversion of rights to Licensors would then be automatically included in the license grant to TDTx as provided in Section 2.1. 

  
 10. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.4 Reserved Rights. The licenses granted by Licensors hereunder are subject
to the following reserved rights: 
 2.4.1 Retained Rights of MEE; Requirements. Any and all licenses granted hereunder by
Licensors are subject to: 
 (a) the retained right of MEE and MEE’s Affiliates and academic, government and not-for-profit institutions to make and to use the subject matter described and/or claimed in the Licensed Intellectual Property; provided, however, that such
making and using shall not include the production, commercialization or manufacture of products for sale and only to the extent that such making and using by academic, government and
not-for-profit institutions does not conflict with any of the provisions of this Agreement; and 

(b) for Licensed Intellectual Property supported by federal funding, the rights, conditions and limitations imposed by U.S. law (see
35 U.S.C. § 202 et seq. and regulations pertaining thereto), including without limitation: 
 (i) the royalty-free non-exclusive license granted to the U.S. government; and 
 (ii) the requirement that any
Licensed Products used or sold in the United States shall be manufactured substantially in the United States. 
 2.4.2 Upon the
written request of TDTx, such request to be provided in each case within [***] after the end of a Calendar Quarter, MEE shall have a period of at least [***] to provide TDTx with the name(s) of the applicable academic, governmental or not-for-profit organizations to which MEE has entered into any written agreement granting any rights under the Licensed Intellectual Property in connection with the rights
retained by MEE pursuant to Section 2.4.1 and a general description of the research being conducted by such organizations, all such information to be provided to TDTx subject to the confidentiality obligations of such written agreement between
MEE and such academic, governmental or not-for-profit organization. 

2.4.3 Technology Transfer. MEE (through [***] or his designee) shall use reasonable efforts to disclose and transfer to TDTx,
under the confidentiality obligations of this Agreement, within [***] after the Effective Date of this Agreement, the Ancestral Technology Know-How that is listed on Schedule E as of the Effective Date. In
addition, within [***] after the Effective Date, MEE will provide to TDTx an identification of further Ancestral Technology Know-How resulting from the SRA, and the Parties will agree on an amendment to
Schedule E to incorporate such further Ancestral Technology Know-How. Upon such amendment, MEE (through [***] or his designee) will use reasonable efforts to disclose and transfer to TDTx such further
Ancestral Technology Know-How, under the confidentiality obligations of this Agreement, within [***]. 

2.5 Sublicensing. 

2.5.1 Right to Grant Sublicenses. Subject to the terms and conditions of this Agreement, TDTx shall have the right to sublicense
its rights under the Agreement, in whole or in part, to one or more Third Parties, and to one or more TDTx Affiliates, subject always to the requirements of Section 2.5.2 regarding the content of all such Sublicenses. TDTx (and its Affiliates)
may permit any of its Sublicensees to grant further sublicenses to Third Parties, including through multiple tiers, under their rights to the Licensed Intellectual Property; provided, however, that each such Sublicense through each
tier shall be subject to and shall comply with the requirements of Section 2.5.2. TDTx shall be responsible for any breach of a Sublicense by a Sublicensee that results in a material breach of this Agreement. 

  
 11. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.5.2 Content of Sublicenses. Each Sublicense granted hereunder shall be
consistent with the terms and conditions of this Agreement, excluding [***], and will include but not be limited to, in the same or substantially the same form, the provisions of [***] of this Agreement, shall incorporate terms and conditions
sufficient to enable TDTx to comply with this Agreement, shall allow further Sublicenses by a Sublicensee through multiple tiers, in each case (and for each tier) only on terms that are consistent with the requirements of this Section 2.5.2,
and shall provide that MEE and Lonza are each third party beneficiaries thereof. Upon termination of this Agreement or any Sublicense granted hereunder for any reason, any Sublicenses shall be addressed in accordance with the terms and conditions of
Section 11.5.7 (Sublicense Survival). Any Sublicense which is not in accordance with the requirements of this Section 2.5.2 shall be null and void. 

2.5.3 Copies of Sublicenses to Licensors. TDTx shall deliver or cause to be delivered to Licensors a copy of any and all [***]
Sublicenses and any amendments thereto, including all exhibits, attachments and related documents thereto, (which copy may be redacted only to remove specific technical or scientific information pertaining to sensitive proprietary technology or
information of a Sublicensee which are not necessary to monitor compliance with this Agreement, but may not be redacted to remove any of the financial terms of the Sublicense) within [***] after execution by TDTx or its Affiliate, as applicable, and
the relevant Sublicensee. TDTx shall also provide Licensors [***] with a copy of the reports received by TDTx or its Affiliate, as applicable, from its Sublicensees during the preceding [***] period, beginning [***] from the effective date of the
sublicense agreement, to the extent such reports are related to (1) TDTx’s compliance with its obligations under Section 6.1 of this Agreement and (2) TDTx’s financial obligations under Article 3 of this Agreement. 

2.5.4 TDTx’s Continuing Obligations. Nothing in Section 2.5 may be construed to relieve TDTx of its obligations to
Licensors under this Agreement, including but not limited to TDTx’s obligations under Section 6.1. 
 2.6 Option to
License Arising Patent Rights after the Effective Date. During the Term, TDTx shall have the exclusive option to obtain an exclusive license, on behalf of itself and its Affiliates, in the Field of Use to any Arising Patent Rights which Lonza or
MEE owns or Control prior to or after the Effective Date according to the following terms: 
 2.6.1 At any time prior to or after the
Effective Date, if either of the Licensors obtain ownership or Control of any Arising Patent Rights, Licensors shall notify TDTx in writing of such Arising Patent Rights and shall provide TDTx with a description of such Arising Patent Rights. If
Lonza’s ownership or Control of such Arising Patent Rights is the result of Lonza or its Affiliates having acquired or exercised its option rights under the SRA in any Intellectual Property that is subject to a license, sublicense, or other
agreement between Lonza and/or its Affiliates and MEE, it shall automatically be deemed Licensed Intellectual Property and included in the license granted under Section 2.1. If MEE’s ownership or Control of any Arising Patent Rights is not
subject to a license, sublicense, or other agreement between Lonza and/or its Affiliates and MEE either [***], MEE will notify TDTx of such Arising Patent Rights and TDTx shall have [***] from its receipt of such notice to decide whether it wishes
to obtain a license to the Arising Patent Rights (the “Evaluation Period”). If TDTx notifies MEE within the Evaluation Period that it wishes to acquire an exclusive license to the Arising Patent Rights in the Field of Use in
accordance with and subject to all of the terms and conditions set forth in this Agreement, upon payment of reasonable compensation (the “License Fee”) paid to MEE, as negotiated in good faith by MEE and TDTx, TDTx shall have
a license to such Arising Patent Rights and such Arising Patent Rights shall be deemed included as Licensed Intellectual Property under Section 2.1 of this Agreement. Prior to the expiration of the Evaluation Period (or such earlier time as
TDTx may notify Lonza in writing of its decision to not include such Arising Patent Rights within the scope of this Agreement), MEE shall not grant any licenses under or to such Arising Patent Rights in the Field of Use to any Third Party. 

  
 12. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.6.2 In the event that any Arising Patent Rights are added to the exclusive license
granted to TDTx under Section 2.1 by operation of the provisions of Section 2.6.1, the following terms and conditions shall apply with respect to the respective rights of MEE, Lonza and TDTx under the SRA: 

(a) The retained rights of MEE with respect to any such included Arising Patent Rights shall be as described and defined in
Section 2.4.1 of this Agreement, and not as the MEE Retained Rights are defined and described in the SRA; and 
 (b) Licensors
hereby grant to TDTx a fully-paid and royalty-free, non-exclusive, non-transferable (except in accordance with Article 17) and
non-sublicenseable (except to its Affiliates) license to use the SRA Process Intellectual Property solely for limited internal research or evaluation purposes only for Licensed Products, in the Field of Use
within the Territory but not for any development or commercial use. 
 2.6.3 For clarity, the
Know-How relating to the SRA Ancestral Technology shall be deemed to be included within the Licensed Intellectual Property as part of the Ancestral Technology Know-How
as of the Effective Date under the exclusive license granted to TDTx under Section 2.1 without any requirement for the exercise of any option rights under the SRA by either Lonza or by TDTx, it being understood that the exercise of option
rights under the SRA pursuant to Section 2.6.1 shall be required only for the Arising Patent Rights, and not for such Know-How relating to the SRA Ancestral Technology. The Parties shall describe any new
Arising Patent Rights that arise after the Effective Date and are licensed hereunder at any time during the Term in the form of updates to Schedule A and within [***] of the Effective Date for updates to Schedule E as set forth in
Section 2.4.3, which updated Schedule A and/or E shall replace any prior version(s) thereof when signed by the Parties; provided that failure to update such Schedule A shall not affect the rights granted to TDTx under this
Section 2.6. In the event TDTx does not exercise its rights to any Arising Patent Rights of which it has been notified by MEE under this Section 2.6 prior to the end of the applicable Evaluation Period, MEE shall be free to grant licenses
under and to such Arising Patent Rights in the Field of Use to any Third Party, subject to TDTx’s and its Affiliates’ existing rights in the Licensed Intellectual Property granted under this Agreement. 

2.7 MEE’s Ophthalmology Target Option. 

ln the event that an investigator at MEE or at any of its Affiliates is pursuing an ongoing active research program with respect to any
transgene or biological target within the “Ophthalmology Field”, which shall be defined as [***], wherein such ongoing research program has received at least [***] in aggregate total funding (excluding indirect costs) from
MEE or from Third Party grant sources (a “Qualifying MEE Ophthalmology Program”), and MEE desires to obtain a commercial sublicense from TDTx under any of the Licensed Intellectual Property with respect to such transgene or
biological target in the Ophthalmology Field, the following terms and conditions shall apply. For clarity, neither MEE (nor any of its Affiliates or any Third Party) shall be able to invoke the option rights of MEE under this Section 2.7 in the
absence of such a Qualifying MEE Ophthalmology Program. 
 (a) MEE will notify TDTx at the JSC of its interest in obtaining a
commercial sublicense under the relevant Licensed Intellectual Property for such transgene or biological target in the Ophthalmology Field, and then, unless TDTx can demonstrate at the JSC that such transgene or biological target is not an Available
Target (in which case MEE shall have no right to obtain a commercial sublicense under the Licensed Intellectual Property for any transgene or biological target that is not an Available Target at the time of request by MEE at the JSC), the following
process shall apply; 
 (b) If the transgene or biological target is an Available Target at the time of request by MEE at the JSC,
TDTx shall have a period of [***] for TDTx to decide whether it wishes to pursue a collaboration with MEE for the research, development and commercialization of any Licensed Products directed to such Available Target in the Ophthalmology Field; 

(c) If TDTx notifies MEE in writing during such [***] period that it desires to pursue such a collaboration with MEE, MEE and TDTx
shall enter into good faith negotiations for a definitive collaboration agreement with respect to the relevant transgene or biological target in the Ophthalmology Field; 

  
 13. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (d) If TDTx does not notify MEE during such [***] period that it desires to pursue
such a collaboration with MEE, or if it does notify MEE during such [***] period of its interest in pursuing such a collaboration but MEE and TDTx are not able to consummate a definitive collaboration agreement after good faith negotiations, TDTx
shall grant a commercial sublicense to MEE or shall grant a Sublicense directly to MEE’s proposed Third Party Sublicensee, the recipient of such commercial Sublicense to be determined at the sole discretion of MEE, under the relevant Licensed
Intellectual Property for the relevant transgene or biological target solely in the Ophthalmology Field. If such commercial sublicense is between MEE and TDTx, then the commercial sublicense shall be sublicenseable by MEE to MEE’s proposed
Third Party Sublicensee. A commercial sublicense granted to either MEE or a Sublicense granted by TDTx to MEE’s proposed Third Party Sublicensee shall be subject to all of the terms and conditions of this Agreement applicable to Sublicenses
granted by TDTx, including, without limitation, the provisions on Sublicense Income as set forth in Section 3.7, and will be granted on financial terms and conditions to be negotiated by TDTx and MEE or MEE’s proposed Third Party
Sublicensee in good faith having considered the commercially reasonable, risk-adjusted fair market value of such Licensed Intellectual Property at the time of such commercial sublicense or Sublicense, as applicable. For clarity, if MEE’s
proposed Third Party Sublicensee enters into a Sublicense thereunder with TDTx, any and all license payments, including upfront license payments, annual maintenance payments and milestone and royalty payments due for such Sublicense will be owed by
MEE’s proposed Third Party Sublicensee, and not by MEE. For further clarity, if the commercial sublicense in the Ophthalmology Field is between TDTx and MEE and there is a subsequent related commercial sublicense thereunder directly between MEE
and MEE’s proposed Third Party Sublicensee in the Ophthalmology Field, any such license payments, to the extent such license payments are attributable to the Licensed Intellectual Property licensed to TDTx hereunder and not to any other
Intellectual Property of MEE, including upfront license payments, annual license maintenance payments and milestone and royalty payments, received by MEE from such commercial Sublicensee shall be paid to TDTx by MEE. In the event of any termination
of any such Sublicense granted to MEE’s proposed Third Party Sublicensee under the provisions of this Section 2.7, all rights to the relevant Licensed Intellectual Property for the relevant transgene or biological target in the
Ophthalmology Field shall revert fully to TDTx, at no additional cost to TDTx; provided, however, that MEE shall retain all of its rights to any new intellectual property generated by MEE in the course of conducting the Qualifying MEE
Ophthalmology Program, excluding the Licensed Intellectual Property. 
 ARTICLE 3 

FINANCIAL TERMS 
 As the
sole monetary consideration for the rights granted by Licensors under this Agreement, TDTx shall make the following payments to Licensors according to this Article 3. As additional consideration for such rights, TDTx shall issue certain shares of
TDTx’s common stock in accordance with Section 3.1. 
 3.1 Equity. 

3.1.1 On the Effective Date, TDTx shall issue, pursuant to a Stock Issuance Agreement between TDTx and Lonza (the “TDTx-Lonza Stock Issuance Agreement”) a total number of shares of common stock of TDTx, $0.001 par value per share [***] of TDTx’s issued and outstanding common stock calculated on a Fully-Diluted
Basis after giving effect to such issuance, (the “Lonza Shares”) in the name of Lonza. On the Effective Date, TDTx shall issue, pursuant to a Stock Issuance Agreement between TDTx and MEE (the “TDTx-MEE Stock Issuance Agreement”) a total number of shares of common stock of TDTx, $0.001 par value per share equivalent to [***] of TDTx’s issued and outstanding common stock calculated on a
Fully-Diluted Basis after giving effect to such issuance, (the “MEE Shares”), in the name of MEE. TDTx represents to Licensors that, immediately following the Effective Date, the aggregate number of Lonza Shares and MEE
Shares (the Lonza Shares and MEE Shares collectively referred to as the “Shares”) equals [***] of TDTx’s issued and outstanding common stock calculated on a Fully-Diluted Basis after giving effect to such issuances. For
purposes of this Section 3.1, “Fully-Diluted Basis” shall mean that the total number of issued and outstanding shares of the DTx’s capital stock, which shall be calculated to include conversion of all issued and
outstanding securities then convertible into capital stock, the exercise of all then outstanding options and warrants to purchase shares of capital stock, whether or not then exercisable, and shall assume the issuance or grant of all securities
reserved for issuance pursuant to any TDTx stock or stock option plan in effect on the date of the calculation. In addition, on the Effective Date, TDTx, Lonza, MEE and certain other holders of common stock of TDTx shall enter into Shareholder
Agreement (the “Shareholder Agreement”). 

  
 14. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3.1.2 Partners Innovation Fund and Lonza Purchase Right. Beginning on the
Effective Date, MEE, through Partners Innovation Fund, LLC (“PIF”) and Lonza, shall each have the right, but not the obligation, to purchase up to MEE’s and Lonza’s respective Share of the securities issued in any
Qualifying Offer on the terms and conditions set forth in this Section 3.1.2 (“Purchase Right”). 
 (a)
Exercise of Purchase Right. Within a reasonable period of time immediately following the receipt of a Qualifying Offer, TDTx shall, in accordance with Article 14 of this Agreement, provide written notice to PIF and Lonza of any such
Qualifying Offer. PIF and Lonza will both then have [***] to exercise their Purchase Right either in whole or in part by providing written notice to TDTx (“Exercise Period”). PIF and Lonza shall then have [***] following
TDTx’s receipt of PIF’s and/or Lonza’s written notice to exercise the Purchase Right to negotiate an investor rights agreement with TDTx (“Purchase Period”). 

(b) Termination of Purchase Right. The Purchase Right shall terminate upon the earliest to occur of the following (each a
“Termination Event”): 
 (i) PIF’s or Lonza’s execution of an investor rights agreement or similar
agreement in connection with a Threshold Offer; 
 (ii) PIF and/or Lonza fails to give notice of its desire to exercise the Purchase
Right during the Exercise Period for a Qualifying Offer which has its final closing within [***] of the date such notice was received by PIF and Lonza and which is closed on terms that are the same or less favorable to the investors than the terms
contained within the notice given by TDTx to PIF and Lonza in accordance with Section 3.1.2(a); 
 (iii) The closing of a firm
commitment underwritten public offering of TDTx’s common stock; or 
 (iv) The closing of the sale of all or substantially all
of TDTx’s assets to a company publicly traded on one of the Major Recognized Exchanges. 
 (c) Definitions. The
following terms shall have the definitions ascribed to them under this Section for the purposes of interpreting Sections 3.1.2(a) and 3.1.2(b). 

(i) “Adjustment Event” means the final closing of the first Threshold Offer occurring after the Effective Date
of this Agreement. 
 (ii) “Fully-Diluted Basis” means all of TDTx’s capital stock either outstanding
or reserved for issuance, assuming the exercise of all options, warrants and other convertible securities and the conversion of all preferred stock and convertible debt instruments and assuming the grant of all shares reserved under any equity
incentive or similar plans. 
 (iii) “Major Recognized Exchange” shall mean the New York Stock Exchange, the
NASDAQ, or any comparable stock exchange reasonably acceptable to the holders of registrable securities. 

  
 15. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (iv) “Qualifying Offer” means a private offering of the
TDTx’s equity securities (or securities convertible into or exercisable for the TDTx’s equity securities) for cash (or in satisfaction of debt issued for cash) having its final closing on or after the Effective Date of this Agreement and
which includes investment by one or more [***] other than PIF and Lonza. 
 (v) “Share” means: 

(A) [***] with respect to any Qualifying Offer having a closing on or before the date of an Adjustment Event; or 

(B) (B) with respect to any Qualifying Offer having a closing after an Adjustment Event, but before a Termination Event, the
percentage necessary for PIF and Lonza to maintain its pro rata ownership interest in the TDTx on a Fully-Diluted Basis. 
 (vi)
“Threshold Offer” means any Qualifying Offer which either: (x) is at least [***] in size or (y) involves the sale to outside investors of at least [***] of the equity securities outstanding after such round on a
Fully-Diluted Basis. 
 With regard to each Qualifying Offer, the number of securities that may be purchased by PIF pursuant to this
Section 3.1.2 shall be reduced by the number of such securities purchased by PIF (or MEE, or delegee, successor, assignee, beneficial interest holder or Affiliate (as defined in the Shareholder Agreement, as may be amended from time to time) of
PIF or MEE) pursuant to the pre-emptive right under the Shareholder Agreement, and the number of securities that may be purchased by Loma pursuant to this Section 3.1.2 shall be reduced by the number of
such securities purchased by Lonza (or its delegee, successor, assignee, beneficial interest holder or Affiliate (as defined in the Shareholder Agreement) pursuant to the pre-emptive right under the
Shareholder Agreement. 
 3.2 Milestone Payments. 

(a) With respect to at least one (1) Licensed Product directed to a named biological target or transgene pursued within the Field
of Use , TDTx or its Affiliate or Sublicensee, as applicable, shall make the development and sales milestone payments in the amounts corresponding to the achievement by either TDTx or any of its Affiliates, or its Sublicensees of the development and
sales milestones set forth on Schedule B. Within [***] after achievement of any such milestone event by TDTx or any of its Affiliates or Sublicensees or within [***] after receiving notice from any of its Sublicensees that any such sales or
development milestone event has been achieved, as the case may be, TDTx shall notify Licensors of such achievement in writing and Licensors shall issue TDTx an invoice for the amount of the corresponding milestone payment, which invoice TDTx shall
pay or cause to be paid within [***] following its receipt thereof if such milestone was achieved by TDTx, and within [***] after TDTx’s receipt of payment from its Affiliate or from its Sublicensee if such milestone was achieved by its
Affiliate or Sublicensee, as applicable. 
 (b) For Sublicensees, each milestone payment set forth on Schedule B shall be payable
for [***] Licensed Product per named biological target or transgene that is pursued within the Field of Use, for [***] Licensed Product to achieve the milestone event, and [***] directed to the same named biological target or transgene unless [***],
it being understood and agreed by the Parties that [***]. 
 (c) For TDTx or its Affiliate, each milestone payment set forth on
Schedule B shall be payable for only one (1) Licensed Product per named biological target or transgene that is pursued within the Field of Use by TDTx or its Affiliate, for only the first Licensed Product to achieve the milestone event, and
[***] directed to the same named biological target or transgene; provided, however, that if TDTx or its Affiliate is able to achieve the [***] shown in Schedule B for a second Licensed Product directed to the same named biological
target or transgene, then TDTx or its Affiliate (as applicable) shall be required to pay the milestone amount shown on Schedule B for such second Licensed Product for the [***] and shall be obligated to pay retroactively all prior milestone event
payments shown in Schedule B for any such second Licensed Product directed to the same named biological target or transgene. 

  
 16. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (d) For clarity, if a first Licensed Product progressed by either TDTx, its
Affiliate or by a Sublicensee for a given named biological target or transgene fails and is no longer progressed, and is replaced with a second Licensed Product that is directed to the same named biological target or transgene, the milestone amounts
shown in Schedule B will only be payable for the second Licensed Product for the milestone events that were not yet achieved by the first Licensed Product. Also for clarity, a Licensed Product will not be considered to be a second or different
Licensed Product under this Section 3.2 relative to any first or other Licensed Product merely due to [***]. As used herein [***]. 

3.3 Royalties. 

3.3.1 Licensed Products Commercialized by TDTx. In further consideration of the license granted to TDTx in this Agreement and
subject to Sections 3.3.3, 3.4 and 3.5, TDTx shall pay to Licensors, during each applicable Royalty Term, royalties at the applicable royalty rates set forth in Schedule C, based on the portion of annual worldwide Net Sales within each of the
royalty tiers set forth in such Schedule C. For the avoidance of doubt, such royalties shall be payable in respect of annual worldwide Net Sales of each Licensed Product only for such Net Sales made and recorded by TDTx or its Affiliates. In
addition, in no event shall [***]. 
 3.3.2 Licensed Products Commercialized by a Sublicensee. In further consideration of the
license granted to TDTx in this Agreement and subject to Sections 3.3.3, 3.4 and 3.5, TDTx shall pay to Licensors, during each applicable Royalty Term, a portion of the royalty income payments received from a Sublicensee, such royalty income
payments based on the applicable royalty sharing rates set forth in Schedule D for the Sublicensee royalty income payment. For the avoidance of doubt, such royalty payments shall be payable in respect of annual worldwide Net Sales of each Licensed
Product only for such Net Sales made and recorded by Sublicensees. In addition, [***]. 
 3.3.3 Royalty Reductions. The
royalties payable to Licensors hereunder shall be subject to the following reductions set forth in paragraphs (a) through (c) of this Section 3.3.3, which shall apply in addition to the royalty offsets as described in Section 3.4:

 (a) Non-Valid Claim Covered Licensed Products during Royalty Term. If the [***] of
a Licensed Product is not Covered by a Valid Claim in the country of [***] and at the time of [***] (either because no Valid Claim within the Ancestral Technology Patent Rights ever existed Covering such Licensed Product in the relevant country or
the Valid Claim within the Ancestral Technology Patent Rights no longer exists), but the [***] of the Licensed Product occurs within the Royalty Term in the relevant country, then, in respect of Net Sales in such country, the royalties payable on
the annual Net Sales of such Licensed Products sold in such country by TDTx, its Affiliates and Sublicensees during such period of the Royalty Term shall be calculated at rates that are reduced [***] from the amounts set forth in Schedule C. 

(b) Compulsory Licenses. In the event that Lonza, MEE or TDTx receives a request for a Compulsory License anywhere in the
world, it shall promptly notify the other Parties. If any Third Party obtains a Compulsory License in any country, then Lonza, MEE or TDTx (whoever has first notice) shall promptly notify the other Parties. For the purposes of calculating the
royalties due to Licensors under Section 3.3 with respect to Net Sales of any Licensed Product in such country where a Compulsory License has been granted, the royalty rate payable by TDTx hereunder for Net Sales of any Licensed Product in such
country will be adjusted to [***]. In the event any Third Party is granted a sublicense of the rights under Section 2.1 by TDTx in order to avoid the imposition of a Compulsory License (such Third Party, a “Compulsory
Sublicensee”), where the royalty rate payable by such Compulsory Sublicensee on Net Sales of Licensed Products is less than the royalty rate paid by TDTx’s other Sublicensee(s) on the Net Sales of Licensed Products, then the
royalty rate payable by TDTx to Licensors hereunder for Net Sales the of Licensed Product by the Compulsory Sublicensee shall be reduced [***]. For example, [***]. 

  
 17. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (c) Generic Competition. Royalties payable on Net Sales of Licensed Products
in any given country shall be, on a Licensed Product by Licensed Product basis, subject to additional reductions of (i) [***] following a decrease in Net Sales of at least [***] and (ii) [***] following a decrease in Net Sales of [***]; in each
case, where such decrease in Net Sales is [***] to entry of one or more “generic” or “biosimilar” product(s) (as applicable) in such country in a particular Calendar Quarter compared to the average Net Sales of such Licensed
Product in such country over the [***] entry of such generic or biosimilar product. 
 3.4 Offsets from Royalty Payments; Minimum
Royalty Rates. 
 3.4.1 Third Party Intellectual Property. If TDTx and/or any of its Affiliates, or Sublicensees enter
into one or more Third Party License Agreements that TDTx or its Affiliate or Sublicensee, as applicable, reasonably determines is [***] for TDTx or any of its Affiliates, or Sublicensees to develop, make, use, import, or sell the relevant Licensed
Product, TDTx or its Affiliate or Sublicensee, as applicable, will have the right to offset [***], against the royalty payments due to Licensors with respect to the annual Net Sales of such Licensed Product in such country, subject to the minimum
royalty rate requirements of Sections 3.4.2 and 3.4.3, as applicable. 
 3.4.2 Notwithstanding the right of TDTx and its Affiliates
to apply in a cumulative manner the royalty rate reductions and offset rights as described in Section 3.3.3 and Section 3.4.1, in no event shall the final adjusted royalty rate due to Licensors on the basis of annual Net Sales of Licensed
Products by TDTx or its Affiliates as shown in Schedule C be reduced [***] for any given Calendar Quarter, provided, however, that TDTx or its Affiliate shall have the right to carry forward any such offsets or reductions that would
result in the royalty rate being reduced [***] in any given Calendar Quarter for any Licensed Product into subsequent Calendar Quarters, [***]. 

3.4.3 Notwithstanding the right of Sublicensees of TDTx or Sublicensees of its Affiliates to apply in a cumulative manner the royalty
rate reductions and offset rights as described in Section 3.3.3 and Section 3.4.1, in no event shall the final adjusted royalty rate owed by any Sublicensees of TDTx or Sublicensees of its Affiliates under any Sublicense Agreement on the
basis of annual Net Sales of Licensed Products by such Sublicensee be less than [***] without the application of any of the reductions or offsets described in Section 3.3.3 or Section 3.4.1, and in no event shall such final adjusted
royalty rate owed [***] after the cumulative application of all applicable reductions and offsets described in Section 3.3.3 and Section 3.4.1; provided, however, that [***] Covering the Licensed Product in the relevant
country at the time of [***] of the Licensed Product. Sublicensees shall have the right to carry forward any such offsets or reductions that would result in the royalty rate being reduced to an amount less than the minimum required royalty rate in
any given Calendar Quarter for any Licensed Product into subsequent Calendar Quarters, [***]. In addition, in cases where the minimum royalty rate requirement under this Section 3.4.3 is applicable, TDTx or its Affiliate shall have the right to
[***] an exception to the minimum royalty rate requirement under this section based upon the grounds that the minimum royalty rate requirement would result in [***], and if [***], such exception to the minimum royalty rate requirement shall be
[***]. For clarity, regardless of the final adjusted royalty rate that applies to a Sublicensee under a Sublicense Agreement, the Royalty Income Sharing percentages as shown in Schedule D shall apply to all royalty income received by TDTx or its
Affiliates for the annual Net Sales of Licensed Products by all Sublicensees of TDTx or Sublicensees of its Affiliates. 
 3.5 [Reserved]

 3.6 Payment. TDTx shall pay such royalties due to Licensors under this Agreement within [***] after the last day of
each Calendar Quarter in which such royalty payments are owed, by [***]. 
 3.7 Sublicense Income. 

3.7.1 Sublicense Income Payments. Except as set forth in Section 3.7.2, and subject to the reductions as described in
Section 3.8 and the exclusions described in Section 3.7.3, TDTx shall pay Licensors a percentage of all types of payments and consideration ([***]) TDTx or any of its Affiliates receives under a Sublicense Agreement from a Sublicensee,
including but not limited to [***] (collectively, the “Sublicense Income”) in the applicable percentage payment as set forth below (each such percentage payment of Sublicense Income is referred to as a “Sublicense
Income payment” and each such percentage reduction to be applicable for a Sublicense Income Payment is referred to as a “Step-Down”): 

(a) [***] of Sublicense Income attributable to all Licensed Products received under a Sublicense Agreement entered into after [***]
and prior to [***]; 

  
 18. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (b) A Step-Down to [***] of the Sublicense Income attributable to all Licensed
Products received under a Sublicense Agreement entered into on or after [***] and prior to [***], whichever occurs first; 
 (c) A
Step-Down to [***] of the Sublicense Income attributable to all License Products received under a Sublicense Agreement entered into after [***] and prior to [***]; and 

(d) A Step-Down to [***] of Sublicense Income attributable to all Licensed Products received under a Sublicense Agreement entered into
on or after [***]. 
 For clarity, a Step-Down is [***], and the Step-Downs will [***]. For further clarity, each Sublicense Agreement will
[***] and the applicable Step-Down will be applied [***]. 
 3.7.2 Greater of Sublicense Income Payments Payable to Licensors.
Without limiting TDTx’s rights under Section 3.7.4, where the Sublicense Income Payment corresponds to the achievement of one of the same (or [***]) development and/or sales milestone events as those listed in Schedule B, TDTx shall
pay to Licensors the greater of the amount associated with such milestone in Schedule B or the payment amount due after applying the applicable percentage under Section 3.7.1 to the Sublicense Income received from a Sublicensee in connection
with the achievement of such milestone event. 
 3.7.3 Exclusions. Excluded from Sublicense Income with respect to which TDTx
must pay such percentage pursuant to Section 3.7.1 or 3.7.2, as applicable, are [***]. 
 3.7.4 No Double Payment.
Notwithstanding anything to the contrary in Section 3.7, TDTx shall be entitled to (i) deduct from any Sublicense Income Payment due to Licensors the amount of [***], and (ii) deduct from any Sublicense Income Payment due to Licensors
the amount of [***]; provided, however, that in both (i) and (ii) any amount paid to Licensors pursuant to Section 3.2 may be deducted from Sublicense Income Payments received from any Sublicensee only once. 

3.7.5 Apportionment for Broader Transactions involving Third Party IP. In the event that a Sublicense is part of a broader
transaction (other than an M&A Transaction) that involves, in addition to the grant of a Sublicense under the Ancestral Technology Patent Rights, the grant of license or option rights or other rights to other assets, programs or intellectual
property that were obtained or licensed by TDTx or its Affiliate from any Third Party, TDTx will have the right to apply a fair apportionment to [***] under any such broader transaction [***] to the value of the rights being sublicensed from
Licensors hereunder relative to the value of the other rights, assets, programs or intellectual property licensed or obtained from a Third Party that are part of such broader transaction other than the Ancestral Technology Intellectual Property;
provided, however, that (a) the right of apportionment under this Section 3.7.5 shall [***], and (b) TDTx shall [***], and (c) the [***] shall be [***], and (d) the [***]. 

3.8 Reduction of Sublicense Income Fees Payable to Licensors during [***]. Notwithstanding anything to the contrary under
this Article 3, TDTx shall be entitled to (i) during [***], permanently retain [***] of the Sublicense Income Payments that would otherwise be due to Licensors; and (ii) during [***], permanently retain [***] of the Sublicense Income
Payments that would otherwise be due to Licensors. Following the expiration of the [***] and continuing for the remainder of the Term, notwithstanding any reductions in the Sublicense Income Payment provided for under this Section 3.8, TDTx
shall pay to Licensors [***] of the Sublicense Income Payments due for any Sublicense Income received by TDTx after the expiration of [***], as applicable under the provisions of Section 3.7. 

  
 19. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3.9 Patent Expenses. TDTx shall be responsible to reimburse MEE for [***] of
the patent expenses for any Licensed Product incurred and paid by MEE for the Ancestral Technology Patent Rights after the Effective Date of the Agreement, to the extent such portion of those expenses is not required to be reimbursed by a Third
Party; provided, however, that with respect to the patent expenses incurred by MEE after the Effective Date for all other Ancestral Technology Patent Rights, TDTx shall be responsible for [***] of such expenses with the remaining [***]
being paid by Existing Third Party Licensees/Sublicensees; provided however that should TDTx obtain license rights that currently reside with an Existing Third Party Licensee/Sublicensee, then TDTx shall be responsible for the relevant
additional expenses associated with the obtained license rights, and such [***] allocation to TDTx shall be adjusted upwards accordingly to account for the proportional reduction in share by the termination of the relevant Existing Third Party
License/Sublicense. TDTx shall have the right to defer its obligations under this Section 3.9 to make any such reimbursement payments until the date that TDTx raises a total of at least [***] in Capital Funding in satisfaction of the
requirements of Section 6.2.2, which within [***] upon receiving the Capital Funding, TDTx shall provide written notice to MEE. TDTx shall pay the amounts due for reimbursement commencing on the date that such [***] requirement in Capital
Funding is achieved, and MEE shall submit invoices to TDTx for TDTx’s share of such patent expenses not later than [***] after the date that such [***] requirement in Capital Funding is achieved and then on a [***] basis thereafter for future
patent expenses. Each such invoice shall include a reasonably detailed description of the expenses. TDTx shall pay amounts shown on such invoices within [***] after TDTx’s receipt of the invoice. 

3.10 Waiver or Deferral. Waiver or deferral by Licensors of any payment owed under Section 3.2 or Section 3.3 may not
be construed as a waiver or deferral of any subsequent payment owed by TDTx to Licensors. 
 3.11 Form of Payments and Taxes.

 3.11.1 Payments to Lonza. Payments may be paid by check or made by wire transfer using the following information: 

Lonza Sales AG. 
 UBS Switzerland
AG, POF Box 450, CH-8098 
 Zuerich, Switzerland [***] 

For Wires and EFT payments, please email remittance advice to [***]. 

3.11.2 Payments to MEE. Payments may be paid by check made payable to MEE and sent to: 

Massachusetts Eye and Ear Infirmary BOA-Lockbox Services 

[***] 
 or such other addresses which MEE may
designate in writing from time to time. Checks are to be made payable to “Massachusetts Eye and Ear Infirmary”. Payments may instead be made by wire transfer using the following information: 

[***] 
 TDTx shall pay all amounts
payable to Licensors under this Agreement in United States funds without deduction for taxes, exchange, collection or other charges that may be imposed by any country or political subdivision with respect to any amounts payable to Licensors under
this Agreement. TDTx is responsible for paying, or ensuring payment of, such taxes, exchange, collection or other charges, other than taxes attributable to Lanza or MEE’s net income. 

  
 20. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3.12 Currency Conversion. If any currency conversion is required in connection
with any payment owed to Licensors, the conversion will be made at the buying rate for the transfer of such other currency as quoted by [***] in the case of any payment payable with respect to a specified accounting period or, in the case of any
other payment, the last business day before the date the payment is due. 
 3.13 Interest. Any payment owed to Licensors under
this Agreement that is not made when due will accrue interest beginning on the first day following the due date specified in Article 3. The interest will be calculated at the [***] rate of the sum of [***]. However, the annual rate may not exceed
the maximum legal interest rate allowed in Massachusetts. The payment of interest as required by this Section 3.13 does not foreclose Licensors from exercising any other rights or remedies they have as a consequence of the lateness of any
payment. 
 3.14 Right to Offset. Without limiting its rights under Section 11.3, TDTx shall have the right to offset any
amount owed to it by Licensors under or in connection with this Agreement, including in connection with any breach, against any future payments owed by TDTx to Licensors under this Agreement, in each case based on a final determination by an
arbitrator pursuant to an arbitration proceeding administered pursuant to Section 15.2. Such offsets shall be in addition to any other rights or remedies available under this Agreement and applicable law; provided, however, that,
[***]. In the event that TDTx is not able to deduct the full amount of the permitted deduction from the amount due to Licensors as a result of the proviso set forth in the preceding sentence, TDTx shall be entitled to deduct any undeducted excess
amount from subsequent amounts owed to Licensors (subject in each case to the proviso set forth in the preceding sentence). 
 ARTICLE 4

 ROYALTY REPORTS, PAYMENTS AND FINANCIAL RECORDS 

4.1 Royalty Reports. Within [***] after March 31, June 30, September 30 and December 31, of each year in
which this Agreement is in effect following First Commercial Sale of a Licensed Product in any country, TDTx shall deliver to Licensors full, true and accurate reports of its activities and those of its Affiliates, or Sublicensee(s), if any,
relating to the sale of Licensed Products and any Sublicense Income received during the preceding three (3) month period (each such three (3) month period, a “Calendar Quarter”). These reports must include the
following with respect to the preceding Calendar Quarter: 
 (a) Number of Licensed Products sold by TDTx, and any Affiliates, or
Sublicensees, in the Territory; 
 (b) Total revenues recorded for the Licensed Products sold by TDTx and any Affiliates, or
Sublicensees; 
 (c) Deductions applicable to determining Net Sales; 

(d) The nature and amount of Sublicense Income received by TDTx, its Affiliates or Sublicensees; and 

(e) Total royalties due to Licensors. 

With each report, TDTx shall pay to Licensors the royalties accrued during the preceding Calendar Quarter. If no royalties are due, TDTx shall
so report. If multiple Licensed Products are Covered by the license granted under this Agreement, TDTx shall separately identify Net Sales of each Licensed Product in the section of the royalty report responsive to clause (b) above. 

  
 21. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.2 Record Keeping. 

4.2.1 Books and Records. TDTx shall keep, and shall require its Affiliates, and Sublicensees to keep, true books of account
containing an accurate record (together with supporting documentation) of all data necessary for determining the amounts payable to Licensors for a period of [***] following the end of the calendar year to which they pertain. TDTx shall keep it
records at its principal place of business or the principal place of business of the appropriate division of TDTx to which this Agreement relates and shall require its Affiliates and Sublicenses to keep their books and records in the same manner.

 4.2.2 Inspections. In order for Licensors to determine the correctness of any report or payment made under this Agreement,
TDTx shall make its records available for inspection in accordance with this Section 4.2.2 for a period of [***] following the end of the calendar year to which they pertain. TDTx shall also require any Affiliates to make their records
available for inspection by Licensors, in the same manner as provided in this Section 4.2.2. 
 [***] per calendar year, Licensors may
cause a certified public accountant ‘ selected by Licensors and reasonably acceptable to TDTx to inspect such records during regular business hours; provided, however, Licensors may [***]. In conducting inspections under this
Section 4.2.2, TDTx agrees that Licensors’ accountant may have access to all records which Licensors reasonably believe to be relevant to calculating royalties owed to Licensors under Article 3. TDTx may require the accountant to sign a
customary nondisclosure agreement prior to undertaking any such inspection, and any and all books, records, reports and other documents inspected by such accountant shall be deemed TDTx’s Confidential Information. Licensors may receive a
summary of the accountant’s findings but shall not permit the accountant to disclose such books, records, reports and other documents to Licensors. 

If the inspections show an underpayment of any payment owed to Licensors under Article 3, TDTx shall pay Licensors the unpaid amounts due
hereunder, plus interest as set forth in Section 3.12, within [***] after receiving a written audit report from the accountant. Licensors are responsible for the cost of any inspection, unless the examination shows an underreporting in excess
of [***] for any [***] period, in which case TDTx shall reimburse Licensors for the cost of the inspection within [***] of receipt of an invoice. 

ARTICLE 5 
 JOINT
STEERING COMMITTEE 
 5.1 Formation and Representatives. Promptly after execution of this Agreement, the Parties shall
establish a steering committee (the “Joint Steering Committee” or “JSC”). Each Party shall name a mutually agreed upon equal number of [***] for the Joint Steering Committee, each of whom shall be
[***]. 
 5.2 JSC Chairman. The chairperson of the JSC shall be initially selected by [***] and shall rotate among Lonza and
MEE from meeting to meeting. The role of the chairperson shall be to prepare an agenda for the meetings of the JSC, convene and preside at meetings of the JSC and to ensure the preparation and distribution of minutes, but the chairperson shall
otherwise have no additional powers or rights beyond those held by the other JSC representatives. 
 5.3 Meetings by the JSC.
Until such time when the diligence obligations of TDTx under Article 6 expire, the Joint Steering Committee shall meet [***] during the Term of the Agreement, or as otherwise necessary or mutually agreed by the Parties or as may reasonably be
requested by any Party on an ad hoc basis as necessary. Such meetings may be conducted by videoconference, teleconference or in person, as determined by the Parties. The Joint Steering Committee shall not have the authority to approve any activities
by TDTx or its Affiliates or Sublicensees under this Agreement, but (i) shall have the right to serve as a forum for review and discussion between the Parties with respect to, among other things, (a) review of the sublicensing strategy of
TDTx to ensure consistency with the terms and conditions of this Agreement and share sublicenses granted to Third Parties under the Agreement for commercialization and development efforts, (b) review the progress of the commercialization and
development plans, efforts and objectives of TDTx, including sales, marketing, distribution and support of the Ancestral Technology, (c) review the progress of the sales and marketing of the Ancestral Technology and exchange information related
thereto, (d) review option rights granted to biological targets and transgenes by TDTx, and review the requests of Existing Third Party Licensees/Sublicensees for the naming of Unnamed Option Rights thereunder; and (e) review and discuss
all 3-way external communications by the Parties and press releases and (ii) shall have, solely with respect to the members of the JSC from Lonza and MEE, and solely to the extent that the members from
Lonza and MEE unanimously agree, the right to approve any request for an exception to any sublicense requirements under this Agreement, but excluding right to approve any request to change diligence and payment terms. For clarity, the JSC shall not
have any ability or authority to amend, waive, or modify the terms of this Agreement. 

  
 22. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 6 

OPERATIONS UNDER THE LICENSE 

6.1 Diligence Obligations. 

6.1.1 General Obligations. With respect to only those programs ([***]) of TDTx or its Affiliates that TDTx intends to apply
towards meeting its Minimum Potential Revenue Stream obligations as stated under Section 6.3, and for each program of a Sublicensee, within [***] after the Effective Date, and as updated within [***] after the start of every Calendar Year
thereafter during the Term, TDTx shall provide Licensors with a bona fide written business plan (“General Development Plan”) that describes: 

(a) TDTx’s, its Affiliates and Sublicensees efforts during the prior year for researching, developing and commercializing
Licensed Products in the Field of Use, including (i) information regarding specific Licensed Products in development and their specific applications; (ii) key activities and milestones achieved and status of applications for INDs, CTAs or
equivalents and regulatory approvals; and (iii) [***]; 
 (b) a list of all new sublicense transactions completed and [***]; and

 (c) TDTx’s business [***] goals and objectives for [***]. 

The General Development Plan must contain a sufficient level of detail for Licensors to assess whether TDTx is in compliance with its
obligations under Section 6.1.2 and an outline of TDTx’s, its Affiliates and Sublicensees intended efforts for the subsequent [***] including [***]. TDTx shall also provide Licensors with [***] and annual report to investors which shall
include [***]. 
 6.1.2 Licensed Product Minimum Diligence Obligations. Applicable to TDTx, only for those programs ([***]) of
TDTx or its Affiliates that TDTx intends to apply towards meeting its Minimum Potential Revenue Stream obligations as stated under Section 6.3, and applicable for each program of its Sublicensees, TDTx shall, or shall cause its Affiliates
and/or Sublicensees as applicable to, use Commercially Reasonable Efforts to achieve the following development objectives with respect to each Licensed Product it develops in the Field of Use on its own or with its Affiliates or Sublicensees: 

(a) [***]; 
 (b)
[***]; 
 (c) [***]; 

(d) [***]; and 

(e) [***]. 

  
 23. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 For the avoidance of doubt, TDTx shall not be required to cause its Sublicensees to use
Commercially Reasonable Efforts to achieve the foregoing development objectives to the extent such objectives have already been achieved as of the date the relevant Sublicense was granted. 

6.1.3 Failure to Achieve Development Objectives. With respect to only those programs ([***]) of TDTx or its Affiliates that TDTx
intends to apply towards meeting its Minimum Potential Revenue Stream obligations as stated under Section 6.3, and for each program of a Sublicensee, the following provisions of this Section 6.1.4 shall apply to TDTx (or its Affiliate or
Sublicensee as applicable). 
 In the event that, despite the use of Commercially Reasonable Efforts, TDTx becomes aware that, due to any
relevant scientific, regulatory, safety, development, or commercial circumstances beyond the reasonable control of TDTx or any of its Affiliates or Sublicensees, as applicable, (a) any of the development or regulatory or commercial launch
milestone dates set forth in Section 6.1.2 will not be achieved or (b) any [***] will not be achieved, or (c) it will be unable to [***], then TDTx will notify Licensors in writing via the JSC in advance of such failure to achieve the
expected development or regulatory or commercial launch milestone dates, and the Parties will confer in good faith via the JSC to discuss a revised General Development Plan that is reasonably acceptable to TDTx and Licensors and mitigates or
otherwise takes into account such circumstances to the extent reasonably feasible in view of [***]. For the avoidance of doubt, [***]. Licensors shall notify TDTx via the JSC of any objections to any revised General Development Plan within [***]
after submission by TDTx to the JSC, failing which such General Development Plan shall be deemed approved by Licensors. In the event that Licensors provide TDTx with timely notice via the JSC of its objection to any revised General Development Plan
and, following at least [***] of good faith discussions and efforts to reach agreement on a revised General Development Plan, the Parties cannot agree on a reasonably acceptable revision or other remedy, then Licensors may request that TDTx provide
further evidence of its Commercially Reasonable Efforts to achieve the relevant milestone set forth above. If, and only if, after reviewing such further information requested and provided, Licensors make a determination that TDTx has failed to
demonstrate that it has used Commercially Reasonable Efforts to meet its diligence obligations as stated under this Article 6 for any Licensed Product, Licensors shall notify TDTx of such determination in writing and may treat such failure to meet
its diligence obligations as a material breach of this Agreement. Any such allegation of breach shall be subject to TDTx’s rights under this Agreement to dispute and/or cure it. 

6.2 Minimum Capital Funding. TDTx shall be required to have a Minimum Capital Funding according to the following: 

6.2.1 During the time period from the Effective Date of this Agreement until the [***], TDTx will use Commercially Reasonable Efforts to
raise a total of at least [***] across all fundraising rounds, tranches and sources to fund its operations, including cash for the purchase of capital stock, debt financing, lines of credit, grant funding and other sources of non-dilutive capital such as collaborative R&D funding, and Sublicense Income (net of any Sublicense Income Payment to Licensors) (collectively referred to as “Capital Funding”). 

6.2.2 During the time period from the Effective Date of this Agreement until [***] TDTx will use Commercially Reasonable Efforts to
raise a total of at least [***] in Capital Funding. 
 6.2.3 In the event that TDTx has not actually received funding in the total
amount described above in Section 6.2.1 or Section 6.2.2, despite having used Commercially Reasonable Efforts to secure funding in that amount, but is expected to have received such amount if all amounts that are then committed under
binding definitive agreements or under ongoing bona fide term sheet negotiations with third parties under pending additional tranches of funding that are due and expected within the subsequent [***] period, then TDTx shall not be considered in
breach of the relevant section and the Parties shall discuss and consider in good faith and shall make a reasonable adjustment to the total amounts described above, or an extension to such period as may be reasonable in the circumstances. 

  
 24. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 6.3 Minimum Potential Revenue Stream Requirements. 

6.3.1 TDTx shall be required to achieve, either by the progression by TDTx or its Affiliate of its own internal programs (such programs
to be based on and defined by the relevant biological target or transgene or Licensed Product) that are not the subject of any Sublicense, or from Sublicenses to the Licensed Products, a minimum Potential Revenue Stream amount for all Licensed
Products in each Contract Year for the [***] according to the following requirements (the “Minimum Potential Revenue Stream”): 

(a) [***]; 
 (b)
[***]; 
 (c) [***]; and 

(d) [***]. 

6.3.2 Potential Revenue Stream Rollover. Notwithstanding the foregoing, if TDTx, in a given Contract Year, achieves a total
Potential Revenue Stream that exceeds the Minimum Potential Revenue Stream requirement for that Contract Year, then TDTx will be permitted to apply the excess Potential Revenue Stream to subsequent Contract Years to reduce the Contract Year Minimum
Potential Revenue Stream requirements in the subsequent Contract Years. For example, if [***]. For clarity, in the event that [***]. 

6.3.3 Penalty For Failure To Meet Minimum Potential Revenue Stream. In the event that TDTx fails to satisfy any such Minimum
Potential Revenue Stream requirement for a relevant Calendar Year, TDTx shall be required to satisfy one of the following three options, such option to be selected at the sole discretion of TDTx. If TDTx chooses [***]: 

(a) Option One: Penalty Payments. Pay the following relevant penalty payments (the “Penalty Payments”):

 (i) [***]. 

(ii) [***]. 

(b) Option Two: Amend Financial Payments to Licensors. The Parties will confer to negotiate in good faith an amendment to the
financial terms in Article 3 of this Agreement, as applicable, that is [***]. If, after negotiating in good faith for a period of [***], the three Parties fail to agree to an amendment to the financial terms Article 3 of the Agreement], then, unless
mutually agreed between all three of the Parties to further extend the negotiations of the amendment, [***]. 
 (c) Option Three:
Obligation to Sublicense Licensed Transgenes. 
 (i) After receiving notice from MEE or Lonza that there is a Third Party
interested in obtaining a license under the Licensed Intellectual Property with respect to a particular biological target or transgene or Licensed Product, for which TDTx has not [***], (such request, a “Third Party License
Request”), within [***] after TDTx’s receipt of any such notice of a Third Party License Request, TDTx shall [***]. Such notice from MEE or Lonza shall be [***]. 

(ii) Negotiation of Sublicense. TDTx shall [***] commence good faith negotiations to enter into a Sublicense with the Third
Party that submitted the Third Party License Request. So long as the relevant Third Party [***], TDTx shall [***]. In no event shall TDTx be required, in connection with the execution of any Sublicense, to [***]. Upon execution and delivery of such
Sublicense, the Sublicense shall [***]. 

  
 25. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (iii) [***]. 

6.4 Regulatory Matters. As between TDTx and Licensors, TDTx shall own and maintain all Regulatory Approvals for the Licensed
Product in its, or its Affiliates or Sublicensees, own name and shall act as the sole point of contact for all communications with Regulatory Authorities in connection with the development, commercialization and manufacturing of the Licensed
Product. Licensors shall provide TDTx with all reasonably requested assistance in connection TDTx’s filings and correspondence with Regulatory Authorities. 

6.5 Other Government Laws. TDTx shall comply with, and ensure that its Affiliates and Sublicensees comply with, all mandatory
and applicable government statutes and regulations that relate to Licensed Products. These include but are not limited to FDA statutes and regulations, the Export Administration Act of 1979, as amended, codified in 50 App. U.S.C. 2041 et seq. and
the regulations promulgated thereunder or other applicable export statutes or regulations. 
 6.6 Patent Marking. To the
extent commercially feasible and consistent with prevailing business practices and applicable law, TDTx shall mark, and shall require its Affiliates and Sublicensees to mark, all Licensed Products sold in the United States with the word
“Patent” and the number or numbers of the Patent Rights applicable to the Licensed Product. 
 6.7 Ongoing
Communication. Subject to any obligations of confidentiality to which each respective Party may be subject, each Party shall make appropriate personnel available from time to time at the other Party’s reasonable request to answer questions
from the other Party concerning the status of the development of the Ancestral Technology and to discuss and attempt to resolve any issues or concerns a Party may have. 

ARTICLE 7 
 TDTX-LONZA STRATEGIC MANUFACTURING RELATIONSHIP 
 7.1 Manufacturing Agreements. TDTx
and Lonza will enter into good faith negotiations for a definitive manufacturing services agreement wherein TDTx and its Affiliates and Sublicensees will obtain the right to earn and obtain preferential rights to manufacturing services from Lonza in
return for TDTx voluntarily fulfilling certain “frequent flyer” criteria related to the manufacture of Licensed Products with Lonza, as further outlined in Schedule H. 

ARTICLE 8 

CONFIDENTIALITY 

8.1 Non-Disclosure Obligation. Each Party agrees, during the term of this Agreement, and
for [***] thereafter, to employ all reasonable efforts to maintain the other Party’s Confidential Information secret and confidential, such efforts to be no less than the degree of care employed by such Party to preserve and safeguard its own
confidential information. The Receiving Party shall not use the Disclosing Party’s Confidential Information for any purpose other than as expressly permitted under this Agreement and shall not disclose or reveal the Disclosing Party’s
Confidential Information to anyone except employees or agents of or consultants or advisors to the Receiving Party or its Affiliates (and in the case of TDTx as the Receiving Party, its actual or bona fide potential Sublicensees, licensees,
subcontractors, collaborators, investors, lenders and/or acquirers) (collectively, “Representatives”) who have a need to know the information and who are subject to written obligations of confidentiality under which they are
required to abide by the obligations of confidentiality and restrictions on use set forth in Section 8 and are advised by the Receiving Party of the confidential nature of the Confidential Information. The Receiving Party shall be responsible
for any breach of this Article 8 by its Representatives. The Receiving Party’s obligations under this Section 8.1 shall not extend to any information that: 

8.1.1 at the time of disclosure is in the public domain; 

  
 26.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 8.1.2 becomes part of the public domain, by publication or otherwise, through no
breach of this Agreement by the Receiving Party; 
 8.1.3 at the time of disclosure is already in possession of the Receiving Party,
as established by contemporaneous written records; 
 8.1.4 is lawfully provided to the Receiving Party, without restriction as to
confidentiality or use, by a Third Party not known by the Receiving Party to be subject to any obligation of confidentiality with respect to such information; or 

8.1.5 is or was independently developed by a Party without use of or reference to the other Party’s Confidential Information, as
established by contemporaneous written records. 
 8.2 Government-Required Disclosure. If a duly constituted government
authority, court or regulatory agency orders that a Party hereto disclose information subject to an obligation of confidentiality under this Agreement, such Party shall comply with the order, but shall notify the other Party as soon as possible, so
as to provide the said Party an opportunity to apply to a court of record for relief from the order or to limit the scope of the order. In addition, nothing in this Agreement shall prohibit the Receiving Party from disclosing Confidential
Information to the extent such disclosure is necessary to comply with the rules of any stock exchange, so long as the Receiving Party uses reasonable efforts to seek confidential treatment therefor. 

ARTICLE 9 
 INTELLECTUAL
PROPERTY 
 9.1 Ancestral Technology Patent Preparation, Filing, Prosecution and Maintenance. 

9.1.1 Responsibility. MEE shall be responsible for prosecuting and maintaining all patents and patent applications within the
Ancestral Technology Patent Rights. Title to all such patents and patent applications shall reside in MEE. MEE shall have full and complete control over all patent matters in connection therewith under the Ancestral Technology Patent Rights. For
purposes of this Agreement, patent prosecution includes [***]. MEE shall provide, or cause its agent to provide, copies of all proposed patent application filings and all office actions and other material correspondence with the United States Patent
Office or the various foreign patent offices to TDTx and shall provide to TDTx a timely opportunity to review, comment and provide input on all such proposed patent application filings and on all decisions on where to file patent applications and on
all office action responses and material correspondence with patent offices, and all of TDTx’s comments and input shall be taken into account with good faith consideration by MEE. TDTx designates the following individual or department for
receiving the patent-related correspondence: 
 Chief Legal Officer 

TDTx, Inc. 
 One Broadway, 14th
Floor, Kendall Square 
 Cambridge, MA 02142 

MEE shall make itself available to consult with TDTx on matters relating to preparing, filing, prosecuting or maintaining any of the applications or patents
within the Ancestral Technology Patent Rights, solely with respect to matters which are reasonably likely to pertain to the practice of the Ancestral Technology Patent Rights in the Field of Use, which matters may be of particular interest to TDTx,
and MEE shall consider any comments received from TDTx with respect thereto in good faith. 

  
 27. 

***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 9.2 Election Not to File and Prosecute Patent Rights. If MEE elects not to
file or to continue to prosecute or maintain any Ancestral Technology Patent Rights directly related to the Field of Use in any particular country or territory, then it shall notify TDTx in writing at least [***] before any deadline applicable to
the filing, prosecution or maintenance of such Ancestral Technology Patent Rights in the relevant country or territory, as the case may be, or any other date by which an action must be taken to establish or preserve such Ancestral Technology Patent
Rights in such country or territory. In such case, and subject to the rights of Existing Third Party Licensees/Sublicensees as of the Effective Date to file, prosecute or maintain such Patent Rights in such country or territory, TDTx shall have the
right, but not the obligation, with respect to the Ancestral Technology Patent Rights directly related to the Field of Use, to pursue the filing or support the continued prosecution or maintenance of such Ancestral Technology Patent Rights in such
country or territory using patent counsel that is reasonably acceptable to MEE, and, subject to the rights of Existing Third Party Licensees/Sublicensees as of the Effective Date to file, prosecute or maintain such Patent Rights in such country or
territory, and may delegate any such right to any of its Affiliates, or Sublicensees. 
 9.2.1 If TDTx or any of its Affiliates, or
Sublicensees assumes responsibility as permitted under Section 9.2 for the prosecution and maintenance of any Ancestral Technology Patent Rights in the Field of Use in any country or territory, and at any time thereafter elects not to continue
prosecution or maintenance of any such Ancestral Technology Patent Rights in such country or territory, then TDTx shall notify MEE in writing at least [***] before any deadline applicable to the filing, prosecution or maintenance of such Ancestral
Technology Patent Rights in such country or territory, as the case may be, or any other date by which an action must be taken to establish or preserve such Ancestral Technology Patent Rights in such country. If TDTx elects not to assume
responsibility for the prosecution and maintenance of any Ancestral Technology Patent Rights in such country or territory, then it will notify MEE within [***] after TDTx’s receipt of the notice from MEE referred to in Section 8.2.1. 

9.2.2 If TDTx (or any of its Sublicensees) does not continue prosecution or maintenance of any abandoned Ancestral Technology Patent
Rights, then such Ancestral Technology Patent Rights shall not extend the Royalty Term ([***]). 
 9.3 Notice. TDTx shall
provide prompt notice to MEE of any information that comes to its attention that TDTx reasonably believes is likely to materially affect the patentability, validity or enforceability of any patent application or patent within the Ancestral
Technology Patent Rights. 
 9.4 Relinquishing Rights. TDTx may surrender its licenses under any of the patents or patent
applications within the Ancestral Technology Patent Rights in any country or territory of the Territory by giving [***] advance written notice to MEE. However, if TDTx is surrendering any patent or application within the Ancestral Technology Patent
Rights on which an interference proceeding or opposition has been declared or filed, the notice period is [***]. If TDTx so surrenders its rights, it will remain responsible for its portion of the patent-related expenses incurred by MEE during the
applicable notice period. Thereafter, TDTx will have no further obligation to pay any patent expenses for the patents or patent applications that it surrendered. Notwithstanding the foregoing, if such surrender is with respect to all Ancestral
Technology Patent Rights in all countries licensed to TDTx under this Agreement, and thus results in termination of all of TDTx’s other rights under this Agreement, then the termination notice provision in Section 11.3 below shall apply.

 9.5 Intellectual Property Rights. 

9.5.1 Licensed Intellectual Property Rights. Except as expressly stated in this Agreement, TDTx will not, under this Agreement,
acquire any right, title, license or other interest in any Licensed Intellectual Property. 
 9.5.2 Lonza Intellectual Property
Rights. Except as expressly stated in this Agreement, neither TDTx nor MEE will, under this Agreement, acquire any right, title, license or other interest in any Lonza Intellectual Property. 

  
 28. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 9.5.3 MEE Intellectual Property Rights. Except as expressly stated in this
Agreement, neither TDTx nor Lonza will, under this Agreement, acquire any right, title, license or other interest in any MEE Intellectual Property. 

9.5.4 TDTx Intellectual Property Rights. Neither MEE nor Lonza will, under this Agreement, acquire any right, title, license or
other interest in any TDTx Intellectual Property. 
 9.5.5 Inventorship and Ownership of Inventions. Except as otherwise
expressly stated to the contrary herein, the ownership of all Intellectual Property made, conceived, reduced to practice or otherwise arising under or in connection with this Agreement will be determined in accordance with inventorship. Inventorship
of all Intellectual Property will be determined in accordance with the applicable patent laws of the United States. 
 9.5.6 TDTx
Owns. TDTx shall own all right, title and interest in all TDTx Intellectual Property conceived by employees, contractors or other individuals working for the benefit of TDTx and/or its Affiliates, either solely or jointly, during and in the
course of the Agreement, including any intellectual property that is an improvement of, modification of, or derivative of, any TDTx Intellectual Property; provided, however, that the provisions of Section 18.1 on MEE Policy
requirements shall apply with respect to any intellectual property generated by any consultant engaged by TDTx under a consulting agreement if such consultant is an employee or faculty member of MEE. 

ARTICLE 10 
 PATENT
INFRINGEMENT AND ENFORCEMENT 
 10.1 Notice. If any Party learns of an infringement, unauthorized use, misappropriation or
ownership claim or threatened infringement or other such claim in the Field of Use by a Third Party with respect to any Licensed Intellectual Property, such Party shall promptly notify the other Parties and shall provide available evidence of such
infringement. Any such infringement, unauthorized use, misappropriation or ownership claim or threatened infringement or other such claim is referred to herein as “Infringement”. 

10.2 Enforcement. 

10.2.1 Procedure. MEE shall have the first right, but not the duty, to institute Infringement actions against Third Parties. If
MEE does not initiate efforts to cease such Infringement or institute an Infringement proceeding against an offending Third Party within [***] after being notified or otherwise learning of such Infringement, TDTx shall have the right, but not the
duty, solely within the Field of Use, to initiate efforts to cease such Infringement or institute an Infringement proceeding against an offending Third Party with respect to any Infringement by such Third Party. If, within [***] from which it has a
right to initiate efforts to cease such Infringement or institute an. Infringement proceeding against an offending Third Party, TDTx does not initiate efforts to cease such Infringement or institute an Infringement proceeding, then Lonza shall have
the right, but not the duty, to initiate efforts to cease such Infringement or institute an Infringement proceeding against the offending Third Party. Before TDTx commences any legal proceeding with respect to the Infringement, TDTx shall consider
in good faith the views of MEE, [***]. If requested by TDTx, Lonza and/or MEE will join, such proceeding as a party-plaintiff if such joinder is required by law (as reasonably determined by TDTx) to maintain standing, at TDTx’s expense. 

10.2.2 TDTx’s Right to Join. TDTx shall have the right to join any legal proceeding brought by MEE and/or Lonza under this
Section 10.2 solely with respect to Infringements in the Field of Use and to fund a pro-rata share of the out-of-pocket
costs and expenses associated with the legal proceeding incurred by the party leading the case (i.e., MEE and or Lonza, as the case may be), from the date of joining based on allocating an equal portion of such expenses to all parties (including any
Third Parties) joining in such proceeding. If TDTx elects to join as a party plaintiff pursuant to this Section 10.2.2, TDTx may jointly participate in the action with MEE and/or Lonza, as applicable, but where MEE is a party its counsel will
be lead counsel and where MEE is not a party but Lonza is a party, TDTx’s counsel will be lead counsel. 

  
 29. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 10.2.3 Lonza and MEE’s Right to Join. Lonza and MEE independently have
the right to join any Infringement proceeding that is brought by TDTx for the Field of Use as permitted under this Section 10.2 and shall be responsible for funding its pro rata portion of the out-of-pocket costs and expenses associated with the legal proceedings incurred by TDTx from the date of joining based on allocating an equal portion of such costs and expenses to TDTx, MEE, Lonza and any
Third Party joining in such proceeding, as applicable. If MEE and/or Lonza elect to join as a party plaintiff pursuant to this Section 10.2.3, MEE and/or Lonza may jointly participate in the action with TDTx, but TDTx’s counsel will be
lead counsel. 
 10.2.4 Cooperation. Each Party shall execute all necessary and proper documents, take such actions as shall
be appropriate to allow the other Party to institute and prosecute such Infringement actions and shall otherwise cooperate in the institution and prosecution of such actions (including, without limitation, consenting to being named as a nominal
party thereto) at the initiating Party’s request and expense. 
 10.2.5 Costs and Expenses. The costs and expenses of any
Infringement action (including fees of attorneys and other professionals) shall be borne by the Party instituting the action, or, if the Parties elect to cooperate in instituting and maintaining such action, such costs and expenses shall be borne by
the Parties in such proportions as set forth in Sections 10.2.2 and 10.2.3, as applicable. 
 10.2.6 Settlement. Regardless of
whether MEE and/or Lonza is joined or joins any Infringement proceeding initiated by TDTx pursuant to this Article 10, no settlement, consent judgment or other voluntary final disposition of the Infringement proceeding may be entered into without
the consent of MEE and Lonza unless such voluntary disposition (a) includes a full release of MEE’s and Lonza’s liability and no admission of guilt or other wrongdoing on the part of MEE or Lonza with respect to the claim(s) giving
rise to the legal proceeding, (b) provides for no obligations or liability on the part of MEE and Lonza and (c) does not adversely affect the validity or enforceability of the Ancestral Technology Patent Rights. For the avoidance of doubt,
for as long as it remains the exclusive licensee of the Licensed Intellectual Property, TDTx shall have the right, without MEE’s or Lonza’s consent, to grant Sublicenses, that meet the obligations of this Agreement, to Third Parties for
the purpose of settling litigation. 
 10.3 Distribution of Amounts Paid by Third Parties. Any award paid by Third Parties as
a result of such an Infringement action (whether by way of settlement or otherwise) solely with respect to the Field of Use shall be applied first to [***]. Any such amounts awarded [***]. 

10.4 Declaratory Judgment or Infringement Actions. In the event that any Third Party initiates an Infringement action in the
form of a declaratory judgment action or similar action alleging the invalidity or unenforceability of the Ancestral Technology Patent Rights, or if any Third Party brings an Infringement action against TDTx or its Affiliates, or Sublicensees
because of the exercise of the licenses granted under this Agreement (any of the foregoing actions, “Third Party Infringement Actions”), then TDTx shall have the right to defend such Third Party Infringement Action under its
own control and at its own expense; provided, however, that MEE and/or Lonza shall have the right to intervene and assume sole control of such defense, at its own expense. The Party in control of the defense of any Third Party
Infringement Action shall not enter into any settlement, consent judgment or other voluntary final disposition of any action under this Section 10.4 without the consent of MEE and the non-controlling
Party, unless such voluntary disposition (a) includes a full release of the MEE’s and the non-controlling Party’s liability and no admission of guilt or other wrongdoing on the part of MEE and
the non-controlling Party with respect to the claim(s) giving rise to the legal proceeding, (b) provides for no obligations or liability on the part of MEE and the
non-controlling Party, and (c) does not adversely affect the validity or enforceability of the Ancestral Technology Patent Rights. 

  
 30. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 10.5 Delegation. TDTx shall have the right to delegate any of its rights and
obligations under this Article 10 to any of its Sublicensees upon written notice to Licensors, in which case all references to TDTx, as they relate to such delegated rights and obligations, shall refer to the relevant Sublicensee. 

ARTICLE 11 
 TERM AND
TERMINATION 
 11.1 Term. Unless terminated earlier under the provisions of this Agreement, the term of this Agreement
(the “Term”) shall commence on the Effective Date and shall expire on the expiration date of the last to expire Royalty Term. 

11.2 Termination by Licensors. Licensors shall have the right to terminate this Agreement: 

11.2.1 if TDTx materially breaches any of its diligence obligations under Article 6 and TDTx has not cured such breach within [***]
after receiving written notice from Licensors; 
 11.2.2 In its entirety if TDTx fails to pay on schedule any milestone or royalty or
other payment not subject to a good faith dispute, which is payable with respect to a particular Licensed Product under Article 3 of this Agreement, and TDTx has not cured the default by making the required payment, together with interest due,
within [***] of receiving a written notice of default from Licensors requesting such payment, unless such failure is due to the failure of a Sublicensee to pay corresponding amounts due to TDTx under the relevant Sublicense Agreement, in which case
termination by Licensors shall only be effective if TDTx fails to cure such breach within [***] after receipt of such corresponding amounts from the relevant Sublicensee; 

11.2.3 (1) in its entirety, if TDTx or any of its Affiliates, or (ii) in part on a Licensed Product-by-Licensed Product basis, if a Sublicensee under the Ancestral Technology Patent Rights, in either case, (clauses (i) or (ii)) initiates or participates as a plaintiff in any legal,
administrative or declaratory action or proceeding in any jurisdiction that seeks to challenge the validity or enforceability of any of the Ancestral Technology Patent Rights (a “Patent Challenge”) and such Patent Challenge
is not required under a court order or subpoena and is not a defense against a claim, action or proceeding asserted by Lonza, MEE or their Affiliates or licensees against TDTx, its Affiliates, or its Sublicensees; provided, however,
Licensors may not terminate this Agreement if (a) such Patent Challenge is brought by a Sublicensee and (b) TDTx or any its Affiliates terminates such Sublicensee’s sublicense to the applicable Ancestral Technology Patent Right(s)
within [***] of Licensors providing notice to TDTx of such Patent Challenge; 
 11.2.4 In its entirety, if TDTx materially breaches
any of its obligations to procure and maintain insurance under Section 12.2, unless TDTx has cured the breach within [***] of receiving written notice from Licensors specifying the nature of the breach; 

11.2.5 In its entirety, if TDTx materially breaches any provision of this Agreement other than for the circumstances described as set
forth in Sections 11.2.1-11.2.4, if Licensors provide written notice to TDTx specifying the nature of the material breach, unless TDTx has cured the breach within [***] of receiving such written notice from
Licensors; or 
 11.2.6 In its entirety if TDTx becomes judicially declared insolvent or has a petition in bankruptcy filed for or
against it, unless (a) TDTx provides reasonable evidence to Licensors showing that it is no longer insolvent within [***] of receiving such termination notice from Licensors or (b) such bankruptcy petition is dismissed or resolved within
[***] of being filed. 
 Notwithstanding anything to the contrary, termination by Licensors pursuant to this Section 11.2 due to acts
or omissions of one or more Sublicensees shall be solely with respect to the Licensed Product(s) or the program relating to potential Licensed Products directed to the relevant biological target or transgene to which such Sublicensee(s) have rights
under the relevant Sublicense(s). 

  
 31. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 11.3 Termination by TDTx. TDTx shall have the right to terminate this
Agreement in its entirety, for any reason with or without cause, by giving Licensors [***] prior written notice. In the event that this Agreement is terminated by TDTx pursuant to this Section 11.3 due to a material breach of this Agreement by
Licensors, which breach remains uncured as of the effective date of termination, and without limiting TDTx’s rights under Section 3.14, TDTx shall also be entitled to set-off against any monies
payable to Licensors hereunder all amounts TDTx reasonably believes constitute its direct damages incurred by such breach, subject to final resolution or settlement in accordance with Sections 16.1 and/or 16.2, without prejudice to any and all of
TDTx’s rights to bring an action against Licensors for damages and any other available remedies in law or equity. In the event TDTx sets off amounts it reasonably believes constitute its direct damages incurred by such breach and, after a final
resolution or settlement of any dispute arising from such breach in accordance with Sections 16.1 and/or 16.2, the actual damages determined by the Parties or by the arbitrator, as the case may be, to have been incurred by TDTx are less than the
amounts so offset, TDTx shall promptly (and in any case within [***] of such final resolution) pay the difference to Licensors, plus interest at the rate of [***], calculated from and after the date TDTx exercised its right to set-off such amount. 
 11.4 Material Breach Dispute. Any dispute regarding an alleged
material breach of this Agreement shall be resolved in accordance with Article 16 hereof. Notwithstanding anything to the contrary contained in Section 11.2 or elsewhere in the Agreement, the applicable cure period for any alleged breach that
is in dispute shall be tolled pending the resolution of such dispute pursuant to Article 16, and it is understood and acknowledged that, during the pendency of a dispute pursuant to Article 16, all of the terms and conditions of this Agreement shall
remain in effect, and the Parties shall continue to perform all of their respective obligations under this Agreement. 
 11.5
Effect of Termination. 
 11.5.1 Expiration of Royalty Term. Upon expiration of the Royalty Term in a particular
country for any Licensed Product ([***]), the license granted to TDTx under this Agreement with respect to such Licensed Product and only for such Licensed Product will become irrevocable, perpetual, and fully-paid in that country and shall remain
exclusive in that country. TDTx shall have no further obligations under Article 6 with respect to such Licensed Product in that country. 

11.5.2 Termination of License Rights. Upon termination of this Agreement for any reason with respect to all Licensed Products,
the Agreement shall be terminated in its entirety and all license rights granted under Section 2.1 shall terminate immediately and automatically upon the effective date of such termination. 

11.5.3 No release. Upon termination of this Agreement for any reason, nothing in this Agreement may be construed to release any
Party from any obligation that accrued prior to the effective date of the termination. 
 11.5.4 Survival. The following
provisions shall survive any expiration or termination of this Agreement for any reason: [***]. 
 11.5.5 Inventory. TDTx and
any Affiliate(s) may, after the effective date of termination for any or all Licensed Transgenes, sell all Licensed Products for such Licensed Transgenes that are in inventory as of the date of written notice of termination, and complete and sell
Licensed Products for such Licensed Transgenes which TDTx can clearly demonstrate were in the process of manufacture as of the date of written notice of termination, provided that TDTx shall pay to Licensors the royalties thereon as required
by Article 3 and shall submit the reports required by Article 4 on the sales of Licensed Products. 
 11.5.6 License Survival.
In the event of any termination of the Amended and Restated Lonza-MEE Agreement, where such termination has not been caused by any action or inaction on the part of TDTx, or any of its Affiliates or
Sublicensees in connection with their sublicensing the Licensed Intellectual Property, such termination of the Amended and Restated Lonza-MEE Agreement resulting in the termination of this Agreement shall be
without prejudice to the rights of TDTx, and MEE shall, if requested by TDTx, enter into a license agreement directly with TDTx (the “Replacement License Agreement”) on substantially the same terms and conditions as those set
forth in this Agreement; provided, however, that [***]. TDTx is named as a Third Party beneficiary of Section 8.8 of the Amended and Restated Lonza-MEE Agreement with the right to enforce it
directly against MEE. 
  

  
 32. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 11.5.7 Sublicense Survival. In the event of any termination of this Agreement
where such termination affects any Sublicense involving any Licensed Products, and such termination has not been caused by any action or inaction on the part of any Sublicensee of such Licensed Products and such Sublicensee is, as of the effective
date of such termination, current and fully compliant with all of its material obligations and with all of the terms and conditions of such Sublicense and is not otherwise in any uncured material breach of its obligations under its Sublicense from
TDTx (such Sublicensee, a “Compliant Sublicensee”), such termination of this Agreement shall be without prejudice to the rights of such Compliant Sublicensee of such Licensed Products of TDTx, and Licensors shall, if
requested in writing by the Compliant Sublicensee, within a period not to exceed [***] from the date of such written request, enter into good faith negotiations for a definitive license agreement directly with the Compliant Sublicensee (the
“Replacement Sublicense Agreement”) on substantially the same terms and conditions as those set forth in this Agreement; provided, however, that [***]. In the event that any such Replacement Sublicense involves
only a pass-through Sublicense of the same or substantially the same scope of sublicensed intellectual property and for the same or substantially the same licensed field of use for the sublicensed intellectual property rights to be granted to such
Compliant Sublicensee relative to the original Sublicense, and does not involve any additional material performance obligations or any other material obligations such as indemnification obligations or other obligations, liabilities, covenants, or
responsibilities for either MEE or Lonza other than the grant of the continued Sublicense rights under the same or substantially the same scope of licensed intellectual property comparable in scope and field to those rights that existed under the
Sublicense that was in place directly with TDTx, Licensors will enter into such Replacement Sublicense with such Compliant Sublicensee during such [***] negotiation period and will not have the right in such case to deny the grant of any such
Replacement Sublicense to any Compliant Sublicensee. 
 11.5.8 No Liability for Termination. Any termination pursuant to this
Article 11 shall be without any additional liability or obligation of the terminating party, other than with respect to any liability due to an uncured breach of this Agreement prior to termination. 

ARTICLE 12 

INDEMNIFICATION AND INSURANCE 

12.1 Indemnification. 

12.1.1 By TDTx 

(a) At TDTx’s sole expense, TDTx shall indemnify, defend and hold harmless (collectively, “indemnify” or
“indemnification”) each of MEE and Lonza, and each of their respective owners, members and Affiliates and their respective trustees, directors, officers, medical and professional staff, employees, students, volunteers, and agents and their
respective successors, heirs and assigns (the “Indemnitees”), against any and all liability, damage (including direct, indirect, consequential and special damages), loss or expense (including reasonable attorney’s fees
and expenses of litigation) (a “Loss”), incurred by or imposed upon the Indemnitees or any one of them in connection with any Third Party claims, suits, actions, investigations, demands or judgments relating to or arising
from, in whole or part: (i) any theory of product liability (including, but not limited to, actions in the form of contract, tort, warranty, or strict liability) concerning any Licensed Product, process or service made, used, sold or performed
pursuant to any right or license granted under this Agreement, or (ii) any claim by a Third Party that the use by TDTx or by any of its Affiliates or Sublicensees of any Licensed Product, process or service made, used or sold or performed
pursuant to any right or license granted under this Agreement infringes any patent, copyright or trade secret, or (iii) TDTx’s breach of its obligations under this Agreement; except to the extent that TDTx can demonstrate [***] that a Loss
as described in clause (i), (ii) or (iii) hereof directly results from the gross negligence or intentional misconduct of MEE or Lonza and/or the Indemnitees. 

  
 33. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (b) TDTx agrees, at its own expense, to provide attorneys reasonably acceptable to
Licensors on behalf of the Indemnitees to defend against any actions brought or filed against any party indemnified hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought;
provided, however, that any of the Indemnitees shall have the right to retain its own counsel, at the expense of TDTx, if representation of such Indemnitee by counsel retained by TDTx would be inappropriate because of conflict of
interests of any such Indemnitees and any other party represented by such counsel. TDTx agrees to keep Licensors informed of the progress in the defense and disposition of such claim and to consult with Licensors prior to any proposed settlement.

 (c) This Section shall survive expiration or termination of this Agreement. 

(d) Any limitation of liability within this Agreement shall not limit the extent of TDTx’s and its assigns’ and
successor’s indemnification obligations indicated within this Section. 
 (e) TDTx shall contractually obligate its
Sublicensees to the same or substantially the same indemnification obligations as set forth for TDTx in this Section. 
 12.1.2 By
Lonza. 
 (a) Lonza shall defend TDTx and its Affiliates and each of their respective employees, officers, directors and agents,
and their successors and assigns (“TDTx Indemnitees”) against any and all Claims to the extent [***] attributable to any breach by Lonza of its representations or warranties set forth in Section 14.2 or to the extent
[***] attributable to any uncured material breach by Lonza of this Agreement. Lonza shall indemnify (i.e., pay) any and all Losses finally awarded to such Third Party by a court of competent jurisdiction, or agreed to in monetary settlement, with
respect to any such Claims. Lonza’s obligations pursuant to this Section 12.1.2 shall not apply (i) to the extent that such Claims are subject to the indemnification obligations of TDTx under Section 12.1.1 or attributable to the
gross negligence or willful misconduct of any of the TDTx Indemnitees or MEE Indemnitees, (ii) to the extent that such Claim is attributable to the allegedly infringing use of any TDTx Intellectual Property, (iii) with respect to Claims
arising out of a breach by TDTx of its representations or warranties set forth in Section 13.1 or out of a breach by MEE of its representations set forth in Section 13.3 or (iv) the breach by TDTx or MEE of any of the other provisions
of this Agreement. For clarity, under no condition shall Lonza be responsible for indemnifying, defending or holding harmless MEE Indemnitees for any Claims arising under this Agreement or for indemnifying, defending or holding harmless TDTx for any
Claims arising under this Agreement, to the extent that any such Claim is attributable to the gross negligence or willful misconduct of any MEE Indemnitee or the breach by any MEE Indemnitee of any provision of this Agreement. 

12.1.3 Each indemnifying Party agrees, at its own expense, to provide attorneys reasonably acceptable to the applicable indemnified
Party to defend against any actions brought or filed against the Licensors Indemnitees or TDTx Indemnitees, as the case may be, with respect to the subject of indemnity contained herein. The assumption of control of the defense of a Claim by a Party
pursuant to Section 11.1 or 11.2, as applicable, shall not be construed as an acknowledgement that such Party is liable to indemnify the Licensors Indemnitees or TDTx Indemnitees (as the case may be) in respect of the Claim, nor shall it
constitute a waiver by such Party of any defenses it may assert against any claim for indemnification. In the event that it is ultimately determined that a Party that has undertaken to indemnify the Licensors Indemnitees or TDTx Indemnitees, as the
case may be, is not obligated to indemnify, defend or hold harmless such Licensors Indemnitees or TDTx Indemnitees, the other Party shall reimburse such Party for any and all costs and expenses (including reasonable lawyers’ fees and costs of
suit) and any Losses incurred by such Party in its defense of the Claim with respect to such the applicable indemnitee(s). 
 12.1.4
Each Party’s obligations under Section 11.1.1 or 11.1.2, as applicable, are contingent on the Licensors Indemnitee(s) or TDTx Indemnitee(s), as applicable, giving the indemnifying Party prompt, written notice of the Claim for which
indemnification is sought, primary control over the defense and/or settlement of the Claim, and all reasonably requested information and assistance in connection therewith. The Licensors Indemnitee(s) or TDTx Indemnitee(s), as applicable, shall be
entitled to participate in (but not control) such defense and/or settlement proceedings at their own cost and expense using counsel of their choosing. 

  
 34. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 12.2 Insurance. (a) Beginning at such time as any Licensed Product is
[***], by TDTx, an Affiliate or Sublicensee, TDTx shall, at its sole cost and expense, procure and maintain commercial general liability (herein, “CGL”) insurance [***]. Such limits of insurance may be achieved by primary
insurance policies alone or in combination with excess-liability and/or umbrella-liability insurance policies. [***] for TDTx’s indemnification under this Section. If TDTx’s CGL insurance does not include [***], TDTx shall, at its sole
cost and expense, procure and maintain [***]. Such limits of insurance may be achieved by [***]. Such insurance within this Section shall be primary, at MEE’s discretion, to any insurance maintained by MEE. If TDTx elects to [***]. The minimum
amounts of insurance coverage required under this Section shall not be construed to create a limit of TDTx’s liability with respect to its indemnification under this Section. 

(b) TDTx shall provide MEE, at its request, with written evidence of such insurance and the additional-insured status of the
Indemnitees. TDTx shall provide MEE with written notice at least [***] prior to the cancellation, non-renewal or material change in such insurance; if TDTx does not obtain replacement insurance providing
comparable coverage prior to the expiration of such [***] period, MEE shall have the right to terminate this Agreement effective at the end of such [***] period without notice or any additional waiting periods. 

(c) TDTx shall maintain such insurance, beyond the expiration or termination of this Agreement during (i) the period that any
such product, process, or service is [***]), by TDTx or by a licensee, affiliate or agent of TDTx and (ii) a reasonable period after the period referred to in (c) (i) above which in no event shall be less than [***]. 

(d) Insurance within this Section must be provided by commercial insurance companies with a [***]. 

(e) This Section shall survive expiration or termination of this Agreement. 

(f) Any limitation of liability within this Agreement shall not limit the extent of TDTx’s and its assigns’ and
successors’ insurance obligations indicated within this Section. 
 (g) TDTx shall contractually obligate any Sublicensees and
Distributors to the same insurance obligations as set forth for TDTx in this Section. 
 12.3 Disclaimer of Warranties; Limitation of
Liability 
 12.3.1 NEITHER LONZA NOR MEE MAKES ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTIES OF MERCHANTABILITY OR OF FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY PATENT, TRADEMARK, SOFTWARE, NON-PUBLIC OR OTHER INFORMATION, OR TANGIBLE RESEARCH PROPERTY, LICENSED OR OTHERWISE
PROVIDED TO TDTx HEREUNDER AND HEREBY DISCLAIMS THE SAME. 
 12.3.2 NEITHER LONZA NOR MEE WARRANTS THE VALIDITY OF THE ANCESTRAL
TECHNOLOGY PATENT RIGHTS LICENSED HEREUNDER NOR MAKES ANY REPRESENTATION WHATSOEVER WITH REGARD TO THE SCOPE OF THE ANCESTRAL TECHNOLOGY PATENT RIGHTS OR THAT SUCH ANCESTRAL TECHNOLOGY PATENT RIGHTS MAY BE EXPLOITED BY TDTx OR ITS AFFILIATE OR
SUBLICENSEE WITHOUT INFRINGING OTHER PATENTS. 

  
 35. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 12.3.3 EXCEPT WITH RESPECT TO ANY BREACH OF ARTICLE 8, NO PARTY, NOR THEIR DIRECTORS,
OFFICERS, EMPLOYEES, OR AGENTS, SHALL BE LIABLE TO THE OTHER WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT FOR ANY INDIRECT, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES, INCLUDING INCIDENTAL, ECONOMIC DAMAGES OR LOST PROFITS, EVEN IF SUCH
PARTY HAS BEEN INFORMED, SHOULD HAVE KNOWN OR IN FACT KNEW OF THE POSSIBILITY OF SUCH DAMAGES. 
 12.4 Acknowledgement. The
Parties acknowledge and agree that they are entering into this Agreement in reliance upon the exclusions and limitations set forth in this Article 12, and that the same reflect an allocation of risk ([***]) and that the same form an essential basis
of the bargain between the Parties. 
 12.5 Article Survival. This Article shall survive expiration or termination of this
Agreement. 
 ARTICLE 13 

REPRESENTATIONS AND WARRANTIES 

13.1 TDTx’s Representations and Warranties. TDTx represents and warrants to Licensors that: (a) it is
and shall be at all times during the Term a valid legal entity existing under the law of its state with the power to carry on its business as it is currently being conducted; (b) the execution and delivery of this Agreement has been duly
authorized and no further approval, corporate or otherwise, is required in order to execute this valid, binding and enforceable Agreement; and (c) its execution, delivery, and performance of this Agreement shall not conflict in any material
fashion with the terms of any other agreement or instrument to which it is or becomes a party or by which it is or becomes bound. 

13.2 Lonza’s Representations and Warranties and Covenants. Lonza represents and warrants to TDTx that, to the
best of the knowledge of the responsible individuals at Lonza, without having conducted any special inquiry or additional review: (a) it is and shall be at all times during the Term a valid legal entity existing under the law of its state with
the power to carry on its business as it is currently being conducted; (b) the execution and delivery of this Agreement has been duly authorized and no further approval, corporate or otherwise, is required in order to execute this valid,
binding and enforceable Agreement; (c) it is not a party to any agreement that is inconsistent or in conflict with the rights and licenses granted to TDTx hereunder; (d) its execution, delivery and performance of this Agreement shall not
conflict with the terms of any other agreement to which it is a party or by which it is bound; (e) as of the Effective Date, that there are no patents or patent applications, other than the Ancestral Technology Patent Rights, owned or otherwise
Controlled by Lonza the claims of which read on any claims in the Licensed Intellectual Property; (f) as of the Effective Date, no claims have been asserted or threatened against Lonza, nor are there any valid grounds for any claim of any such
kind (1) challenging the validity, effectiveness, or ownership of the Licensed Intellectual Property, and/or (2) to the effect that the use, development or commercialization of Licensed Products using the Licensed Intellectual Property as
contemplated for TDTx under this Agreement infringes or will infringe or misappropriate any intellectual property right of any Third Party; and (g) as of the Effective Date, the Ancestral Technology Patent Rights are not the subject of any
litigation procedure, interference, reissue, reexamination, opposition, appeal proceedings or any other formal legal proceeding. Lonza shall not exercise any right it may have to terminate the Amended and Restated
Lonza-MEE Agreement or otherwise materially amend or modify the Amended and Restated Lonza-MEE Agreement in a way that materially adversely affects TDTx’s rights
hereunder with respect to the Licensed Intellectual Property without the prior written consent of TDTx. 

  
 36. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 13.3 MEE’s Representations. MEE agrees that, to the best of
the knowledge of the responsible individuals at MEE’s Office of Innovation as of the Effective Date, without having conducted any special inquiry or additional review: (a) it is and shall be at all times during the Term a valid legal
entity existing under the law of its state with the power to carry on its business as it is currently being conducted; (b) the execution and delivery of this Agreement has been duly authorized and no ‘further approval, corporate or
otherwise, is required in order to execute this valid, binding and enforceable Agreement; (c) each individual listed as an inventor of the Ancestral Technology Patent Rights has assigned all of his or her rights, title and interests in and to
such Ancestral Technology Patent Rights to MEE pursuant to a binding written agreement between such inventor and MEE; (d) it is not a party to any agreement that is inconsistent or in conflict with the rights and licenses granted to TDTx
hereunder; (e) its execution, delivery and performance of this Agreement shall not conflict with the terms of any other agreement to which it is a party or by which it is bound; (f), no claims have been asserted or threatened against MEE in
writing (1) challenging the validity or ownership of the Licensed Intellectual Property, and/or (2) to the effect that the use, development or commercialization of Licensed Products using the Licensed Intellectual Property as contemplated
for TDTx under this Agreement infringes or will infringe or misappropriate any intellectual property right of any Third Party; and (g) the Ancestral Technology Patent Rights are not the subject of any litigation procedure, interference,
reissue, reexamination, opposition, appeal proceedings or any other formal legal proceeding. MEE shall not exercise any right it may have to terminate the Amended and Restated Lonza-MEE Agreement or to
otherwise materially amend or modify the Amended and Restated Lonza MEE Agreement in a way that materially adversely affects TDTx’s rights hereunder with respect to the Licensed Intellectual Property without the prior written consent of TDTx.

 ARTICLE 14 

NOTICES. 
 14.1
Notices to Lonza. Unless otherwise specified in this Agreement, reports, notices and other communications from TDTx or MEE to Lonza as provided hereunder must be sent to: 

Lonza Sales AG 
 Attn: Head of
Licensing 
 Muenchensteinerstrasse 38 CH-4402 

Basel, Switzerland 
 With a copy
to: 
 Assistant General Counsel 

Lonza America, Inc. 
 412 Mt
Kemble Ave. 
 Morristown, NJ 07960 

or other individuals or addresses as Lonza subsequently furnish by written notice to TDTx. 

14.2 Notices to MEE. Unless otherwise specified in this Agreement, reports, notices and other communications from Lonza or TDTx
to MEE as provided hereunder must be sent to: 
 Chief Innovation Officer, Innovation 

Massachusetts Eye and Ear Infirmary 

215 First Street, Suite 500 

Boston MA 02142 
 or other
individuals or addresses as MEE subsequently furnish by written notice to TDTx. 
 14.3 Notices to TDTx. Unless otherwise
specified in this Agreement, reports, notices and other communications from Lonza or MEE to TDTx as provided hereunder must be sent to: 

Chief Legal Officer 
 TDTx, Inc.

 One Broadway, 14`h Floor, Kendall Square 

Cambridge, MA 02142 
 or other
individuals or addresses as TDTx subsequently furnish by written notice to Licensors. 

  
 37. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 15 

DISPUTE RESOLUTION 

15.1 Negotiation between the Parties. The Parties shall first attempt to resolve any controversy or dispute that arises from or
under this Agreement, or any claim for a breach of the Agreement, by good faith negotiations during a [***] period for any payment based breach, and for a [***] period for any non-payment based breach, first
between their respective business development representatives. In the event that no agreement is reached with respect to such dispute during the applicable [***] or [***] period above after the commencement of such discussion, the matter shall be
referred to the Head of Licensing of Lonza, the President and CEO of MEE, and the CEO of TDTx (“Senior Executives”), who will discuss the matter in good faith and attempt to resolve it. 

15.2 Arbitration. Any dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination or
validity thereof, that is not resolved within [***] after its referral to the Senior Executives pursuant to Section 16.1, but excluding any dispute, controversy or claim concerning the validity, enforceability, infringement or misappropriation
of any intellectual property, shall be finally settled by binding arbitration conducted in the English language in [***] by a panel of three (3) neutral arbitrators under the commercial arbitration rules of the American Arbitration Association,
which shall administer the arbitration and act as the appointing authorities. Disputes about arbitration procedure shall be resolved by the arbitrators. The three arbitrators shall be agreed upon by each of the Parties and shall not be current or
former employees, directors, or current stockholders, of any Party and shall be free of any conflict of interest or any appearance of conflict of or any appearance of conflict of interest with respect to any Party, or any of their respective
Affiliates, or Sublicensees. The arbitrators shall be authorized to grant interim relief, including to prevent the destruction of goods or documents involved in the dispute, protect trade secrets and provide for security for a prospective monetary
award. Within [***] after selection of the arbitrator, the arbitrator shall conduct the preliminary conference. In addressing any of the subjects within the scope of the preliminary conference, the arbitrator shall take into account both the
desirability of making discovery efficient and cost-effective and the needs of the Parties for an understanding of any legitimate issue raised in the arbitration. In addition, each Party shall have the right to take up to [***] of deposition
testimony, including expert deposition testimony. The hearing shall commence within [***] after the selection of the arbitrator. The arbitrator shall, in his or her discretion, allow each Party to submit concise written statements of position and
shall permit the submission of rebuttal statements, subject to reasonable limitations on the length of such statements to be established by the arbitrator. The hearing shall be no longer than [***] in duration. The arbitrator shall also permit the
submission of expert reports. The arbitrator shall render his or her decision and award within [***] after the arbitrator declares the hearing closed, and the decision and award shall include a written statement describing the essential findings and
conclusions on which the decision and award are based, including the calculation of any damages awarded. The arbitrator will, in rendering his or her decision, apply the substantive law of the [***], without reference to its conflict of laws
principles, and, with respect to disputes concerning rights in Intellectual Property, the laws of the United States of America. The arbitrator’s authority to award special, incidental, consequential or punitive damages shall be subject to the
limitation set forth in Section 12.3. The decision and award rendered by the arbitrator shall be final, binding and non-appealable, and judgment may be entered upon it in any court of competent
jurisdiction. Each Party shall bear its own attorney’s fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the arbitrator. 

15.3 Governing Law. The construction, validity and performance of the Agreement shall be governed by and construed in accordance
with the internal laws of the [***], without giving effect to its conflicts of laws provisions ([***]). 

  
 38. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 16 

FORCE MAJEURE 
 Any delay
in the performance of any of the duties or obligations of any Party hereto (except the payment of money due hereunder) shall not be considered a breach of this Agreement, and the time required for performance shall be extended for a period equal to
the period of such delay, if such delay has been caused by or is the result of acts of God; acts of public enemy; insurrections; riots; injunctions; embargoes; labor disputes, including strikes, lockouts, job actions, or boycotts; fires; explosions;
earthquakes; floods; shortages of energy; governmental prohibition or restriction; or other unforeseeable causes beyond the reasonable control and without the negligence of the Party so affected. The Party so affected shall give prompt notice to the
other Parties of such cause, and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as reasonably possible. 

ARTICLE 17 

ASSIGNABILITY 
 This
Agreement shall be binding upon the successors and assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of its successors and assigns. No Party may assign its interest under this Agreement without the
prior written consent of the other Parties, such consent not to be unreasonably withheld, conditioned or delayed; provided, however, that any Party shall be entitled, without the requirement to obtain any consent of the other Parties,
to assign this Agreement in its entirety to an Affiliate, or to the acquirer or transferee of all or substantially all of its business or assets pertaining to this Agreement, or to a successor or transferee of a controlling interest in the capital
stock of such Party, whether through purchase, merger, consolidation or other business combination, change of control or otherwise. Notwithstanding the preceding sentence, [***]. Any permitted assignment or transfer of this Agreement by any Party
will be conditioned upon that Party’s permitted assignee agreeing in writing to comply with all the terms and conditions contained in this Agreement and, in the case of assignment or transfer by Lonza or MEE, Lonza’s or MEE’s
permitted assignee assuming sole and exclusive Control of the Licensed Intellectual Property. Any purported assignment in violation of the foregoing will be void ab initio. No assignment shall relieve any Party of responsibility for the performance
of any obligations that accrued prior to the effective date of such assignment except to the extent they are performed by the relevant assignee in accordance with this Agreement. 

ARTICLE 18 

MISCELLANEOUS 
 18.1
MEE Policies. TDTx acknowledges that MEE’s employees and medical and professional staff members and the employees and staff members of MEE’s Affiliates are subject to the applicable policies of MEE and such Affiliates, including,
without limitation, policies regarding conflicts of interest, intellectual property and other matters. TDTx shall provide MEE with any agreement it proposes to enter into with any employee or staff member of MEE or any of MEE’s Affiliates for
MEE’s prior review and shall not enter into any oral or written agreement with such employee or staff member which conflicts with any such policy. MEE shall provide TDTx, at TDTx’s request, with copies of any such policies applicable to
any such employee or staff member. TDTx and MEE shall execute a side letter agreement in parallel with the execution of this Agreement, allowing MEE’s rights in any [***] under any consulting agreement(s) entered into between [***] and [***],
and any Patent Rights and Know-How directed thereto to be added, at no additional cost to TDTx, to the Licensed Intellectual Property exclusively licensed to TDTx under Section.2.1 of this Agreement. In
addition, to the extent that TDTx enters into any future [***], the Parties expect that TDTx and MEE will assess the situation in good faith, and, if appropriate under then-applicable MEE policies, enter into a side letter agreement similar to that
described above [***], and any Patent Rights and Know-How directed thereto to be added, at no additional cost to TDTx, to the Licensed Intellectual Property exclusively licensed to TDTx under Section 2.1
of this Agreement. 

  
 39. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 18.2 Relationship of Parties. Nothing in this Agreement is intended or shall
be deemed to constitute a partnership, agency, employer-employee or joint venture relationship between the Parties. No Party shall incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided herein.

 18.3 Further Actions. Each Party shall execute, acknowledge and deliver such further instruments, and do all such other
acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 18.4 Use of Name;
Publicity. Neither Party shall use the name of any other Party (the non-disclosing Party) or of any trustee, director, officer, staff member, employee, student or agent of the non-disclosing Party, or any logo, trade name or trademark of the non-disclosing Party or any adaptation thereof in any advertising, promotional or sales literature, publicity
or in any document employed to obtain funds or financing without the prior written approval of the Party or individual whose name is to be used. For [***], such approval shall be obtained from [***]. Without the prior written consent as required
above of the non-disclosing Party, such consent not to be unreasonably withheld or delayed, no Party shall make any public announcement concerning this Agreement or the subject matter hereof; provided
however, that nothing in this Section 18.4 shall prevent any Party from the disclosure of any content which is not different from the content previously disclosed in any publicity or press release already approved by the Parties under
this Section 18.4, or from issuing statements that such Party determines to be necessary to comply with applicable law (including any stock exchange on which securities issued by such Party are traded), and provided further, that a Party
may refer to any existing publications in the scientific literature by a Party. 
 18.5 Waiver. A waiver by any Party of any
of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a waiver of such term of condition for the future, or of any subsequent breach hereof. All rights, remedies, undertakings, obligations and
agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of any Party. 

18.6 Severability. When possible, each provision of this Agreement will be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the
remainder of this Agreement. 
 18.7 Amendment. No amendment, modification or supplement of any provisions of this Agreement
shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 
 18.8 Entire
Agreement. This Agreement together with the Stock Grant Agreement(s) and the Schedules hereto sets forth the entire agreement and understanding between Licensors and TDTx as to the subject matter hereof and supersedes any and all prior
discussions and negotiations between them, and no Party shall be bound by any conditions, definitions, warranties, understandings or representations with respect to such subject matter other than as expressly provided herein or as duly set forth on
or subsequent to the date hereof in writing and signed by a proper and duly authorized officer or representative of the Party to be bound thereby. 

18.9 Parties in Interest. All of the terms and provisions of this Agreement shall be binding upon, inure to the benefit of and
be enforceable by the Parties hereto and their respective permitted successors and assigns. 
 18.10 Descriptive Headings. The
descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement. 

  
 40. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 18.11 Counterparts. This Agreement may be signed in counterparts, each and
every one of which shall be deemed an original, notwithstanding variations in format or file designation which may result from the electronic transmission, storage and printing of copies of this Agreement from separate computers or printers.
Facsimile signatures shall be treated as original signatures. 
 18.12 No Presumption. The Parties agree that they have
participated equally in the formation of this Agreement and that the language herein should not be presumptively construed against either of them. 

18.13 Interpretation. The words “include,” “includes” and “including” shall be deemed to be
followed by the phrase “without limitation.” All references herein to Articles, Sections, and Schedules shall be deemed references to Articles and Sections of, and Schedules to, this Agreement unless the context shall otherwise require.
Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or).
Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. Each Party represents that it has been represented by legal counsel or has voluntarily waived representation by legal counsel in
connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which
drafted such terms and provisions. Unless the context otherwise requires, countries shall include all territories and possessions. 
 * * *

  
 41. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date above.

  

			
	TDTx INC.
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	CEO
	
	LONZA HOUSTON, INC.
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Global Head of Intellectual Property
	
	MASSACHUSETTS EYE AND EAR INFIRMARY
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Managing Director, Licensing
	
	THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Managing Director, Licensing

  

SIGNATURE PAGE TO LICENSE AGREEMENT 

 Schedule A 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Schedule B 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 schedule C 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Schedule D 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Schedule E 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Schedule F 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Schedule G 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Schedule H 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.EX-10.2

 Exhibit 10.2 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED 

BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

STRATEGIC COLLABORATION AND LICENSE AGREEMENT 

BETWEEN 
 VERTEX
PHARMACEUTICALS INCORPORATED 
 AND 

AFFINIA THERAPEUTICS INC. 

 STRATEGIC COLLABORATION AND LICENSE AGREEMENT 

This Strategic Collaboration and License Agreement (this “Agreement”) is entered into as of April 14, 2020 (the
“Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a corporation organized under the laws of The Commonwealth of Massachusetts (“Vertex”), and Affinia Therapeutics Inc., a corporation organized
under the laws of Delaware with a place of business at 100 Beaver Street, Waltham, MA 02453 (“Company”). Vertex and Company each may be referred to herein individually as a “Party” or collectively as the
“Parties.” 
 RECITALS 

WHEREAS, Company owns or controls certain Patents and Know-How relating to the discovery of
adeno-associated virus (“AAV”) capsids; 
 WHEREAS, Vertex is a biopharmaceutical company that possesses expertise
in developing and commercializing human therapeutics; 
 WHEREAS, Vertex and Company desire to enter into this Agreement, pursuant to
which the Parties will collaborate in the discovery and characterization of novel AAV Capsids for certain diseases (as specified herein); and 

WHEREAS, Vertex desires to obtain from Company, and Company desires to grant to Vertex, an exclusive license to certain AAV Capsids
Controlled by Company for use in DMD and DM1 (each as defined below), and exclusive licenses to certain other AAV Capsids Controlled by Company for use in Cystic Fibrosis and [***], which licenses with respect to Cystic Fibrosis and [***] may not be
practiced by Vertex until the exercise of the relevant Option and the payment of the relevant Option fee (as set forth below). 
 NOW,
THEREFORE, in consideration of the respective covenants, representations, warranties and agreements set forth herein, the Parties hereto agree as follows: 

ARTICLE 1. 
 DEFINITIONS

 For purposes of this Agreement, the following capitalized terms will have the following meanings: 

 

	 	1.1.	 “AAA” has the meaning set forth in Section 11.12.2. 

 

	 	1.2.	 “AAV” has the meaning set forth in the preamble hereto. 

 

	 	1.3.	 “AAV [***] Capsids” means any Capsid that is Covered by the AAV [***] Patent.

  

	 	1.4.	 “AAV [***] Patent” means the PCT Patent [***]. 

 

	 	1.5.	 “Acquisition Transaction” has the meaning set forth in Section 4.8.

  
 1 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.6. “Adverse Event” has the meaning set forth in the Applicable Law for
such term (or comparable term), and will generally mean any untoward medical occurrence in a subject in any Clinical Trial or patient who has received a Product, medical device or placebo, and which does not necessarily have a causal relationship
with such Product, medical device or placebo, including any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of the applicable Product, medical device or placebo
whether or not related to such Product, medical device or placebo. 
 1.7. “Affiliate” means, as of any point in time and
for so long as such relationship continues to exist with respect to any Person, any other Person that controls, is controlled by or is under common control with such Person. A Person will be regarded as in control of another Person if it
(a) owns or controls, directly or indirectly, more than 50% of the equity securities of the subject Person entitled to vote in the election of directors (or, in the case of a Person that is not a corporation, for the election of the
corresponding managing authority), or (b) possesses, directly or indirectly, the power to direct or cause the direction of the management or policies of such Person (whether through ownership of securities or other ownership interests, by
contract or otherwise). 
 1.8. “Agreement” has the meaning set forth in the Preamble. 

1.9. “Agreement Know-How” means any Know-How
discovered, developed, invented or created solely by a Party or jointly by the Parties (or its or their Affiliates or Third Parties acting on its or their behalf), in each case, in the performance of activities under the Research Programs. 

1.10. “Alliance Manager” has the meaning set forth in Section 3.3.1. 

1.11. “Amended and Restated Lonza-MEE Agreement” means that certain License,
Collaboration and Commercialization Agreement, originally entered into as of [***] and amended and restated as of September 9, 2019, by and between MEE, Lonza and The Schepens Eye Research Institute, Inc. 

1.12. “Ancestral Libraries” means, collectively, all AAV capsid compositions of matter that are Covered by the
“Ancestral Technology Patent Rights” as such term is defined in the MEE/Lonza 3-Way Agreement. 

1.13. “Applicable Law” means all applicable laws, statutes, rules, regulations and other pronouncements having the effect of
law of any federal, national, multinational, state, provincial, county, city or other political subdivision, agency or other body, domestic or foreign, including any applicable rules, regulations, guidelines, or other requirements of the Regulatory
Authorities that may be in effect from time to time. 
 1.14. “Approval Application” means a BLA or similar application or
submission for a Product filed with a Regulatory Authority in a country or group of countries to obtain marketing approval for a biological or pharmaceutical product in that country or group of countries. 

1.15. “Arbitration Notice” has the meaning set forth in Section 11.12.2. 

  
 2 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.16. “BLA” means a Biological License Application that is submitted to the
FDA for marketing approval for a Product pursuant to 21 C.F.R. § 601.2. 
 1.17. “Blocking Third Party Intellectual
Property” means, with respect to a Capsid or Product in any country, [***] in such country owned or controlled by a Third Party that Cover [***] the composition of matter, method of treatment or use (as set forth in the applicable
Regulatory Authority-approved labeling) or Manufacture of such Product or Capsid that [***] for the [***] Manufacture or Commercialization of such Product or Capsid within the Field in such country. 

1.18. “Blocking Third Party Intellectual Property Costs” means Out-of-Pocket Costs, comprising [***] payments arising out of the [***] Manufacture or Commercialization of a Capsid or Product within the Field, in each case solely to the extent attributable to the [***]
Manufacture or Commercialization of such Capsid or Product within the Field, and paid by Vertex or one of its Affiliates to a Third Party ([***]) who owns or controls Blocking Third Party Intellectual Property to license or acquire rights to the
relevant Patents or Know-How; provided that, [***]. In the event that a license agreement for Blocking Third Party Intellectual Property includes rights to one of more Vertex Diseases included in the
Field and a specified number of additional disease fields, then the attributable portion of any payment included in Blocking Third Party Intellectual Property Costs under such license agreement would be [***]. In the event that a license agreement
for Blocking Third Party Intellectual Property does not specify [***] in the scope of rights granted, then the Parties would mutually agree upon a [***]. 

1.19. “Breaching Party” means the Party that the other Party believes is in material breach of this Agreement. 

1.20. “Business Day” means a Monday, Tuesday, Wednesday, Thursday or Friday that is not a day on which banking institutions
in Boston, Massachusetts are authorized or obligated to close. 
 1.21. “Calendar Quarter” means the respective periods of
three consecutive calendar months ending on March 31, June 30, September 30 or December 31, during the Term, or the applicable part thereof during the first or last calendar quarter of the Term. 

1.22. “Calendar Year” means any calendar year ending on December 31, or the applicable part thereof during the first or
last year of the Term. 
 1.23. “Capsid” means (a) any AAV capsid Controlled by Company on the Effective Date or at
any time prior to the [***]), and (b) all improvements to the foregoing Controlled by Company or created by or on behalf of Vertex and its Affiliates or Sublicensees at any time during the Term; provided that, solely with respect to the
foregoing (b), any improvements arising after the [***] shall be included hereunder as a “Capsid” solely to the extent that [***]. For the avoidance of doubt, Capsid includes all AAV [***] Capsids and any other AAV capsid described in the
AAV [***] Patent. For all purposes under this Agreement, the determination of whether an AAV capsid is an “improvement” to an existing Capsid that is included under sub-part (a) of this
Section 1.21 will be made on a capsid-by-capsid basis, based on an assessment of whether such existing Capsid included under
sub-part (a) was used or modified to identify the improved capsid qualifying as a Capsid under sub-part (b) of this Section 1.21. 

  
 3 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.24. “CDA” has the meaning set forth in Section 1.45. 

1.25. “CF Option Exercise Period” has the meaning set forth in Section 4.2.1. 

1.26. “CF Option Fee” has the meaning set forth in Section 4.2.1. 

1.27. “Change of Control” means, with respect to a Party, (a) a merger or consolidation of such Party with a Third Party
that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent more than 50% of the combined voting power of the
surviving entity or the parent of the surviving entity immediately after such merger or consolidation, (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner of
more than 50% of the combined voting power of the outstanding securities of such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of such Party’s business to which the subject matter of this Agreement
relates. Notwithstanding the foregoing, with respect to Company, the term “Change of Control” [***]. 
 1.28. “Clinical
Trial” means a study in humans that is required to be conducted in accordance with GCP and is designed to generate data in support of an Approval Application. 

1.29. “Combination Product” has the meaning set forth in Section 1.108. 

1.30. “Commercialize” or “Commercializing” means to (a) market, promote, distribute, offer for sale,
sell, have sold, import, export or otherwise commercialize a Product, (b) conduct activities, other than Research, Development and Manufacturing, in preparation for the foregoing activities, including obtaining Price Approval or
(c) conduct post-Marketing Approval studies (including Clinical Trials). When used as a noun, “Commercialization” means any activities involved in Commercializing. 

1.31. “Commercially Reasonable Efforts” means with respect to the efforts to be expended by any Person, with respect to any
objective, reasonable, diligent and good faith efforts to accomplish such objective. With respect to any objective relating to the Research, Development, Manufacture or Commercialization of a Capsid or Product by Vertex hereunder, “Commercially
Reasonable Efforts” (a) means that level, caliber and quality of efforts and resources reasonably and normally used by [***], as to a potential or actual product that is important to such [***] overall strategy or objectives, taking into
account, with respect to each Capsid or Product, [***], and (b) will be determined on a country-by-country basis and [***]. 

1.32. “Common Ownership Legislation” means the legislation on Conditions for patentability; novelty, as codified at 35 U.S.C.
§ 102(c) (Common Ownership Under Joint Research Agreements). 
 1.33. “Company” has the meaning set forth in the
Preamble. 
 1.34. “Company Agreement Know-How” has the meaning set forth in
Section 6.1.1. 

  
 4 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.35. “Company Agreement Patents” has the meaning set forth in
Section 6.1.1. 
 1.36. “Company Agreement Technology” has the meaning set forth in Section 6.1.1. 

1.37. “Company Breach Event” has the meaning set forth in Section 9.2.2(a). 

1.38. “Company Indemnified Party” has the meaning set forth in Section 8.1. 

1.39. “Company In-License Agreements” means (i) any agreements between Company
and Third Party licensors or sellers pursuant to which Company has acquired or in-licensed any rights in the Licensed Technology as of the Effective Date, and (ii) any New Company Agreements. The Company In-License Agreements existing as of the Effective Date are set forth on Schedule 1.39 hereto. 

1.40. “Company Inventions” has the meaning set forth in the MTA. 

1.41. “Company Platform” means, collectively, the proprietary technology platform Controlled by Company at any time during
the Term for use in [***], in each case ((i) – (iii)) that does not [***] a Vertex Disease and was not generated by Vertex. For clarity, Company Platform will not include [***]. 

1.42. “Comparator Study” means a non-human primate study meeting the criteria set
forth on Schedule 1.42. 
 1.43. “Competitive Infringement” has the meaning set forth in Section 6.4.1. 

1.44. “Competitive Product” means, with respect to a particular Product in a particular country, a product on the market in
such country commercialized by any Third Party that is not a Sublicensee and that did not purchase such product in a chain of distribution that included any of Vertex or its Affiliates or Sublicensees, that (a) is [***], or (b) is [***].

 1.45. “Confidential Information” means, with respect to each Party, all Know-How
or other information, including proprietary information (whether or not patentable) regarding or embodying such Party’s technology, products, business information or objectives, that is communicated in any way or form by or on behalf of the
Disclosing Party to the Receiving Party or its permitted recipients, pursuant to this Agreement or that certain Confidentiality Agreement between Vertex and Company dated [***] (the “CDA”), whether or not such Know-How or other information is identified as confidential at the time of disclosure. The terms of this Agreement will be considered Confidential Information of both Parties, with both Parties deemed to be the
Receiving Party of such Confidential Information. All information and data regarding Products generated after the Effective Date pursuant to activities contemplated by this Agreement, excluding any information and data that is specific to any of the
Capsids (which information and data will be deemed the Confidential Information of Company), will be deemed to be Vertex’s Confidential Information, and the exceptions set forth in clauses (a), (d) and (e) below will not apply to such
information and data. Notwithstanding any provision of this Section 1.45 to the contrary, Confidential Information does not include any Know-How or information that: (a) was already known by the
Receiving Party (other than under an obligation of confidentiality to the Disclosing Party) at the time of disclosure by or on behalf of the Disclosing Party; (b) was generally available to the public or otherwise part of the public domain at
the time of its disclosure to the Receiving Party; (c) became generally available to the public or otherwise part of the public domain after its disclosure to the Receiving Party, other than through any act or omission of the Receiving Party in
breach of its obligations under this Agreement or the CDA; (d) was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such
information to the Receiving Party; or (e) was independently discovered or developed by or on behalf of the Receiving Party without the use of or reference to any Confidential Information belonging to the Disclosing Party. Confidential
Information disclosed to the Receiving Party hereunder will not be deemed to fall within the foregoing exceptions merely because broader or related information falls within such exceptions, nor will combinations of elements or principles be
considered to fall within the foregoing exceptions merely because individual elements of such combinations fall within such exceptions. 

  
 5 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.46. “Control” or “Controlled” means, with respect to a
Party and to any Know-How, Patent, Regulatory Filings or Materials, possession of the ability by such Party or its Affiliate (whether by sole or joint ownership, license or otherwise) on the Effective Date or
at any time during the Term, other than pursuant to this Agreement, to grant, without violating the terms of any agreement with a Third Party, a license, access or other right in, to or under such Know-How,
Patent or Materials. Notwithstanding anything in this Agreement to the contrary, (a) any Know-How, Patent or Materials deemed “Controlled” by a Party on the Effective Date or at any time during
the Term will continue to be deemed “Controlled” by such Party for the remainder of the Term of this Agreement, and (b) a Party and its Affiliates will be deemed not to Control any Patents or
Know-How that are owned or controlled by a Third Party described in the definition of “Change of Control,” or such Third Party’s Affiliates (other than an Affiliate of such Party prior to the
Change of Control), (i) prior to the closing of such Change of Control, except to the extent that any such Patents or Know-How were developed by such Third Party prior to such Change of Control using or
incorporating such Party’s or its pre-existing Affiliate’s Know-How or Patents, or (ii) after such Change of Control to the extent that such Patents or Know-How are developed or conceived by such Third Party or its Affiliates (other than such Party) after such Change of Control without using or incorporating such Party’s or its
pre-existing Affiliate’s Know-How or Patents and are not developed or conceived by personnel who were employees or consultants of such Party or its pre-existing Affiliates. 
 1.47. “Cover,” “Covering” or
“Covers” means, as to a compound, composition, product or activity and Patent, that, in the absence of a license granted under, or ownership of, such Patent, the making, using, keeping, selling, offering for sale or importation of
such compound, composition or product or the conduct of such activity would infringe such Patent or, as to a pending claim included in such Patent, the making, using, keeping, selling, offering for sale or importation of such compound, composition
or product or the conduct of such activity would infringe such Patent if such pending claim were to issue in an issued patent without modification. 

1.48. “Development” means, with respect to a Capsid or Product, all clinical and
non-clinical research and development activities conducted after filing of an IND for such Capsid or Product, including [***]. When used as a verb, “Develop” or “Developing”
means to engage in Development. 
 1.49. “Disclosing Party” has the meaning set forth in Section 10.1. 

  
 6 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.50. “Dispute” has the meaning set forth in Section 11.12. 

1.51. “Distracting Product” means any product that is intended to treat, diagnose or prevent a Vertex Disease. 

1.52. “Distributor” means a Third Party to whom Vertex or its Affiliates or Sublicensees grant a right to sell or distribute
a Product, that purchases its requirements for such Product from Vertex or its Affiliates or Sublicensees, has no significant responsibility for marketing and promotion of the Product, and does not otherwise make any royalty or other payments to
Vertex or its Affiliates or Sublicensees with respect to its intellectual property rights or Products, including any payments that are calculated on the basis of a percentage of, or profit share on, such Third Party’s sale of Products. 

1.53. “Divest” means, with respect to a Distracting Product, the sale, exclusive license or other transfer by the applicable
Party and its Affiliates of all of their development and commercialization rights with respect to such Distracting Product to a Third Party without the retention or reservation of any development or commercialization obligation, interest or
participation rights (other than solely an economic interest or the right to enforce customary terms contained in the relevant agreements effectuating such transaction). 

1.54. “DM1” means Myotonic Dystrophy Type 1. 

1.55. “DMD” means Duchenne Muscular Dystrophy. 

1.56. “Effective Date” has the meaning set forth in the preamble. 

1.57. “EMA” means the European Medicines Agency and any successor entity thereto. 

1.58. “European Commission” means the European Commission or any successor entity that is responsible for granting marketing
approvals authorizing the sale of pharmaceuticals in the European Union. 
 1.59. “European Union” or “EU”
means (a) the economic, scientific and political organization of member states as it may be constituted from time to time, which as of the Effective Date consists of Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia,
Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and that certain portion of Cyprus included in such organization,
(b) any member country of the European Economic Area that is not otherwise a member of the European Union, and (c) any country not otherwise included in clauses (a) or (b) that participates in the unified filing system under the
auspices of the EMA. For purposes of this Agreement only, the United Kingdom shall be included in the “European Union” or “EU”. Further, for clarity, European Union will at all times be deemed to include each of
Italy, Germany, France and Spain. 
 1.60. “Executive Officers” means the [***] of Company, [***], and the [***] of Vertex,
[***]. 
 1.61. “Existing Third Party Option” has the meaning set forth in Section 2.1.2. 

  
 7 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.62. “FDA” means the United States Food and Drug Administration and any
successor entity thereto. 
 1.63. “FD&C Act” means the United States Federal Food, Drug, and Cosmetic Act, as amended,
and the rules and regulations promulgated thereunder. 
 1.64. “Field” means, separately and collectively, the diagnosis,
treatment or prevention of DMD, DM1, and, subject to the terms and conditions of Section 4.2, Cystic Fibrosis and [***]. 
 1.65.
“First Commercial Sale” means with respect to a Product, the first sale of such Product by Vertex, its Affiliate or its Sublicensee to a Third Party resulting in Net Sales in a particular country; provided that the following will
not constitute a First Commercial Sale: [***]. 
 1.66. “Force Majeure” means a condition, the occurrence and continuation
of which is beyond the reasonable control of a Party, including an act of God, governmental acts or restrictions, pandemic, war, civil commotion, labor strike or lock-out, epidemic, flood, failure or default
of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. 

1.67. “[***] Option Fee” has the meaning set forth in Section 4.2.2. 

1.68. “FTE” means [***] hours of work per annum devoted to or in support of the Research Activities that are carried out by
one or more qualified scientific or technical employees ([***]) of Company or its Affiliates. 
 1.69. “FTE Rate” means,
[***]; provided that such rates will increase or decrease on January 1 of each Calendar Year (starting with January 1, 2021) in accordance with [***]. 

1.70. “GAAP” means United States generally accepted accounting principles, consistently applied. 

1.71. “GCP” means good clinical practices, which are the then-current standards for Clinical Trials for pharmaceuticals, as
set forth in the FD&C Act or other Applicable Law, and such standards of good clinical practice as are required by the Regulatory Authorities of the European Union and other organizations and governmental authorities in countries for which the
applicable Capsid or Product is intended to be Developed, to the extent such standards are not less stringent than United States standards. 

1.72. “Gene Augmentation Modality” means the [***]. 

1.73. “Gene Editing Modality” means the [***]. 

1.74. “Gene Silencing/Other Modality” means [***]. 

1.75. “GLP” means the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21
C.F.R. Part 58, or comparable regulatory standards in jurisdictions outside of the United States, to the extent such standards are not less stringent than United States standards. 

  
 8 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.76. “GMP” means the then-current Good Manufacturing Practices as
specified in the United States Code of Federal Regulations, ICH Guideline Q7A, or equivalent laws, rules or regulations of an applicable Regulatory Authority at the time of manufacture. 

1.77. “Governmental Authority” means any court, agency, department, authority or other instrumentality of any national,
state, county, city or other political subdivision. 
 1.78. “Grantor” has the meaning set forth in Section 5.5.1.

 1.79. “IND” means any Investigational New Drug application filed with the FDA pursuant to Part 312 of Title 21 of the
U.S. Code of Federal Regulations or a similar application or submission for a Product filed with a Regulatory Authority in a country or group of countries. 

1.80. “IND Acceptance Date” means, after filing an IND for a Product with a Regulatory Authority, the 31st consecutive day on
which there is no clinical hold or similar adverse regulatory action with respect to such IND. 
 1.81. “Indemnified Party”
has the meaning set forth in Section 8.1.3. 
 1.82. “Indemnifying Party” has the meaning set forth in
Section 8.1.3. 
 1.83. “Initiation” or “Initiate” means, with respect to any Clinical Trial, dosing
of the first human subject in such Clinical Trial. 
 1.84. “Insolvency Event” has the meaning set forth in
Section 9.2.4. 
 1.85. “Joint Agreement Know-How” has the meaning set forth
in Section 6.1.3. 
 1.86. “Joint Agreement Patents” has the meaning set forth in Section 6.1.3. 

1.87. “Joint Agreement Technology” has the meaning set forth in Section 6.1.3. 

1.88. “JRC” has the meaning set forth in Section 3.1.1. 

1.89. “Know-How” means intellectual property, data, results, pre-clinical and clinical protocols and data from studies and Clinical Trials, chemical structures, chemical sequences, materials, information, inventions, know-how, formulas,
trade secrets, techniques, methods, processes, procedures and developments, whether or not patentable; provided that Know-How does not include Patents. 

1.90. “Knowledge” means, with respect to Company, the actual knowledge of [***] after having consulted with Company’s
external patent counsel. For clarity, [***]. 
 1.91. “Liability” has the meaning set forth in Section 8.1. 

1.92. “Library Expansion Election” has the meaning set forth in Section 2.1.2. 

  
 9 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.93. “Licensed Know-How” means any
Know-How Controlled by Company or its Affiliates (a) on the Effective Date, (b) that is related to a Capsid and arises after the Effective Date but before the [***], or (c) that is related to a
Capsid and arises after the [***], solely to the extent that the practice of such Know-How is Covered by the Licensed Patents (as such Licensed Patents exist immediately prior to such Know-How arising) [***], provided that such Licensed Patents or other Patents are Controlled by Company prior to the [***], in each case ((a)—(c)), that is necessary [***] to Research, Develop, Manufacture or
Commercialize Products in the Field, and with respect to the foregoing (b) and (c), to the extent that any such Know-How is Controlled by Company by virtue of a license from a Third Party, solely to the
extent that Vertex has elected to include such license as a New Company Agreement in accordance with Section 5.5. For the avoidance of doubt, the Licensed Know-How shall exclude the Reserved Library with
respect to DMD unless and until Vertex exercises the Library Expansion Election. 
 1.94. “Licensed Patents” means any
Patents, including Company Agreement Patents and Joint Agreement Patents, Controlled by Company or its Affiliates on or after the Effective Date that Cover the Licensed Know-How. A list of Licensed Patents as
of the Effective Date is set forth in Schedule 1.94. 
 1.95. “Licensed Technology” means the Licensed Patents and
Licensed Know-How. 
 1.96. “Licensed Trademarks” has the meaning set forth in
Section 2.5.2. 
 1.97. “Licensee” has the meaning set forth in Section 5.5.2. 

1.98. “Lonza” has the meaning set forth in Section 1.105. 

1.99. “Major EU Markets” means [***]. 

1.100. “Major Market Countries” means [***]. 

1.101. “Manufacture” or “Manufactured” or “Manufacturing” means activities directed to
making, having made, producing, manufacturing, processing, filling, finishing, packaging, labeling, quality control testing and quality assurance release, shipping or storage of a Capsid or Product. 

1.102. “Marketing Approval” means, with respect to a Product in a particular jurisdiction, all approvals ([***]), licenses,
registrations or authorizations necessary for the Commercialization of such Product in such jurisdiction, including, with respect to the United States, approval of an Approval Application for such Product by the FDA and with respect to the European
Union, approval of an Approval Application for such Product by the European Commission or the applicable Regulatory Authority in any particular country in the EU. 

1.103. “Materials” means all biological materials, chemical compounds and other materials arising out of a Party’s
activities under the Research Programs and provided by such Party to the other Party for use by the other Party or otherwise provided by a Party for use by the other Party, in each case, to conduct activities pursuant to the Research Programs,
including [***]. 
 1.104. “MEE” has the meaning set forth in Section 1.105. 

  
 10 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.105. “MEE/Lonza 3-Way Agreement”
means that certain Exclusive License Agreement entered into on September 9, 2019, by and between Company, Massachusetts Eye and Ear Infirmary (“MEE”) and Lonza Houston, Inc. (“Lonza”). 

1.106. “Modality” means a therapeutic method, consisting of the Gene Augmentation Modality, the Gene Editing Modality, or the
Gene Silencing/Other Modality. 
 1.107. “MTA” means the Material Transfer Agreement entered into by Company and Vertex on
[***] pursuant to which Company has provided to Vertex certain Materials (as defined therein) for Vertex to perform certain specified and limited Research and Manufacturing activities related thereto as expressly stated within such Material Transfer
Agreement, which activities shall be deemed conducted under the Research Programs hereunder. 
 1.108. “Net Sales” means
the gross invoiced price for Products sold by Vertex (including sales generated from named patient programs and excluding sales deferred for GAAP accounting purposes until such sales are recognized), its Affiliates or Sublicensees (the
“Selling Party”) to Third Parties, less the following deductions from such gross amounts: 
 (a) credits or allowances on
account of price adjustments, recalls, claims, damaged goods, rejections or returns of items previously sold (including Product returned in connection with recalls or withdrawals) and [***]; 

(b) import taxes, export taxes, excise taxes (including [***]), but only such portion [***], or government invoiced fees, sales taxes,
value-added taxes, consumption taxes, duties or other taxes levied on, absorbed, determined or imposed with respect to such sales (excluding income or net profit taxes or franchise taxes of any kind), [***]; 

(c) insurance, customs charges, freight, shipping and other transportation costs incurred in shipping Product to such non-related parties, to the extent [***]; 
 (d) discounts (including trade, quantity, cash discounts and
fees for services), cash and non-cash coupons, co-payment support programs, retroactive price reductions, and charge back payments and rebates granted to any non-related party (including [***]); 
 (e) rebates (or their equivalent), [***], chargebacks and
retroactive price adjustments [***]; and 
 (f) compulsory payments [***], provided that any such deduction [***]. 

Only items that are deducted from the Selling Party’s gross sales of Product(s), as included in the Selling Party’s published financial statements
and that are in accordance with GAAP, applied on a consistent basis, will be deducted from such gross sales for purposes of the calculation of Net Sales. Notwithstanding the foregoing, [***]. 

A qualifying amount may be deducted only once regardless of the number of the preceding categories that describes such amount. If a Selling Party makes any
adjustment to such deductions after the associated Net Sales have been reported pursuant to this Agreement, the adjustments and payment of any royalties due will be reported with a subsequent quarterly report. Sales between or among Vertex, its
Affiliates and Sublicensees will be excluded from the computation of Net Sales if such sales are not intended for end use, but Net Sales will include the subsequent final sales to Third Parties by Vertex or any such Affiliates or Sublicensees. A
Product will not be deemed to be sold if [***]. For clarity, Net Sales include [***]. 

  
 11 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 If a sale, transfer or other disposition with respect to a Product involves consideration other than cash or
is not at arm’s length, the Net Sales from such sale, transfer or other disposition will be [***]. 
 Solely for purposes of calculating Net Sales, if
Vertex or its Affiliates or any permitted Sublicensee sells a Product in the form of a combination product containing a Product and [***] that is not a Product (“Other Product”) ([***]) (such combination product, a
“Combination Product”), Net Sales of such Combination Product for the purpose of determining the payments due to Company pursuant to this Agreement will be calculated by [***]. If the gross selling price of a Product in such country
when sold separately in finished form (i.e., without the other active ingredients or delivery device) can be determined but the gross selling price of the Other Product in such country cannot be determined, Net Sales in such country for
purposes of determining royalty payments will be calculated by [***]. If such separate sales are not made in a country, Net Sales will be calculated by [***]. For the avoidance of doubt, [***]. 

1.109. “New Company Agreement” has the meaning set forth in Section 5.5.2. 

1.110. “New Technology” means (a) any Know-How that is Controlled by Company or
its Affiliates on the Effective Date or during [***] that is necessary [***] to Research, Develop, Manufacture or Commercialize Products in the Field, and (b) any Patents Covering the Know-How in the foregoing clause (a), in each case ((a) and
(b)), to the extent not included in the Licensed Technology. For clarity, [***]. 
 1.111.
“Non-Breaching Party” means the Party that believes the other Party is in material breach of this Agreement. 

1.112. “Option” has the meaning set forth in Section 4.2. 

1.113. “Option Exercise Data Package” has the meaning set forth in Section 4.2.2. 

1.114. “Other Product” has the meaning set forth in Section 1.108. 

1.115. “Out-of-Pocket Costs” means, with
respect to a Party, costs and expenses paid by such Party or its Affiliates to Third Parties ([***]), other than employees of such Party or its Affiliates. 

1.116. “Party” or “Parties” has the meaning set forth in the Preamble. 

1.117. “Patents” means the rights and interests in and to issued patents and pending patent applications in any country,
jurisdiction or region (including inventor’s certificates and utility models), including all provisionals, non-provisionals, substitutions, continuations, continuations-in-part, divisionals, renewals and all patents granted thereon, and all reissues, reexaminations, extensions, confirmations, revalidations, registrations and patents of addition thereof,
including patent term extensions and supplementary protection certificates, international patent applications filed under the Patent Cooperation Treaty (PCT) and any foreign equivalents to any of the foregoing. 

  
 12 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.118. “Person” means an individual, sole proprietorship, partnership,
limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political
subdivision or department or agency of a government. 
 1.119. “Phase 3 Clinical Trial” means any Clinical Trial as
described in 21 C.F.R. §312.21(c) (as amended from time to time), or, with respect to a jurisdiction other than the United States, a similar Clinical Trial. 

1.120. “Pivotal Clinical Trial” means (a) a Phase 3 Clinical Trial, or (b) any other Clinical Trial that is
determined by the applicable Regulatory Authority (as evidenced by written correspondence from such Regulatory Authority) prior to the Initiation of such Clinical Trial to be sufficient to form the basis for Regulatory Approval of the applicable
Product. 
 1.121. “Price Approval” means, in any country where a Governmental Authority authorizes reimbursement for, or
approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or determination. 

1.122. “Proceeding” means any action, suit, litigation, arbitration, proceeding (including any civil, criminal,
administrative, investigative or appellate proceeding), prosecution, contest, hearing, inquiry, inquest, audit, examination or investigation that is, has been or may in the future be commenced, brought, conducted or heard at law or in equity or
before any Governmental Authority. 
 1.123. “Product” means any pharmaceutical or biopharmaceutical product, medical
therapy, preparation, substance, or formulation comprising or employing, in whole or in part, (a) a Capsid or (b) any AAV capsid that is [***] and that incorporates the Licensed Technology. 

1.124. “Proposed New Company Agreement” has the meaning set forth in Section 5.5.1. 

1.125. “Prosecution and Maintenance” or “Prosecute and Maintain” means, with regard to a Patent, the
preparing, filing, prosecuting and maintenance of such Patent, as well as handling re-examinations and reissues with respect to such Patent, together with the conduct of interferences, derivation proceedings,
the defense of oppositions, post-grant patent proceedings (such as inter partes review and post grant review) and other similar proceedings with respect to the particular Patent. For clarification, “Prosecution and Maintenance” or
“Prosecute and Maintain” will not include any other enforcement actions taken with respect to a Patent. 
 1.126.
“Receiving Party” has the meaning set forth in Section 10.1. 

  
 13 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.127. “Regulatory Approval” means the technical, medical and scientific
licenses, registrations, authorizations and approvals (including approvals of Approval Applications, supplements and amendments, pre- and post- approvals, and labeling approvals) of any Regulatory Authority,
necessary for the research, development, clinical testing, commercial manufacture, distribution, marketing, promotion, offer for sale, use, import, export or sale of a pharmaceutical product in a regulatory jurisdiction, including Marketing Approval
but excluding Price Approval. 
 1.128. “Regulatory Authority” means, with respect to a country in the Territory, any
national (e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the EMA), regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Authority involved in
the granting of Regulatory Approvals or Price Approvals for pharmaceutical products in such country or countries. 
 1.129.
“Regulatory Filings” means, collectively: (a) all INDs, Approval Applications, establishment license applications, Drug Master Files, applications for designation as an “Orphan Product(s)” under the Orphan Drug Act,
for “Fast Track” status under Section 506 of the FD&C Act (21 U.S.C. § 356) or for a Special Protocol Assessment under Section 505(b)(4)(B) and (C) of the FD&C Act (21 U.S.C. § 355(b)(4)(B)) and all other
similar filings (including counterparts of any of the foregoing in any country or region in the Territory); (b) any applications for Regulatory Approval or Price Approval and other applications, filings, dossiers or similar documents submitted to a
Regulatory Authority in any country for the purpose of obtaining Regulatory Approval or Price Approval from that Regulatory Authority; (c) any Patent-related filings with any Regulatory Authority; (d) all supplements and amendments to any
of the foregoing; and (e) all data and other information contained in, and correspondence with any Regulatory Authority relating to, any of the foregoing. 

1.130. “Remainder” has the meaning set forth in Section 5.1.2. 

1.131. “Research” means conducting research activities to discover, design, optimize, deliver and advance Capsids and
Products, including pre-clinical studies and optimization, but specifically excluding Development, Manufacture and Commercialization. When used as a verb, “Researching” means to engage in
Research. 
 1.132. “Research Activities” means the activities with respect to the Research of Capsids to be conducted by
either Party or jointly by the Parties for each of Cystic Fibrosis, DMD and DM1 during the Research Term. 
 1.133. “Research
Extension” has the meaning set forth in Section 2.1.1. 
 1.134. “Research Program” means the program of
Research Activities for each of (a) Cystic Fibrosis and (b) DMD and DM1 (each of (a) and (b), a separate Research Program). 

1.135. “Research Term” means the period of time commencing upon the Research Term Effective Date and continuing until the
fifth anniversary thereof. 
 1.136. “Research Term Effective Date” has the meaning set forth in Section 5.1.2. 

1.137. “Reserved Library” has the meaning set forth in Section 2.1.2. 

1.138. “Residual Knowledge” means knowledge, techniques, experience and Know-How that
[***] by the Disclosing Party. 

  
 14 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.139. ”Results” has the meaning set forth in the MTA. 

1.140. “ROFN Notice” has the meaning set forth in Section 4.4. 

1.141. “Royalty Term” means, with respect to a Product in a country, the period commencing on the first sale of such Product
giving rise to Net Sales in such country and ending upon the later of: (a) the expiration of the last Valid Claim of a Licensed Patent that Covers such Product in such country; (b) 10 years after the First Commercial Sale of such Product in
such country; or (c) expiration of all applicable regulatory exclusivity periods, including data exclusivity, in such country with respect to such Product. 

1.142. “Rules” has the meaning set forth in Section 11.12.2(a). 

1.143. “Safety Data Exchange Agreement” has the meaning set forth in Section 2.8. 

1.144. “Selling Party” has the meaning set forth in Section 1.108. 

1.145. “Subcontractor” has the meaning set forth in Section 2.1.4. 

1.146. “Sublicense” means, directly or indirectly, to sublicense, grant any other right with respect to, or agree not to
assert, the rights granted to Vertex hereunder. When used as a noun, “Sublicense” means any agreement to Sublicense. 

1.147. “Sublicensee” means an Affiliate or Third Party, other than a Distributor, to whom Vertex (or a Sublicensee or
Affiliate) sublicenses any of the rights granted to Vertex hereunder during the Term. 
 1.148. “Term” has the meaning set
forth in Section 9.1. 
 1.149. “Territory” means worldwide. 

1.150. “Third Party” means any Person other than Vertex, Company or their respective Affiliates. 

1.151. “Third Party Infringement Claim” has the meaning set forth in Section 6.3. 

1.152. “Third Party Optionee” means that certain Third Party to whom [***]. 

1.153. “United Kingdom” means the United Kingdom of Great Britain and Northern Ireland. 

1.154. “United States” or “U.S.” means the United States of America and all of its districts, territories
and possessions. 
 1.155. “Upfront Fee” means an amount equal to Twenty Five Million US Dollars ($25,000,000). 

  
 15 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.156. “Valid Claim” means a claim (a) of any issued, unexpired United
States or foreign Patent, which has not, in the country of issuance, been donated to the public, disclaimed, held invalid or unenforceable by a court of competent jurisdiction in an unappealed or unappealable decision, or (b) of any United
States or foreign patent application, which has not, in the country in question, been cancelled, withdrawn, or abandoned. Notwithstanding the foregoing, on a
country-by-country basis, a patent application pending for more than [***] will not be considered to have any Valid Claim for purposes of this Agreement unless and until
a patent that meets the criteria set forth in clause (a) above with respect to such application issues. 
 1.157.
“Vertex” has the meaning set forth in the Preamble. 
 1.158. “Vertex Agreement
Know-How” has the meaning set forth in Section 6.1.2. 
 1.159. “Vertex
Agreement Patents” has the meaning set forth in Section 6.1.2. 
 1.160. “Vertex Agreement Technology” has
the meaning set forth in Section 6.1.2. 
 1.161. “Vertex Background Know-How”
means any and all Know-How Controlled by Vertex or its Affiliates (a) prior to the Effective Date, or (b) during the Term, to the extent invented, developed, acquired or created independently of the
activities performed under this Agreement. 
 1.162. “Vertex Background Patents” means any Patents Controlled by Vertex or
its Affiliates that Cover the Vertex Background Know-How. 
 1.163. “Vertex Background
Technology” means the Vertex Background Know-How and the Vertex Background Patents. 

1.164. “Vertex Diseases” means Cystic Fibrosis, DMD, DM1 and [***]; provided that if Vertex does not make a timely exercise
of the Option with respect to Cystic Fibrosis or with respect to [***] with respect to at least one Modality, then Cystic Fibrosis or [***], as applicable, will cease to be a Vertex Disease as of the date that each such Option expires pursuant to
Section 4.2. 
 1.165. “Vertex Indemnified Party” has the meaning set forth in Section 8.1.2. 

1.166. “Vertex Inventions” has the meaning set forth in the MTA. 

1.167. “VXc Nomination” means a determination by Vertex, in accordance with its internal policies and procedures consistently
applied, that [***]. 

  
 16 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 2. 

RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION 

2.1. Research. 

2.1.1. Research Activities. During the first two years of the Research Term, Company shall perform the Research Activities under
each Research Program in accordance with Section 2.1.3 and the other terms of this Agreement. Following the first two years of the Research Term, Vertex will have the right, in its sole discretion, to extend Company’s obligation to perform
Research Activities on a Research Program-by-Research Program basis for additional one-year periods at a cost of [***] per year
per Research Program, up to a total of three additional years for each Research Program (each, a “Research Extension”), by providing notice to Company no later than [***] before the expiration of the [***] year of the Research Term,
and thereafter, no later than [***] before the conclusion of each additional year for which Vertex has elected to extend Company’s obligations (as applicable); provided that, for any Research Extension, Vertex will have the right to
update the Capsid criteria set forth on Schedule 2.1.3 for the applicable Research Program, which update will be provided with the applicable notice of a Research Extension. Vertex will have the right to perform Research Activities for each
Research Program at any time during the Research Term, regardless of whether Company is also performing Research Activities pursuant to this Section 2.1.1; provided that, prior to Vertex’s exercise of the Option for Cystic Fibrosis,
Vertex’s activities with respect to the Research of Capsids for Cystic Fibrosis shall be limited to the evaluation of Capsids as set forth in Section 4.2.1, and any other activities agreed to by the Parties. 

2.1.2. Existing Third Party Option. The Parties acknowledge that, as of the Effective Date, Lonza Houston, Inc. has granted to
the Third Party Optionee an option to obtain an exclusive right and license to the Licensed Patents existing as of the Effective Date with respect to [***] (the “Reserved Library”) for the exploitation of products for the treatment,
diagnosis and prevention of DMD, which option expires on [***] (the “Existing Third Party Option”). In the event that the Existing Third Party Option expires or otherwise terminates with respect to all or a portion of the Reserved
Library, such that Company’s rights to Capsids included in the Reserved Library can be licensed to Vertex for DMD (in whole or in part), then Company shall promptly notify Vertex and Vertex will have [***] from such notice to determine whether
it wishes to include the Reserved Library within the scope of the Research Activities for DMD in the Research Program for DMD and DM1 (as being within the Capsid libraries Controlled by Company) (in whole or in part). Company shall provide to Vertex
any and all information in Company’s possession as Vertex may reasonably request during such [***] notice period to assist Vertex in determining whether to exercise the Library Expansion Election. In the event that Vertex elects during the Term
to include (a) such capsids in the Reserved Library and (b) all Know-How and Patents Controlled by Company related to such capsids, in each case, in the Licensed Technology, then Vertex shall notify
Company within such [***] period and together with such notice shall pay to Company a one-time, non-refundable, non-creditable
payment of Two Million Dollars ($2,000,000) (the “Library Expansion Election”); provided that, if Vertex provides notice to Company of such election during the Research Term and the Existing Third Party Option has only
terminated with respect to a portion of the Reserved Library at such time, no further payment shall be owed by Vertex if it subsequently provides an additional notice to Company of such election in the event that the Existing Third Party Option
subsequently terminates with respect to an additional portion of the Reserved Library; and provided further that, if Vertex provides notice to Company of such election after the conclusion of the Company’s Research Activities during the
Research Term for DMD and DM1, then the foregoing fee shall not be payable by Vertex but clauses (ii) and (iii) of the following sentence shall apply. In the event that Vertex makes the Library Expansion Election, (i) solely in the event
that the Library Expansion Election occurs after the conclusion of the Company’s Research Activities during the Research Term for DMD and DM1, then such Capsids shall be automatically included in the Capsids being Researched pursuant to
Company’s Research Activities for DMD, (ii) the capsids in the Reserved Library for which Vertex has made such election shall be deemed Controlled by Company and included in the Capsids hereunder for DMD, and (iii) the Patents and Know-How Controlled by Company related to the Reserved Library that would otherwise be included in the Licensed Technology for DMD but for the Existing Third Party Option shall be deemed to be included in the
Licensed Technology for DMD to the extent of Vertex’s election. 

  
 17 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.1.3. Conduct of the Research. 

(a) Research Efforts. On a Research
Program-by-Research Program basis, during the first two years of the Research Term, and continuing during any applicable Research Extension for such Research Program,
Company shall use Commercially Reasonable Efforts to Research and deliver Capsids to Vertex that meet the criteria set forth on Schedule 2.1.3 hereto (as such criteria may be amended by Vertex pursuant to Section 2.1.1) for such Research
Program, which Commercially Reasonable Efforts shall include [***]. Each Party, directly or through its Affiliates or permitted Subcontractors, will use Commercially Reasonable Efforts to conduct its Research Activities in a professional and timely
manner, and will, and will require its Affiliates and Subcontractors to, perform such Research Activities in compliance with all Applicable Laws. 

(b) Non-Human Primate Studies Research Costs. During the first two years of the
Research Term, if Company intends to initiate a Comparator Study in the Research Programs, then, subject to Vertex’s agreement to fund such study, Vertex and Company shall together design such Comparator Study, [***]. In the event that Vertex
declines to fund such study, then Company shall have no obligation to conduct such study as part of the applicable Research Program. Vertex shall reimburse Company on a Calendar Quarter basis for (i) the reasonable Out-of-Pocket Costs incurred by Company or Company’s Subcontractors, subject to Section 2.1.4 below, and (ii) Company’s approved internal costs at the FTE
Rate, in each case ((i) and (ii)) solely to the extent such costs are in accordance with the approved budget for such Comparator Study. Within [***] following the end of each Calendar Quarter, Company shall provide an invoice to Vertex for the costs
and expenses set forth in, and subject to, the foregoing clauses (i) and (ii), and Vertex shall pay any undisputed amounts set forth in such invoices within [***] of receipt. 

2.1.4. Subcontracting. Each Party may engage consultants, subcontractors, academic researchers or other vendors (each, a
“Subcontractor”) to perform Research Activities; provided that Company shall not engage any Subcontractor without Vertex’s written consent, which consent shall not be unreasonably withheld or delayed; provided,
that no such consent shall be required for any Third Party listed on Schedule 2.1.4 to perform the activities specified for such Third Party on Schedule 2.1.4, as such schedule may be updated at any time during the Research Term by approval of the
JRC, subject to the right of Vertex to have final decision-making authority with respect thereto in its sole discretion, notwithstanding anything in Section 3.1.4 to the contrary; and provided further, that Vertex shall have the right to
withhold its consent, in its sole discretion, with respect to any proposed Subcontractor [***]. Notwithstanding the foregoing, the consent of Vertex shall not be required with respect to any subcontractor if [***]. Each contract between a Party and
a Subcontractor shall be consistent with the provisions of this Agreement and shall include confidentiality provisions that are at least as restrictive as those described in ARTICLE 10. Each Party shall be responsible for the effective and timely
management of and payment of its Subcontractors. The engagement of any Subcontractor in compliance with this Section 2.1.4 shall not relieve the applicable Party of its obligations under this Agreement. 

  
 18 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.1.5. Records. Each Party shall maintain, and cause its Affiliates and
Subcontractors to maintain, records of its Research Activities in sufficient detail and in good scientific manner appropriate for scientific, patent and regulatory purposes, which shall be complete and accurate in all material respects and shall
fully and properly reflect all work done, data and developments made, and results achieved. 
 2.1.6. Progress Reports. During
the Research Term, each Party shall furnish to the JRC, within [***] after the end of each Calendar Quarter an update on such Party’s progress under the Research Programs with respect to the performance of the Research Activities during the
relevant Calendar Quarter, including a [***]. 
 2.2. Development. 

2.2.1. Generally. Vertex will have sole and exclusive control over all matters relating to the Development of Capsids and
Products in the Field. 
 2.2.2. Reporting. Beginning in the first Calendar Year in which Vertex is conducting Development
activities, Vertex will provide Company with a high-level report regarding the status of Vertex’s Development of Products no less than [***] per Calendar Year, which reports will include [***]. Such reports may be provided to Company in
conjunction with meetings and other communications between the representatives of Vertex and Company. 
 2.3. Regulatory
Matters. 
 2.3.1. Responsibilities. Vertex or its designated Affiliates and Sublicensees will have the sole authority
to (a) prepare and file Regulatory Filings, each in its own name, and applications for Regulatory Approval and Price Approval for all Capsids and Products in the Field in the Territory, and (b) communicate with Regulatory Authorities with
respect to Capsids and Products in the Field in the Territory, both prior to and following Regulatory Approval and Price Approval, including all communications and decisions with respect to [***]. 

2.3.2. Ownership. Ownership of all rights in and to all Regulatory Filings, Regulatory Approvals and Price Approvals directed to
any Capsids or Product in the Field in each country of the Territory will be held in the name of Vertex, its Affiliate, designee or Sublicensee. 

2.3.3. Cooperation. Company will, and will cause its Affiliates to, cooperate with Vertex with respect to all regulatory matters
relating to any Product. Without limiting the foregoing, as requested by Vertex, Company will reasonably assist Vertex in preparing Regulatory Filings for Products and make information Controlled by Company or its Affiliates available to Vertex to
the extent necessary or useful in connection with such Regulatory Filings. Vertex will provide Company with copies of all material correspondence between Vertex and a Regulatory Authority. Upon Vertex’s reasonable request and at Vertex’s
sole expense, Company will support the Development of Capsids and Products by providing Regulatory Authorities with access to, and the right to audit, any data or other Know-How and associated documents that
are in Company’s Control and are relied on by Vertex in its Regulatory Filings for Products. For as long as the exclusive license granted to Vertex under this Agreement is in force with respect to the applicable Vertex Disease, Company will not
make any submission to any Regulatory Authority related to any Product for such Vertex Disease in the Field without first obtaining Vertex’s prior written consent. 

  
 19 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.3.4. Right of Reference. Company hereby grants Vertex, its Affiliates and
Sublicensees a “Right of Reference,” as that term is defined in 21 C.F.R. § 314.3(b) and any foreign counterpart to such regulation, to any Regulatory Filings Controlled by Company or its Affiliates to the extent necessary or
useful to Research, Develop, Manufacture or Commercialize Capsids or Products in the Field in the Territory. If requested by Vertex, Company will provide a signed statement to this effect in accordance with 21 C.F.R. §314.50(g)(3) or any
foreign counterpart to such regulation. In the event of a termination of this Agreement in its entirety or with respect to a Vertex Disease, except in the event of any such termination by Vertex pursuant to Section 9.2.2(a) or
Section 9.2.4, Vertex will grant to Company, its Affiliates and Sublicensees a “Right of Reference,” as that term is defined in 21 C.F.R. § 314.3(b) and any foreign counterpart to such regulation, to any Regulatory Filings
Controlled by Vertex or its Affiliates to the extent necessary or useful to Research, Develop, Manufacture or Commercialize Capsids or Products for the applicable terminated Vertex Disease(s), provided that [***]. If requested by Company,
Vertex will provide a signed statement to this effect in accordance with 21 C.F.R. §314.50(g)(3) or any foreign counterpart to such regulation. 

2.4. Manufacturing. Vertex will have the exclusive right to Manufacture and supply Products itself or through one or more
Affiliates or Third Parties selected by Vertex in its sole discretion for Research, Development and Commercialization in the Field in the Territory. Company shall Manufacture Capsids as necessary for use in the Research Activities and, subject to
Section 4.7.1, may Manufacture Capsids for the research, development and manufacture of products outside of the Field. 
 2.5.
Commercialization. 
 2.5.1. General. Vertex will have sole and exclusive control over all matters relating to
the Commercialization of Products in the Field in the Territory. 
 2.5.2. Branding. Vertex or its designated Affiliates or
Sublicensees will select and own all trademarks used in connection with the Commercialization of any Product in the Field in the Territory, except with respect to any trademarks specifically related to a Capsid, for which Company will have the right
to select and own such trademarks and will license such trademarks to Vertex pursuant to Section 4.1.3 (such trademarks, the “Licensed Trademarks”). Company will not use nor seek to register, anywhere in the Territory, any
trademark that is confusingly similar to any trademark used by or on behalf of Vertex, its Affiliates or Sublicensees in connection with any Product. 

2.6. Diligence. 

2.6.1. Generally. 

(a) Commencing as of the Research Term Effective Date, for each of DMD and, in the event that Vertex exercises the applicable Option, Cystic
Fibrosis (commencing on the date that such Option is exercised), Vertex (acting directly or through one or more Affiliates or Sublicensees) shall use Commercially Reasonable Efforts to Research, Develop and Commercialize [***] Product for such
Vertex Disease in [***] Modality in each of the Major Market Countries; provided that if, (i) with respect to DMD, [***] for [***] Modality, or (ii) with respect to Cystic Fibrosis, [***] for [***] Modality, then Vertex (acting
directly or through one or more Affiliates or Sublicensees) shall use Commercially Reasonable Efforts to Research, Develop and Commercialize [***] Product for DMD or Cystic Fibrosis (as applicable) in [***]. 

  
 20 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (b) Commencing as of the Research Term Effective Date, for each of DM1 and, in the event
that Vertex exercises the applicable Option, [***] (commencing on the date that such Option is exercised), Vertex (acting directly or through one or more Affiliates or Sublicensees) shall use Commercially Reasonable Efforts to Research, Develop and
Commercialize [***] Product for such Vertex Disease in [***] Modality in each of the Major Market Countries. 
 2.6.2. Consequence of
Diligence Failure. In the event that Company believes in good faith that Vertex has failed to satisfy the diligence obligations set forth in Sections 2.6.1(a) or 2.6.1(b) with respect to a Vertex Disease, Company shall promptly notify
Vertex, which notice shall include a reasonably detailed description of the basis for such belief, and Vertex shall have [***] from receipt of such notice to cure such breach. Vertex may challenge the occurrence of such breach in good faith through
the dispute resolution process set forth in Section 11.12. Unless it is determined through such dispute resolution process that no breach occurred, if Vertex fails to cure such breach within such [***] period, which [***] period may be tolled
during the pendency of any dispute resolution proceedings provided for herein and [***], then the license granted to Vertex in Section 4.1 with respect to such Vertex Disease shall, upon notice by Company to Vertex, be terminated (i) in
the case of Cystic Fibrosis or DMD, on a [***] and (ii) in the case of DM1 or [***], with respect to all Modalities for such Vertex Disease. Following any such termination, the exclusivity obligations of Company set forth in Section 4.7.1
with respect to such Modality for such Vertex Disease shall no longer apply. Notwithstanding anything in this Agreement to the contrary, Company’s sole and exclusive remedy for Vertex’s failure to satisfy its diligence obligations set
forth in Sections 2.6.1(a) and 2.6.1(b) shall be limited to the remedy set forth in this Section 2.6.2. 
 2.7. Applicable
Laws. Vertex will, and will require its Affiliates and Sublicensees to, comply with all Applicable Law in its and their Research, Development, Manufacture and Commercialization of Capsids and Products, including where appropriate GMP, GCP
and GLP (or similar standards). 
 2.8. Safety Data Exchange. Upon Vertex’s request, the Parties will negotiate and enter
into a separate safety data exchange agreement (a “Safety Data Exchange Agreement”). The Safety Data Exchange Agreement will set forth guidelines and procedures for the receipt, investigation, recording, review, communication,
reporting and exchange between the Parties of Adverse Event reports, that, for purposes of information exchange between the Parties, will include Adverse Events and serious Adverse Events, and any other information concerning the safety of any
Product or Capsid. Without limiting the foregoing, the Parties will meet to establish a safety oversight working group comprised of members of both Parties, which, except as otherwise provided in the Safety Data Exchange Agreement, will discuss
processes and procedures for sharing information needed to support each Party’s regulatory responsibilities and to comply with applicable regulatory pharmacovigilance requirements. Any such procedures will not be construed to restrict either
Party’s ability to take any action that it deems to be appropriate or required of it under the applicable regulatory requirements, if permitted by Applicable Laws. Without limiting the foregoing, Company will promptly disclose to Vertex in
writing any information in Company’s possession regarding the occurrence of any Adverse Event that may reasonably relate to the safety of a Capsid. In addition, Vertex will (a) maintain a unified worldwide Adverse Event database for
Products, and be responsible for reporting Adverse Events and serious Adverse Events to the applicable Regulatory Authorities and (b) be responsible for all signal detection and risk management activities with respect to Products and will
develop and approve the contents of all safety communications to Regulatory Authorities, including but not limited to expedited non-clinical and clinical safety reports and aggregate reports to health
authorities, institutional review boards and ethics committees. 

  
 21 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 3. 

GOVERNANCE 
 3.1.
Joint Research Committee. 
 3.1.1. Formation. Within [***] after the Effective Date, the Parties will establish
a joint research committee (the “JRC”) to oversee and coordinate the Research Programs under this Agreement. The JRC will be comprised of three representatives from each Party. Each Party’s representatives on the JRC shall be
[***]. In addition, each Party may invite a reasonable number of additional representatives to participate in discussions and meetings of the JRC. Each Party’s representatives on the JRC and all other individuals participating in discussions
and meetings of the JRC on behalf of a Party will be subject to confidentiality and non-use obligations with respect to information disclosed at such meeting that are no less restrictive than the provision of
ARTICLE 10. The JRC will designate a chairperson at its first meeting. The chairperson of the JRC will be responsible for setting the agenda for meetings of the JRC with input from the other members, and for conducting the meetings of the JRC. The
JRC will conduct its responsibilities hereunder in good faith and with reasonable care and diligence. 
 3.1.2.
Responsibilities. The JRC will oversee and coordinate the Research Programs under this Agreement. Without limiting the foregoing, the JRC will: 

(a) review all material Research Activities undertaken by or on behalf of the Parties, including the exchange and review of data and
information generated pursuant to the Research Activities; 
 (b) discuss Company’s plans for Research Activities and [***]; 

(c) prioritize the performance of Research Activities; 

(d) oversee and coordinate the transfer of Licensed Technology to Vertex in accordance with Section 4.3; and 

(e) perform such other duties as are specifically assigned to the JRC under this Agreement. 

  
 22 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3.1.3. Meetings; Minutes. 

(a) The JRC will meet in person or by teleconference at least [***] on such dates and at such times and places as agreed to by the members of
the JRC; provided that at least [***] such meeting per [***] shall be in person unless the Parties agree otherwise. Each Party will be responsible for its own expenses relating to attendance at, or participation in, JRC meetings. 

(b) The Alliance Managers will provide the members of the JRC with draft written minutes for approval from each meeting within [***] after
each such meeting. The responsibility for preparing the minutes will alternate between the Alliance Managers on a meeting-by-meeting basis. If the minutes of any meeting
of the JRC are not approved by the JRC ([***]) within [***] after the meeting, the objecting Party will append a notice of objection with the specific details of the objection to the proposed minutes. 

3.1.4. Decision-Making. Each Party’s representatives on the JRC will [***] on all matters within the scope of the
JRC’s responsibilities. The JRC members will use reasonable efforts to reach agreement on all JRC matters. If the JRC is unable to reach consensus with respect to a particular matter for which it is responsible within [***] after the matter is
first presented to the JRC, the matter will be referred to the Executive Officers, who will use reasonable efforts to reach agreement on such matters. If such Executive Officers are unable to reach consensus with respect to a particular matter
within [***] after the matter is first referred to such Executive Officers, [***]; provided that, [***] will not have the right to: (i) amend, modify or waive compliance with any term or condition of this Agreement; (ii) make any
decision that is expressly stated to require the mutual agreement of the Parties; (iii) resolve any claim or dispute regarding whether or in what amount a payment is owed under this Agreement; (iv) exercise its final decision-making
authority in a manner that would require [***] to perform any act that [***] reasonably believes would violate Applicable Law; or (v) make a determination that a Party is in material breach of any obligation under this Agreement. 

3.1.5. Discontinuation of the JRC. The JRC’s authority will continue to exist until the first to occur of (a) the
Parties mutually agreeing to disband the JRC and (b) the conclusion of the Research Term. 
 3.2. Other Committees. The
Parties may, by mutual agreement, form such other committees or working groups as may be necessary or desirable to facilitate activities under this Agreement. Any dispute arising from such committees or working groups will be escalated to the JRC
for resolution; provided that, following discontinuation of the JRC pursuant to Section 3.1.5, any such disputes will be resolved in the manner mutually agreed to by the Parties at the time of the formation of such committee or working
group. 
 3.3. Alliance Managers. 

3.3.1. Appointment. Each Party will appoint a representative of such Party to act as its alliance manager under this Agreement
(each, an “Alliance Manager”). Each Party may replace its Alliance Manager at any time upon notice to the other Party. The initial Alliance Managers will be: 

[***] 

  
 23 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3.3.2. Specific Responsibilities. The Alliance Managers may attend meetings of
the JRC but may not be members of the JRC. The Alliance Managers will serve as the primary contact point between the Parties for the purpose of providing each Party with information regarding the other Parties’ activities pursuant to this
Agreement and will have the following responsibilities: 
 (a) schedule meetings of the JRC and circulate draft written minutes as provided
in Section 3.1.3(b); 
 (b) facilitate the flow of information and otherwise promote communication, coordination and collaboration
between the Parties; 
 (c) provide a single point of communication for seeking consensus both internally within the respective
Party’s organization and between the Parties regarding key strategy and planning issues; and 
 (d) perform such other functions as
requested by the JRC. 
 ARTICLE 4. 

LICENSE GRANTS; OPTIONS; EXCLUSIVITY 

4.1. License Grants to Vertex. 

4.1.1. License. Subject to the terms of this Agreement, including Section 4.7.2, Company grants to Vertex and its
Affiliates an exclusive, royalty-bearing license, including the right to grant and authorize Sublicenses in accordance with Section 4.1.2, under Company’s and its Affiliates’ interest in the Licensed Technology to Research, Develop,
Manufacture, have Manufactured, use, keep, sell, offer for sale, import, export and Commercialize Capsids and Products in the Field in the Territory. 

4.1.2. Sublicensing. Vertex and its Affiliates may grant Sublicenses of any rights granted to Vertex by Company under this
Agreement through multiple tiers of Sublicenses to one or more Sublicensees. Each such Sublicense will be consistent with the terms of this Agreement and will require such Sublicensee to comply with all applicable terms of this Agreement. Vertex
will remain responsible for each Sublicensee’s compliance with the applicable terms of this Agreement. 
 4.1.3. Trademark
License. Subject to the terms and conditions of this Agreement, including Section 2.5.2, Company hereby grants to Vertex an exclusive right and license to use the Licensed Trademarks in the Territory during the Term in connection with
the exploitation, including Commercialization, of Products in the Field hereunder. Vertex shall mark all Products in accordance with applicable trademark laws, and shall require all of its Affiliates and Sublicensees to do the same. 

4.1.4. Limitations. Notwithstanding the license granted to Vertex pursuant to Section 4.1.1, subject to the terms of this
Agreement, Company will retain rights under the Licensed Technology in the Field for the sole purpose of performing Research Activities or, with respect to [***], pursuant to Research activities conducted outside of the Research Programs in
accordance with Sections 4.2.2 and 4.7.1 below. 

  
 24 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.1.5. Retained Rights of MEE. The license grant set forth in
Section 4.1.1 shall be subject to: 
 (a) the retained right of MEE and MEE’s Affiliates and academic, government and not-for-profit institutions to make and to use the subject matter described or claimed in the Licensed Technology that has been
in-licensed by Company under the MEE/Lonza 3-Way Agreement; provided, however, that such making and using shall not include the production, Commercialization or
Manufacture of Products for sale and only to the extent that such making and using by academic, government and not-for-profit institutions does not conflict with any of
the provisions of this Agreement or the MEE/Lonza 3-Way Agreement; and 
 (b) certain effects
resulting from the fact that the Licensed Technology that has been in-licensed by Company under the MEE/Lonza 3-Way Agreement that is supported by federal funding, the
rights, conditions and limitations imposed by 35 U.S.C. Section 202 et seq. (and regulations pertaining thereto), including without limitation: 

(i) the royalty-free, non-exclusive license granted to the U.S. government; and 

(ii) the requirement that any Products used or sold in the United States shall be manufactured substantially in the United States. 

4.2. Cystic Fibrosis and [***] Option. Subject to the terms and conditions of this Agreement, Company hereby
grants to Vertex and its Affiliates the option and right to terminate the covenant set forth in Section 4.7.2 with respect to Cystic Fibrosis and [***] (the “Option”) in accordance with the following: 

4.2.1. Cystic Fibrosis. Vertex’s Option with respect to Cystic Fibrosis may be exercised at any time prior to the date that
is [***] following the later of (a) the conclusion of the first two years of the Research Term or (b) the conclusion of the last Research Extension for the Cystic Fibrosis Research Program (as applicable); provided that, prior to
the exercise of the Option for Cystic Fibrosis, Vertex shall have the right to evaluate the Capsids in [***], and provided further, that if Vertex is so evaluating a Capsid(s) for Cystic Fibrosis on the date that is [***] following the later
of (a) or (b) above, or is scheduled to commence such evaluation within [***] thereafter, then the Option will expire upon the earlier of (i) [***] after Vertex’s receipt of the final data from such evaluation, or (ii) [***] following the
later of (A) the conclusion of the first two years of the Research Term or (B) the conclusion of the last Research Extension for the Cystic Fibrosis Research Program (as applicable) (such period, the “CF Option Exercise
Period”). Upon timely notice to Company during the CF Option Exercise Period that Vertex wishes to exercise the Option for Cystic Fibrosis and payment to Company of a one-time, non-refundable, non-creditable option exercise fee of [***] (the “CF Option Fee”), the covenant set forth in Section 4.7.2 with respect to Cystic
Fibrosis shall expire. For the avoidance of doubt, Vertex’s exercise of the Option for Cystic Fibrosis shall not affect Company’s obligation to conduct Research Activities with respect to Cystic Fibrosis in accordance with Section 2.1
during the first two years of the Research Term and during any applicable Research Extension for the Cystic Fibrosis Research Program, as applicable. If Vertex does not make a timely exercise of the Option for Cystic Fibrosis during the CF Option
Exercise Period, the Option for Cystic Fibrosis will lapse and the diagnosis, treatment and prevention of Cystic Fibrosis shall no longer be included in the Field, effective as of the conclusion of the CF Option Exercise Period, and any and all
rights granted hereunder by Company to Vertex with respect to Cystic Fibrosis as a Vertex Disease will revert automatically to Company, and all exclusivity obligations of Company and its Affiliates and successors under Section 4.7.1 with
respect to Cystic Fibrosis shall automatically terminate. 

  
 25 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.2.2. [***]. If at any time during the Research Term Company identifies a Capsid through
its Research activities ([***]) that meets the criteria for [***] set forth on Schedule 4.2.2(a), Company shall promptly (a) notify Vertex of such Capsid, (b) provide Vertex with a data package that contains, at a minimum, data
showing that such Capsid has satisfied the requirements set forth on Schedule 4.2.2(a) and the additional information set forth in Schedule 4.2.2(b) (an “Option Exercise Data Package”), and any other information
reasonably requested by Vertex with respect to such Capsid, and (c) allow Vertex to evaluate the Capsid for up to [***] in [***] in accordance with a study design and analysis plan selected by Vertex in its discretion. In addition, unless and
until Company identifies a Capsid that meets the criteria for [***] set forth on Schedule 4.2.2(a) and provides to Vertex an Option Exercise Data Package for such Capsid in accordance with the foregoing (a) and (b), Vertex shall have the
right to request an Option Exercise Data Package at any time during the Research Term with respect to any Capsid that [***], and to perform the evaluation activities set forth in the foregoing clause (c) with respect to such Capsid.
Vertex’s Option with respect to [***] may be exercised at any time after the Effective Date until the date that is [***] following the later of (i) delivery to Vertex of the complete Option Exercise Data Package with respect to a Capsid
that meets the criteria for [***] set forth on Schedule 4.2.2(a), or (ii) if Vertex elects to conduct an evaluation of a Capsid that meets the criteria for [***] set forth on Schedule 4.2.2(a), Vertex’s receipt of the final
data from such evaluation confirming [***] and satisfaction of such criteria as determined in accordance with Vertex’s study design and analysis plan. If Company does not identify a Capsid that meets the criteria for [***] set forth on
Schedule 4.2.2(a) prior to the conclusion of the Research Term and Vertex does not otherwise exercise its Option for [***] after receipt of an Option Exercise Data Package with respect to any other Capsid disclosed to Vertex pursuant to
Section 3.1.2(b), then Vertex’s Option with respect to [***] shall expire on the date that is [***] following the conclusion of the Research Term. Further, Vertex shall have the right to exercise the Option for [***] with respect to [***].
Upon timely notice to the Company that Vertex wishes to exercise the Option for [***]([***]) and payment to Company of a one-time, non-refundable, non-creditable option exercise fee of [***] ([***] Option Fee”), the covenant set forth in Section 4.7.2 with respect to [***] shall expire, either for all Modalities or the Modality selected by
Vertex pursuant to this Section 4.2.2, as applicable. If Vertex does not make a timely exercise of the Option for [***] with respect to one Modality, multiple Modalities or all Modalities, then the Option for [***] will lapse with respect to
such Modalities for which Vertex has not exercised its Option, and the diagnosis, treatment and prevention of [***] in such Modalities shall no longer be included in the Field, effective as of the date that the Option for [***] lapses, and any and
all rights granted hereunder by Company to Vertex with respect to [***] as a Vertex Disease will revert automatically to Company, and all exclusivity obligations of Company and its Affiliates and successors under Section 4.7.1 with respect to
[***] shall automatically terminate. 

  
 26 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.3. License Grant for Research Activities. Subject to the terms and
conditions of this Agreement, during the Research Term, (a) Vertex hereby grants to Company and its Affiliates a non-exclusive license in the Territory, with no right to grant sublicenses except to
permitted Subcontractors, (i) under any Vertex Background Technology or Vertex Agreement Technology necessary or useful to perform the Research Activities, to the extent actually disclosed by Vertex to Company, and (ii) under its and its
Affiliates’ interest in the Joint Agreement Technology, in each case, solely to perform any Research Activities under this Agreement, and (b) Company hereby grants to Vertex and its Affiliates a
non-exclusive license in the Territory, with no right to grant sublicenses except to permitted Subcontractors, (i) under any Licensed Technology or Company Agreement Technology necessary or useful to
perform the Research Activities, and (ii) under its and its Affiliates’ interest in the Joint Agreement Technology, in each case, solely to perform any Research Activities. 

4.4. Right of First Negotiation. In the event that any New Technology arises during [***], Vertex will have an exclusive right
of first negotiation for such New Technology in accordance with this Section 4.4, such right to be exercised on a New Technology-by-New Technology basis and on a
Vertex Disease-by-Vertex Disease basis. Company will provide written notice to Vertex of New Technology, which notice shall include a reasonably detailed description of
such New Technology, within [***] after (a) with respect to internally-developed New Technology, the earlier of [***], and (b) with respect to New Technology for which rights are acquired or licensed from a Third Party, [***] (a
“ROFN Notice”). Vertex will have a period of [***] from the date of receipt of such ROFN Notice (or, [***]) to notify Company in writing that Vertex desires to enter into negotiations with Company for the New Technology identified
in the applicable ROFN Notice. If Vertex so notifies Company during such [***], then, for the period commencing upon Company’s receipt of such notice from Vertex and continuing until [***] thereafter, such [***] period to be extendable by
mutual written agreement, the Parties will negotiate exclusively in good faith the terms (including financial terms) on which Company would grant a license to such New Technology to Vertex. If Company and Vertex agree on such terms within such
[***]-period, then such New Technology will be included as Licensed Technology hereunder, and subject to the terms and conditions of this Agreement and a written agreement (which may be in the form of an amendment to this Agreement) with respect to
the new financial terms and any other additional terms negotiated between Company and Vertex which will be applicable to the license of such New Technology to Vertex by Company. If Company and Vertex are unable to agree on such terms within such
[***]-period (as extended, as applicable), then Company will be free to continue the internal development of such New Technology, or to enter into negotiations with a Third Party with respect to such new Technology (as applicable), provided
that [***]. For the avoidance of doubt, Vertex shall have a right of first negotiation, as set forth in this Section 4.4, with respect to any New Technology that arises during the Term, regardless of [***]. For the avoidance of doubt, nothing
in this Section 4.4 shall limit the restrictions set forth in Section 4.7.1. Further, unless otherwise agreed to in writing by the Parties, any new agreement (or amendment to this Agreement) entered into with respect to the license of New
Technology pursuant to this Section 4.4 shall be limited to the Field. 

  
 27 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.5. Technology Transfer. 

4.5.1. Initial Transfers. Company will transfer to Vertex a copy of all Licensed
Know-How in its possession or Control as of the Effective Date pertaining to the AAV [***] Capsids and any other Capsid that is necessary or reasonably likely to be useful for the Research, Development,
Manufacture and Commercialization of Capsids and Products for DMD or DM1 including, for the avoidance of doubt, any and all relevant materials ([***]), and any documentation ([***]) or similar removable media ([***]), but excluding any Licensed Know-How comprising the Company Platform. Company will provide such Licensed Know-How to Vertex within [***] after the Effective Date; provided that, in accordance with
Section 11.3 (but without the need to provide notice required by such Section 11.3) such time period may be tolled if Company is unable to transfer such Licensed Know-How as a result of any Force
Majeure. Company will transfer to Vertex a copy of all Licensed Know-How in its possession or Control as of the date of the exercise of the Option with respect to Cystic Fibrosis or [***] (as applicable)
pertaining to any Capsid that is necessary or reasonably likely to be useful for the Research, Development, Manufacture and Commercialization of Capsids and Products for Cystic Fibrosis or [***] (as applicable) including, for the avoidance of doubt,
any and all relevant materials (e.g., [***]), and any documentation ([***]) or similar removable media ([***]), but in each case excluding any Licensed Know-How comprising the Company Platform. Company will
provide such Licensed Know-How to Vertex within [***] after the applicable Option exercise. 

4.5.2. Additional Transfers. Following the initial transfer described in Section 4.5.1, no more than [***], Company will
provide updates to Vertex regarding any newly acquired or generated Licensed Know-How pertaining specifically to the AAV [***] Capsids and [***] that are necessary or reasonably likely to be useful for the
Research, Development, Manufacture and Commercialization of DMD and DM1, and following the date on which Vertex exercises the Option for Cystic Fibrosis or [***], Cystic Fibrosis and [***] (as applicable) (but in each case excluding any Licensed Know-How comprising the Company Platform), and improved procedures for synthesis or manufacture of Capsids or Products. During the Term, as reasonably requested by Vertex, Company will promptly provide Vertex with
any specific information included in the Licensed Technology that is necessary or [***] for Vertex to Research, Develop, Manufacture or Commercialize Capsids or Products in the Field. 

4.5.3. Assistance by Company Personnel. To assist with the transfer of Licensed Know-How
under this Section 4.2 and Vertex’s exploitation thereof in accordance with the terms of this Agreement, Company will make its personnel reasonably available to Vertex during normal business hours to transfer such Licensed Know-How to Vertex and respond to Vertex’s inquiries with respect thereto. 
 4.6. No Implied
Licenses. Except as expressly provided in this Agreement, no Party will be deemed by estoppel or implication to have granted the other Party any licenses or other right with respect to any intellectual property. 

  
 28 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.7. Covenants. 

4.7.1. Exclusivity. Except in the performance of its obligations or exercise of its rights under this Agreement, neither Company
nor any of its Affiliates will work independently or for or with any Third Party (including the grant of any license to any Third Party) with respect to the discovery, research, development, manufacture or commercialization of any product using a
Modality for use in the treatment, prevention or diagnosis of a Vertex Disease; provided that the foregoing restrictions shall not apply with respect to (a) rights granted by Company as of the Effective Date pursuant to the Existing
Third Party Option, and (b) Company’s internal Research ([***]) and Manufacture of Capsids or Products for [***], unless and until Vertex exercises the Option for [***], in which case the foregoing restrictions on Company would be deemed
to apply to any Modalities for which Vertex has exercised such Options for [***]. The covenants set forth in this Section 4.7.1 shall expire with respect to all Vertex Diseases on [***], provided that such covenants may sooner expire
(i) with respect to Cystic Fibrosis and [***], if Vertex does not timely exercise the applicable Option, on the date that such Option expires pursuant to Section 4.2, and (ii) with respect to DMD and DM1 (and, following Option
exercise, Cystic Fibrosis and [***] (as applicable)), on a Vertex Disease-by-Vertex Disease [***] basis, upon the termination of the license granted to Vertex in
Section 4.1 with respect to such Vertex Disease and [***] as set forth in Section 2.6.2 or under the termination provisions of Article 9 of this Agreement. 

4.7.2. Cystic Fibrosis and [***]. Until such time as Vertex has paid to Company (a) with respect to Cystic Fibrosis, the CF
Option Fee, and (b) with respect to [***], the [***] Option Fee, Vertex shall not practice the Licensed Technology in the Territory to Research, Develop, Manufacture or Commercialize any Capsids or Products for Cystic Fibrosis or [***] (as
applicable), but shall, notwithstanding the foregoing, be permitted to practice the Licensed Technology solely for the limited purposes of (i) performing non-clinical, internal Research evaluation of
Capsids for Cystic Fibrosis and [***] pursuant to Sections 4.2.1 and 4.2.2, and (ii) conducting the Research Activities that are allocated to Vertex under the Research Program. The covenant as described herein shall apply to Vertex and its
Affiliates and shall be binding upon its and their respective successors and assigns until such time as the terms and conditions of this Section 4.7.2 are satisfied by the payment of the CF Option Fee or the [***] Option Fee, each as
applicable. 
 4.8. Acquisition of Distracting Product. Notwithstanding the provisions of Section 4.7, if Company or any
of its Affiliates acquires rights to research, develop or commercialize a Distracting Product in the Field as the result of a merger, acquisition or combination with or of a Third Party other than a Change of Control (each, an “Acquisition
Transaction”) and, on the date of the closing of such Acquisition Transaction, such Distracting Product is being researched, developed or commercialized and such activities would, but for the provisions of this Section 4.8, constitute
a breach of Section 4.7, Company or its Affiliate will, within [***] after the closing of such Acquisition Transaction notify Vertex in writing of such acquisition and either: 

(a) request that such Distracting Product be [***], in which case, the Parties will [***]; 

(b) notify Vertex in writing that Company or its Affiliate will Divest its rights to such Distracting Product, in which case, within [***],
Company or its Affiliate will Divest such Distracting Product; or 
 (c) notify Vertex in writing that it is ceasing all such research,
development and commercialization activities with respect to the Distracting Product, in which case, within [***], Company and its Affiliates will cease all such activities. 

  
 29 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 During the discussion period under clause (a), prior to the time of divestiture pursuant to clause
(b) or prior to the termination of activities pursuant to clause (c), as applicable, Company and its Affiliates will use Commercially Reasonable Efforts to segregate all research, development or commercialization activities relating to the
Distracting Product from Research, Development and Commercialization with respect to Capsids or Products under this Agreement, including Commercially Reasonable Efforts to ensure that (i) [***] and (ii) [***]. 

4.9. Change of Control. If there is a Change of Control involving Company (where Company is the acquired entity), the
obligations of Sections 4.7 will not apply to any Distracting Product that is controlled by the relevant acquirer or its Affiliates and that exists prior to the closing of such Change of Control; provided that [***]. 

ARTICLE 5. 
 FINANCIAL
PROVISIONS 
 5.1. Up-Front Fee. 

5.1.1. Initial Payment. Within [***] Business Days following the Effective Date, Vertex will pay to Company one half of the
Upfront Fee (equal to Twelve-Million, Five-Hundred Thousand US Dollars ($12,500,000)) payable by wire transfer of immediately available funds. 

5.1.2. Remainder. Company shall provide notice to Vertex promptly following Company’s determination in good faith that
Company’s employees have generally resumed on-site activities at Company’s facilities, which notice shall include a reasonably detailed description of the FTEs available to conduct Research
Activities under the Research Programs in accordance with this Agreement. Following Vertex’s receipt of such notice or any time after Company’s employees have generally resumed on-site activities at
Company’s facilities, Vertex shall notify Company after Vertex has substantially resumed its normal business operations, provided, however, [***]. Vertex shall pay the remaining one half of the Upfront Fee (equal to
Twelve-Million, Five-Hundred Thousand US Dollars ($12,500,000)) (the “Remainder”) within [***] Business Days after the earlier of Vertex providing notice to Company of its resumption of its operations as described in the preceding
sentence or Company providing notice of [***] as described in the preceding sentence by wire transfer of immediately available funds (the date of either such notice, the “Research Term Effective Date”). In the event that the
Research Term Effective Date [***], then Vertex shall [***]. 
 5.2. Milestone Payments. 

5.2.1. Research Milestones. Vertex will pay Company the milestone payments set forth in this Section 5.2.1 in accordance
with the procedure set forth in Section 5.2.4 upon the achievement of the relevant milestone event by Company in the case of milestone events 1, 2 or 3, or by Vertex (at Vertex’s sole cost) in the case of milestone event 4, in each case,
regardless of whether such milestone event is achieved during or after the Research Term or within or outside the Research Program, and regardless of whether achieved by a Capsid identified within or outside of the Research Program. [***] 

 

					
	 	 	 Milestone Event
	  	 Milestone Payment

	1	 	[***]	  	[***]
	2	 	[***]	  	[***]
	3	 	[***]	  	[***]
	4	 	[***]	  	[***]

  
 30 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 5.2.2. Development & Regulatory
Milestones. Vertex will pay Company the milestone payments set forth in this Section 5.2.2 in accordance with the procedure set forth in Section 5.2.4 upon the achievement of the relevant milestone event with respect to a Product
by Vertex or its Affiliates or any Sublicensees. Each milestone payment set forth below shall be payable [***] for the [***] Product for each Modality to achieve the relevant milestone event for each Vertex Disease (i.e., each milestone may be
achieved no more than [***] for each Vertex Disease). 
  

							
	 	  	 Milestone Event
	  	 Milestone Payment for each

of Cystic Fibrosis
 and
[***]
	  	 Milestone Payment for

each of DM1 and DMD
[***]

	5	  	[***]	  	[***]	  	[***]
	6	  	[***]	  	[***]	  	[***]
	7	  	[***]	  	[***]	  	[***]
	8	  	[***]	  	[***]	  	[***]
	9	  	[***]	  	[***]	  	[***]
	10	  	[***]	  	[***]	  	[***]

 5.2.3. Commercial Milestones. Vertex will pay Company the milestone payments set forth in this
Section 5.2.3 in accordance with the procedure set forth in Section 5.2.4 upon the achievement of the relevant milestone event by Vertex or its Affiliates or any Sublicensees whether such milestone event is achieved by Vertex or its
Affiliates or any of their Sublicensees. Each milestone payment set forth below shall be [***] (i.e., each milestone may be achieved no more than [***] for each Vertex Disease). 

 

					
	 Milestone Event
	  	 Milestone Payment for each

of Cystic Fibrosis and [***]
	  	 Milestone Payment for each

of DM1 and DMD [***]

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 5.2.4. Notice; Payment; Skipped Milestones. Company will provide Vertex with written notice upon
the achievement of each of the milestone events 1-3 set forth in Section 5.2.1, and Vertex will provide Company with written notice upon the achievement of each of the milestone event 4 set forth in
Section 5.2.1 and the milestone events set forth in Section 5.2.2 and Section 5.2.3, such written notice, by each of Company and Vertex, to be provided (a) with respect to any milestone event under Section 5.2.1 or
Section 5.2.2, within [***] after such achievement and (b) with respect to any milestone event under Section 5.2.3, [***] to the date of delivery of the royalty report under Section 5.3.6 for the Calendar Quarter in which such
milestone event is first achieved. Following delivery of such written notice by Company with respect to milestone events 1-3 set forth in Section 5.2.1, or receipt of such written notice by Company with
respect to the milestone event 4 set forth in Section 5.2.1 or the milestone events set forth in Section 5.2.2 and Section 5.2.3, Company will promptly invoice Vertex for the applicable milestone and Vertex will make the appropriate
milestone payment within [***] after receipt of such invoice. Milestone payments corresponding with the milestones events [***] as set forth in Section 5.2.2 are intended to be successive; if a Product is not required to undergo an applicable
event associated with any such milestone event, such skipped milestone will be deemed to have been achieved [***]; provided that, the first achievement of any of milestone events [***] shall be deemed to trigger payment for milestones [***]
that have not, as of the date of such achievement with respect [***], been paid. Payment for any such skipped milestone that is owed in accordance with the provisions of the foregoing sentence with respect to [***] will be due [***]. 

  
 31 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 5.3. Royalties. 

5.3.1. Royalty Rates. Subject to Sections 5.3.2, 5.3.3, 5.3.4 and 5.3.5, on a Product-by-Product and country-by-country basis, Vertex will pay Company royalties based on the aggregate Net Sales of each
Product sold by Vertex, its Affiliates or Sublicensees in the Field in the Territory during a Calendar Year at the rates set forth in the table below. The obligation to pay royalties will be imposed only once with respect to the same unit of a
Product. 
  

			
	 Calendar Year Net Sales (in Dollars)

for such Product in the Territory
	  	 Royalty Rates as a Percentage

(%) of Net Sales

	Portion of Calendar Year Net Sales [***]	  	[***]
	Portion of Calendar Year Net Sales [***]	  	[***]
	Portion of Calendar Year Net Sales [***]	  	[***]

 5.3.2. Royalty Term. Vertex will pay royalties to Company under this Section 5.3 on a Product-by-Product and a country-by-country basis during the Royalty Term. Upon the expiration
of the Royalty Term for a given Product in a given country, the license granted to Vertex under Section 4.1.1 will become fully-paid, perpetual and irrevocable with respect to such Product. 

5.3.3. Reduction for Lack of Patent Coverage. If during any period within the applicable Royalty Term for a country, no Valid
Claim of a Licensed Patent exists that would, but for the licenses granted herein, be infringed by the [***] in such country, Net Sales of such Product in such country will be reduced [***] for purposes of calculating the royalty owed under
Section 5.3.1. 
 5.3.4. Reduction for Competition. If during any Calendar Quarter during the Royalty Term for a Product
in a given country, the aggregate number of units of Competitive Products with respect to such Product sold during such Calendar Quarter in such country [***] of the aggregate units of the sum of all such Competitive Products and such Product sold
in such Calendar Quarter in such country, then Net Sales of such Product in such country (after any applicable reduction pursuant to Section 5.3.3) will be reduced by [***] for purposes of calculating the royalty owed under Section 5.3.1.

  
 32 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 5.3.5. Third Party Licenses. In the event that, with respect to a Product in a
country, [***], then Vertex may deduct from the royalties payable to Company under this Section 5.3, [***] of all such Blocking Third Party Intellectual Property Costs paid by Vertex; provided, however, that in no event will the
royalties that would otherwise be payable to Company with respect to Net Sales of Products, after any applicable reduction to such Net Sales under Sections 5.3.3 and 5.3.4, be reduced [***] in any given Calendar Quarter as a result of any deduction
under this Section 5.3.5; and provided further, that Vertex will be entitled to carry forward to subsequent Calendar Quarters any amounts with respect to which Vertex would have been entitled to make a deduction pursuant to this
Section 5.3.5 but is unable to take such deduction pursuant to the first proviso in this Section 5.3.5. 
 5.3.6. Aggregate
Limitation on Deductions. Notwithstanding Sections 5.3.3, 5.3.4, and 5.3.5, in no event will the combined effect of all reductions to the royalties payable to Company under Sections 5.3.3, 5.3.4 and 5.3.5 reduce the royalty payable by Vertex
to Company under this Section 5.3 for any Product in any country during a Calendar Quarter to [***] of the amount that would otherwise be due under Section 5.3.1, but for such deductions; provided that, if in a particular Calendar
Quarter, Vertex is entitled to a royalty reduction under both Sections 5.3.3 and 5.3.4, then the royalty payable by Vertex to Company under this Section 5.3 for any Product in any country for such Calendar Quarter may be reduced [***] of the
amount that would otherwise be due under Section 5.3.1; and provided further, that Vertex shall have the right to apply any uncredited reduction in royalties to any subsequent Calendar Quarter until such reduction is fully realized. 

5.3.7. Royalty Reports. Following the first sale of a Product giving rise to Net Sales and continuing for the remainder of the
Royalty Term for such Product, within [***] after the end of each Calendar Quarter, Vertex will deliver a report to Company specifying on a Product-by-Product and country-by-country basis: (a) Net Sales in the relevant Calendar Quarter; (b) to the extent such Net Sales include sales not denoted in US Dollars, a summary of the
then-current exchange rate methodology then in use by Vertex, and (c) royalties payable on such Net Sales. All royalty payments due under Section 5.3 for each Calendar Quarter will be due and payable within [***] after the end of each
Calendar Quarter. 
 5.4. Payments Owed Under Company In-License Agreements. Except as
set forth in Section 5.5, any payment obligations arising under the Company In-License Agreements as a result of the Research, Development, Manufacture and Commercialization of a Product by or on behalf
of Vertex under this Agreement will be paid solely by Company. In the event that Vertex enters into a direct license with the licensor under any Company In-License Agreement following a termination of such
Company In-License Agreement, then Vertex may deduct [***] due to such licensor under any such direct license from any payments owed to Company hereunder ([***]), provided that, such deductions shall be
subject to the limitation on aggregate deductions set forth in Section 5.3.6, except with respect to [***], for which no such limitation on aggregate deductions shall apply. 

  
 33 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 5.5. New Company Agreements. 

5.5.1. Company may, during the Term, acquire or in-license rights to additional intellectual property
that is related to a Capsid and is necessary [***] to Research, Develop, Manufacture or Commercialize Products in the Field and that, if solely owned by Company, without any encumbrance or restriction on licensing, [***] (such agreements, the
“Proposed New Company Agreements”), provided that, [***], and provided further that, the Agreement has not been terminated with respect to the applicable Vertex Disease. In the event that [***], Company [***] a Proposed New
Company Agreement, Company shall so notify Vertex [***] with respect to the applicable Vertex Disease(s) within the Field pursuant to such Proposed New Company Agreement, and the terms that would be applicable to Vertex, [***], if the intellectual
property rights to be acquired or in-licensed within the Field pursuant to such Proposed New Company Agreement [***]. Company shall use [***] to include in any such Proposed New Company Agreement a provision
[***]. Company shall provide Vertex with [***] such Proposed New Company Agreement, [***], sufficiently [***]. Vertex may [***], and Company shall [***] the Proposed New Company Agreement. For the avoidance of doubt, Company will control the
negotiations with the Grantor with respect to the Proposed New Company Agreement. Any Proposed New Company Agreement shall be [***] under this Agreement. 

5.5.2. Promptly following execution of a Proposed New Company Agreement, Company shall provide to Vertex [***] of such Proposed New Company
Agreement with [***] thereunder (a “Licensee”) and [***] subject to the applicable Proposed New Company Agreement. Company and Vertex will discuss in good faith to determine whether Vertex will take a license or sublicense (as the case may
be) under all or a portion of the intellectual property rights that are the subject of such Proposed New Company Agreement and if so, Company and Vertex will enter into a written agreement setting forth the terms under which Vertex will take such
license or sublicense. Following such written agreement, subject to the terms of such Proposed New Company Agreement that are applicable to a Licensee thereunder, such intellectual property rights described in such notice shall [***] (any such
Proposed New Company Agreement with respect to intellectual property rights that are [***] pursuant to this sentence, a “New Company Agreement”). Any payment obligations arising under the New Company Agreements directly as a result
of the Research, Development, Manufacture or Commercialization of a Product in the Field by or on behalf of Company, Vertex, or any of their respective Affiliates or Vertex’s Sublicensees, after application of all available reductions to and
deductions from such payment obligations under the applicable New Company Agreement (but, for the avoidance of doubt, [***]), will be paid by Company and reimbursed by Vertex in accordance with this Section 5.5 and the written agreement
described above, and Company shall be responsible for all other payment obligations under such agreements ([***]). Company shall provide Vertex with a reasonably detailed invoice for any reimbursable payments made by Company pursuant to this
Section 5.5.2 within [***] of the end of each Calendar Quarter in which any such payments were made by Company, and Vertex shall pay the undisputed portion of such invoices within [***] of receipt thereof. For clarity, Vertex and its Affiliates
will be obligated to reimburse a given amount owed under a New Company Agreement one time only. Notwithstanding the foregoing, Vertex may, at its sole discretion, notify Company that it elects to abandon its payment obligations under this
Section 5.5.2 with respect to a New Company Agreement, whereupon such New Company Agreement, as applicable, shall be deemed not to be a New Company Agreement, as applicable, under this Agreement. Except as otherwise provided in this Agreement,
as between the Parties, Company shall be responsible for all payments in connection with this Agreement, including with respect to the Research, Development, Manufacture and Commercialization of Products, that arise under any license or other
agreement to which Company or its Affiliate is a party, including any New Company Agreement. The provisions of Section 5.6 shall apply to such amounts paid or payable by Vertex, mutatis mutandis. 

  
 34 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 5.6. Payment Terms. 

5.6.1. Currency; Payment Method. All payments under this Agreement are expressed in U.S. Dollars and will be paid in U.S.
Dollars, by wire transfer or Automated Clearing House (ACH) payment to an account designated by Company (which account Company may update from time to time in writing). 

5.6.2. Exchange. If any amounts that are relevant to the determination of amounts to be paid under this Agreement or any
calculations to be performed under this Agreement are denoted in a currency other than U.S. Dollars, such amounts will be converted to their U.S. Dollar equivalent using [***], including [***] or, in the case of Sublicensees, such similar
methodology, consistently applied. Calculation of Net Sales will exclude [***]. 
 5.7. Withholding Tax. Where any sum due to
be paid to Company hereunder is subject to any withholding or similar tax, Vertex will pay such withholding or similar tax to the appropriate Governmental Authority and deduct the amount paid from the amount then due to Company. Vertex will timely
transmit to Company an official tax certificate or other evidence of such withholding sufficient to enable Company to claim such payment of taxes. The Parties will cooperate with one another and use reasonable efforts to reduce or eliminate tax
withholding or similar obligations in respect of royalties, milestone payments, and other payments made by Vertex to Company under this Agreement. Company will provide Vertex any tax forms that may be reasonably necessary in order for Vertex not to
withhold tax or to withhold tax at a reduced rate under an applicable income tax treaty. Each Party will provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes, value added taxes,
or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax. 

5.8. Records; Audits. Vertex will keep and maintain accurate and complete records regarding Net Sales during the [***] preceding
Calendar Years. Upon [***] prior written notice from Company, Vertex will permit an independent certified public accounting firm of internationally recognized standing, selected by Company and reasonably acceptable to Vertex, to examine the relevant
books and records of Vertex and its Affiliates, as may be reasonably necessary to verify the royalty reports submitted by Vertex in accordance with Section 5.3.7. An examination by Company under this Section 5.8 will occur not more than
[***] in any Calendar Year and will be limited to the pertinent books and records for any Calendar Year ending not more than [***] before the date of the request. The accounting firm will be provided access to such books and records at Vertex’s
facility or facilities where such books and records are normally kept and such examination will be conducted during Vertex’s normal business hours. Vertex may require the accounting firm to sign a customary
non-disclosure agreement before providing the accounting firm access to its facilities or records. Upon completion of the audit, the accounting firm will provide to both Parties a written report disclosing
whether the reports submitted by Vertex are correct or incorrect and the specific details concerning any discrepancies. No other information will be provided to Company. If the report or information submitted by Vertex results in an underpayment or
overpayment, the Party owing the underpaid or overpaid amount will promptly pay such amount to the other Party. The costs and fees of any audit conducted by Company under this Section 5.8 will be borne by Company, unless such audit reveals an
underpayment of amounts owed to Company of more than [***] of the amount that was owed by Vertex with respect to the relevant period, in which case, Vertex will reimburse Company for the reasonable expense incurred by Company in connection with the
audit. 

  
 35
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 5.9. Late Payment. Any payments or portions thereof due hereunder that are not
paid when due will accrue interest from the date due until paid at [***]. 
 ARTICLE 6. 

INTELLECTUAL PROPERTY 

6.1. Ownership of Agreement Technology. For purposes of determining ownership under this Section 6.1, except as expressly
set forth in this Section 6.1, ownership will be determined in accordance with inventorship, and inventorship will be determined in accordance with United States patent laws (regardless of where the applicable activities occurred). 

6.1.1. Company Agreement Technology. As between the Parties, Company will be the sole owner of any and all Agreement Know-How, whether created solely by a Party or jointly by the Parties, (a) that is not included in the Vertex Agreement Know-How, and (b) to the extent specifically
relating to (i) any Capsid or (ii) the Company Platform (“Company Agreement Know-How”) and any Patents that Cover such Know-How
(“Company Agreement Patents” and together with the Company Agreement Know-How, the “Company Agreement Technology”), and will retain all of its rights thereto, subject to any
rights or licenses expressly granted by Company to Vertex under this Agreement. For the avoidance of doubt, Company Inventions arising out of the MTA shall be deemed Company Agreement Know-How hereunder.
Company will promptly disclose to Vertex in writing, and will cause its Affiliates to so disclose, the discovery, development, invention or creation of any Company Agreement Know-How or Company Agreement
Patent under this Agreement, excluding any Company Agreement Know-How or Company Agreement Patents that comprise the Company Platform. 

6.1.2. Vertex Agreement Technology. As between the Parties, Vertex will be the sole owner of any and all Agreement Know-How, whether created solely by a Party or jointly by the Parties, (a) that is specific to a Vertex Disease, or (b) to the extent specifically relating to an improvement to the Vertex Background
Technology, in each case ((a) and (b)), to the extent that such Know-How is not an improvement to or a further development or modification of the Company Platform (the “Vertex Agreement Know-How”) and any Patents that Cover Vertex Agreement Know-How (“Vertex Agreement Patents” and together with the Vertex Agreement Know-How, the “Vertex Agreement Technology”), and will retain all of its rights thereto, subject to any rights or licenses expressly granted by Vertex to Company under this Agreement. For the
avoidance of doubt, Vertex Inventions arising out of the MTA shall be deemed Vertex Agreement Know-How hereunder. Vertex hereby grants to Company a worldwide,
non-exclusive, fully paid-up, sublicenseable (through multiple tiers) royalty-free license under the Vertex Agreement Technology that relates to any Capsid for use in
any and all diseases that are not Vertex Diseases for which Vertex continues to maintain exclusive license rights in force under this Agreement. 

  
 36 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 6.1.3. Joint Agreement Technology. Any and all Agreement Know-How developed, invented or created jointly by (a) Vertex, its Affiliates or Third Parties acting on its or their behalf and (b) Company, its Affiliates or Third Parties acting on its or their behalf,
in each case ((a) and (b)), (i) in the performance of activities under this Agreement (including in any meeting of the JRC) and (ii) to the extent not included in the Company Agreement Know-How or the
Vertex Agreement Know-How (such Know-How, “Joint Agreement Know-How”), and any Patents that claim or cover such
Joint Agreement Know-How (“Joint Agreement Patents,” and together with the Joint Agreement Know-How, the “Joint Agreement Technology”),
will be owned jointly by Vertex and Company on an equal and undivided basis, including all rights thereto, subject to any rights or licenses expressly granted by one Party to the other Party under this Agreement. For the avoidance of doubt, the
Results arising from the MTA shall be deemed Joint Agreement Know-How hereunder. Except as expressly provided in this Agreement, neither Party will have any obligation to account to the other for profits with
respect to, or to obtain any consent of the other Party to license or exploit, Joint Agreement Technology by reason of joint ownership thereof, and each Party hereby waives any right it may have under the laws of any jurisdiction to require any such
consent or accounting. 
 6.2. Prosecution and Maintenance of Patents. 

6.2.1. Company Agreement Patents; Company Platform. As between the Parties, and subject to the expressly stated rights of Lonza
or MEE under the Lonza/MEE 3-Way Agreement as applicable, Company will have the sole right, at Company’s expense, to control the Prosecution and Maintenance of the Patents (a) within the Company
Agreement Patents, other than those Company Agreement Patents that are included within the Licensed Patents for which Vertex has the first right to Prosecute and Maintain pursuant to Section 6.2.3, and (b) that claim the Company Platform.

 6.2.2. Vertex Agreement Patents. As between the Parties, Vertex will have the sole right, at Vertex’s expense, to
control the Prosecution and Maintenance of the Vertex Agreement Patents. 
 6.2.3. Licensed Patents and Joint Agreement
Patents. As between the Parties, Vertex will have the first right, at Vertex’s expense, to control the Prosecution and Maintenance of the Licensed Patents (other than any Licensed Patents that claim the Company Platform) and Joint
Agreement Patents, using counsel reasonably acceptable to Company (and to MEE as applicable with respect to the Licensed Patents); provided that, the Parties acknowledge [***]. Vertex agrees to keep Company reasonably informed with respect to
such Prosecution and Maintenance and consult in good faith with Company regarding such matters. If Vertex decides to abandon a Licensed Patent or Joint Agreement Patent, Vertex will provide Company with notice at least [***] prior to the date such
abandonment would become effective. Following such notice, Company may elect, upon written notice to Vertex, to control the Prosecution and Maintenance of such Patent at its own expense in Company’s name. Upon such election, Vertex will
cooperate and assist in transitioning the Prosecution and Maintenance of such Patent to Company, Company agrees to keep Vertex reasonably informed with respect to such Prosecution and Maintenance and consult in good faith with Vertex regarding such
matters. 

  
 37 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 6.2.4. Cooperation. Vertex and Company will obtain the cooperation of their
respective employees or obligated Third Parties that are inventors in the Prosecution and Maintenance directed to any inventions that may arise hereunder. 

6.3. Defense of Claims Brought by Third Parties. If any Third Party brings a claim or otherwise asserts that a Product or Capsid
infringes such Third Party’s Patent or misappropriates such Third Party’s Know-How (each, a “Third-Party Infringement Claim”), the Party first having notice of the claim or assertion
will promptly notify the other Party in writing. Subject to Section 8.1.2, and subject to the expressly stated rights of Lonza or MEE under the Lonza/MEE 3-Way Agreement as applicable with respect to any
Third Party Infringement Claim brought against Company, Vertex will have the sole right to undertake and control the defense or settlement of any Third-Party Infringement Claim using counsel of its choice, at its cost and expense. If Company is
named as a defendant in such suit, Company will have the right to participate in such defense and settlement with its own counsel, at its cost. Vertex will not enter into any settlement of any Third-Party Infringement Claim that is instituted or
threatened to be instituted against Company without Company’s prior written consent, which will not be unreasonably withheld, conditioned or delayed; except that, such consent will not be required if such settlement includes a release of
all liability in favor of Company or an assumption of any unreleased liability by Vertex. As requested by Vertex, Company will provide reasonable cooperation and assistance to Vertex in connection with Vertex’s control of the defense or
settlement of a Third-Party Infringement Claim. Such cooperation and assistance will include executing all necessary and proper documents and taking such actions as will be appropriate to allow Vertex to control the defense and settlement of such
Third-Party Infringement Claim. Vertex will reimburse Company for the reasonable Out-of-Pocket Costs incurred by Company in providing such assistance and cooperation;
except that Vertex will have no obligation to reimburse Company for any costs or expenses incurred if Company exercises its right to participate in the defense and settlement of a Third-Party Infringement Claim with its own counsel. Vertex
will keep Company reasonably informed of the progress of any Third Party Infringement Claim. To the extent reasonable, both Parties will cooperate in good faith to (a) ensure that Vertex has the ability to continue to commercialize Products and
(b) avoid or minimize any additional royalties on Products. 
 6.4. Enforcement of Patents Against Competitive
Infringement. 
 6.4.1. Duty to Notify of Competitive Infringement. If either Party learns of an infringement,
unauthorized use, misappropriation or threatened infringement by a Third Party with respect to any Licensed Technology by reason of the making, using, offering to sell, selling or importing of a compound or product that would be competitive with a
Capsid or Product in the Field in the Territory (a “Competitive Infringement”), such Party will promptly notify the other Party in writing and will provide such other Party with available information regarding such Competitive
Infringement. 

  
 38 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 6.4.2. Enforcement. Subject to the expressly stated rights of Lonza or MEE
under the Lonza/MEE 3-Way Agreement as applicable, Vertex will have the first right, but not the obligation, to institute, prosecute, and control a Proceeding to enforce the Licensed Technology (excluding any
Patents that are included in the Company Platform, for which Company will have the sole enforcement right) with respect to any Competitive Infringement by counsel of its own choice, at its own expense. If Vertex fails to initiate a Proceeding within
[***] after written notice of such Competitive Infringement is first provided by a Party under Section 6.4.1, Company will have the right to initiate and control a Proceeding with respect to such Competitive Infringement by counsel of its own
choice, at its own expense and Vertex will have the right, at its own expense, to be represented in any such action by counsel of its own choice; provided, that if Vertex notifies Company during such [***] period that it is electing in good
faith not to institute any Proceeding against such Competitive Infringement for strategic reasons, Company will not have the right to initiate and control any Proceeding with respect to such Competitive Infringement. The Party prosecuting and
controlling any such Proceeding will (a) keep the other Party reasonably apprised of the progress of such Proceeding, (b) reasonably consider the other Party’s comments with respect to the conduct of such Proceeding and (c) not
enter into a settlement, consent judgment or other voluntary final disposition of a Proceeding that disclaims, limits the scope of, admits the invalidity or unenforceability of, or grants a license, covenant not to sue, or similar immunity that has
an adverse effect on the other Party’s rights hereunder without the other Party’s prior written consent, not to be unreasonably withheld. 

6.4.3. Joinder. 

(a) If a Party initiates a Proceeding in accordance with this Section 6.4, the other Party agrees to be joined as a party plaintiff
where necessary and to give the first Party reasonable assistance and authority to file and prosecute the Proceeding. Subject to Section 6.4.4, the costs and expenses of each Party incurred pursuant to this Section 6.4.3(a) will be borne
by the Party initiating such Proceeding. 
 (b) If one Party initiates a Proceeding in accordance with this Section 6.4, the other
Party may join such Proceeding as a party plaintiff where necessary for such other Party to seek lost profits with respect to such infringement. 

6.4.4. Share of Recoveries. Any damages or other monetary awards recovered with respect to a Proceeding brought pursuant to this
Section 6.4 will be shared as follows: 
 (a) the amount of such recovery will first be applied to the Parties’ reasonable Out-of-Pocket Costs incurred in connection with such Proceeding (which amounts will be allocated pro rata if insufficient to cover the totality of such expenses); then

 (b) any remaining proceeds [***] will be [***]; provided that [***]; and 

(c) any remaining proceeds [***] will be [***]. 

6.4.5. Settlement. Notwithstanding anything to the contrary under this ARTICLE 6, neither Party may enter a settlement, consent
judgment or other voluntary final disposition of a suit under this ARTICLE 6 that disclaims, limits the scope of, admits the invalidity or unenforceability of, or grants a license, covenant not to sue or similar immunity under a Patent Controlled by
the other Party or its Affiliates without first obtaining the written consent of the Party that Controls the relevant Patent; provided, that the foregoing restriction will not apply with respect to any Sublicense granted by Vertex. 

  
 39 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 6.5. Other Infringement. 

6.5.1. Joint Agreement Patents. With respect to the infringement of a Joint Agreement Patent that is not a Competitive
Infringement, neither Party shall enforce any Joint Agreement Patent unless mutually agreed by the Parties, provided that the Parties will cooperate in good faith to bring suit together against such infringing party or the Parties may decide to
permit one Party to solely bring suit. Any damages or other monetary awards recovered with respect to a Proceeding brought pursuant to this Section 6.5.1 will be shared as follows: [***]. 

6.5.2. Patents Solely Owned by Company. Subject to the expressly stated rights of Lonza or MEE under the Lonza/MEE 3-Way Agreement as applicable, Company will retain all rights to pursue an infringement of any Patent solely owned by Company that is not a Competitive Infringement and Company will retain all recoveries with
respect thereto. 
 6.5.3. Patents Solely Owned by Vertex. Vertex will retain all rights to pursue an infringement of any
Patent solely owned by Vertex and Vertex will retain all recoveries with respect thereto. 
 6.6. Patent Listing. Vertex will
have the sole right, but not the obligation, to submit to all applicable Regulatory Authorities patent information pertaining to each applicable Product pursuant to 21 U.S.C. § 355(b)(1)(G), any similar statutory or regulatory requirement
enacted in the future regarding biologic products, or any similar statutory or regulatory requirement in any non-U.S. country or other regulatory jurisdiction. Vertex shall consult with Company reasonably in
advance of any such submission, and shall reasonably consider Company’s and Licensors’ (as defined in the MEE/Lonza 3-Way Agreement) comments with respect thereto (it being understood that Company
may disclose to Licensors Vertex’s intention regarding such submission for purposes of obtaining Licensors’ comments, if any, with respect thereto). 

6.7. Common Ownership Legislation. Notwithstanding anything to the contrary in this ARTICLE 6, neither Party will have the right
to make an election under the Common Ownership Legislation when exercising its rights under this ARTICLE 6 without the prior written consent of the other Party, which will not be unreasonably withheld, conditioned or delayed. With respect to any
such permitted election, the Parties will use reasonable efforts to cooperate and coordinate their activities with respect to any submissions, filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a
“joint research agreement” as defined in the Common Ownership Legislation. Notwithstanding the foregoing, the other Party’s consent under this Section 6.7 will not be required in connection with an obviousness-type double
patenting rejection in any patent application claiming a Capsid, Product, or uses thereof. 
 6.8. Patent Term Extension.
Vertex will be solely responsible for obtaining patent term restoration in any country in the Territory under any statute or regulation equivalent or similar to 35 U.S.C. § 156, where applicable to a Product. Vertex will determine which
relevant patents will be extended (including, without limitation, by filing supplementary protection certificates and any other extensions that are now or in the future become available). Company will abide by Vertex’s determination and
cooperate, as reasonably requested by Vertex, in connection with the foregoing (including by providing appropriate information and executing appropriate documents). Vertex shall consult with Company reasonably in advance of making any such patent
term extension determination, and shall reasonably consider Company’s and Licensors’ (as defined in the MEE/Lonza 3-Way Agreement) comments with respect thereto (it being understood that Company may
disclose to Licensors Vertex’s intention regarding such determination for purposes of obtaining Licensors’ comments, if any, with respect thereto). 

  
 40 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 6.9. Recording. If Vertex deems it necessary or desirable to register or
record this Agreement or evidence of this Agreement with any patent office or other appropriate Governmental Authority in one or more jurisdictions in the Territory, Company will reasonably cooperate to execute and deliver to Vertex any documents
accurately reflecting or evidencing this Agreement that are necessary or desirable, in Vertex’s reasonable judgment, to complete such registration or recordation. Vertex will reimburse Company for all reasonable
Out-of-Pocket Costs, including attorneys’ fees, incurred by Company in complying with the provisions of this Section 6.9. 

6.10. Unitary Patent System. Vertex will have the exclusive right to opt-in or opt-out of the EU Unitary Patent System for all Licensed Patents, Joint Agreement Patents and Vertex Agreement Patents. For clarity, “to opt-in or opt-out” refers to both the right to have or have not a European patent application or an issued European patent registered to have unitary effect within the meaning of Regulation (EU) No 1257/2012 of
December 17, 2012 as well as the Agreement on a Unified Patent Court as of February 19, 2013; and to the right to opt-in or opt-out from the exclusive
competence of the Unified Patent Court in accordance with Article 83(3) of that Agreement on a Unified Patent Court. Without limiting the generality of the foregoing, unless a Party or its Affiliate has expressly opted in to the EU Unitary Patent
System with respect to a given Patent, the other Party will not initiate any action under the EU Unitary Patent System without such Party’s prior written approval, such approval to be granted or withheld in such Party’s sole discretion.

 6.11. Trademarks. As between the Parties, all trademarks and trade dress rights used in connection with the
Commercialization of the Products in the Field in the Territory will be owned exclusively by Vertex. 
 ARTICLE 7. 

REPRESENTATIONS AND WARRANTIES 

7.1. Representations and Warranties of Vertex. Vertex hereby represents and warrants to Company, as of the Effective Date, that:

 (a) Vertex is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or
organization; 
 (b) Vertex (i) has the requisite power and authority and the legal right to enter into this Agreement and to perform
its obligations hereunder, and (ii) has taken all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; 

(c) this Agreement has been duly executed and delivered on behalf of Vertex, and constitutes a legal, valid and binding obligation,
enforceable against Vertex in accordance with the terms hereof; 

  
 41 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (d) the execution, delivery and performance of this Agreement by Vertex will not constitute
a default under or conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, or violate any law or regulation of any court, governmental body or administrative or other agency having
jurisdiction over Vertex; and 
 (e) Vertex has obtained all necessary consents, approvals and authorizations of all Governmental
Authorities and other Persons or entities required to be obtained by it in connection with the execution and delivery of this Agreement. 

7.2. Representations and Warranties of Company. Company hereby represents and warrants to Vertex, as of the Effective Date,
that: 
 (a) it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or
organization; 
 (b) it (i) has the requisite power and authority and the legal right to enter into this Agreement and to perform its
obligations hereunder, including the right to grant a sublicense to Vertex under the Licensed Technology pursuant to the Company In-License Agreements existing as of the Effective Date, and (ii) has taken
all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; 

(c) this Agreement has been duly executed and delivered on behalf of Company, and constitutes a legal, valid and binding obligation,
enforceable against it in accordance with the terms hereof; 
 (d) the execution, delivery and performance of this Agreement by Company
will not constitute a default under or conflict with any agreement (including any Company In-License Agreement existing as of the Effective Date), instrument or understanding, oral or written, to which it is a
party or by which it is bound, or violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it; 

(e) it has obtained all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons or entities
required to be obtained by it in connection with the execution and delivery of this Agreement; 
 (f) the Licensed Technology constitutes
all of the Patents and Know-How owned by or licensed to Company or its Affiliates that are necessary or useful to Research, Develop, Manufacture or Commercialize Capsids and Products in the Field, and as of
the Effective Date, Company has provided to Vertex all material information and data concerning the Licensed Technology; 
 (g) Company is
the exclusive licensee or sublicensee of the Licensed Technology within the Field, all of which are free and clear of any liens, charges and encumbrances, and, as of the Effective Date, neither any license granted by Company or its Affiliates to any
Third Party, nor any agreement between any Third Party and Company or its Affiliates conflicts with the license grants to Vertex hereunder and Company is entitled to grant all rights and licenses (or sublicenses, as the case may be) under the
Licensed Technology within the Field that it purports to grant to Vertex under this Agreement; 

  
 42 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (h) (i) Company Controls the AAV [***] Capsids to the extent necessary to grant the
licenses to Vertex hereunder for the diagnosis, treatment or prevention of DMD, DM1, Cystic Fibrosis and [***], and the Ancestral Libraries for the diagnosis, treatment or prevention of Cystic Fibrosis, DM1 and [***], and (ii) neither Company
nor Lonza nor MEE has granted any right or license, or option to acquire any right or license, to the Third Party Optionee under the AAV [***] Capsids for the diagnosis, treatment or prevention of DMD, DM1, Cystic Fibrosis or [***]; 

(i) Schedule 1.94 sets forth a true, correct and complete list of all Licensed Patents as of the Effective Date and indicates whether
each such Patent is owned by Company or licensed by Company from a Third Party and if so, identifies the licensor or sublicensor from which the Patent is licensed; 

(j) the Licensed Know-How is free and clear of liens, charges or encumbrances other than licenses
granted to Third Parties that are not inconsistent with the rights and licenses granted to Vertex hereunder; 
 (k) to its Knowledge, the
Licensed Patents, are, or, upon issuance, will be, valid and enforceable patents and no Third Party (i) is infringing any such Patents or (ii) has challenged the extent, validity or enforceability of such Patents (including by way of
example through the institution or written threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority); 

(l) to its Knowledge, [***] with respect to any such Patents for which it controls Prosecution and Maintenance; 

(m) it has obtained assignments from the inventors of all inventorship rights relating to the Licensed Patents, and all such assignments of
inventorship rights relating to such Patents are valid and enforceable; 
 (n) except for the Company
In-License Agreements, there are no agreements between Company or any of its Affiliates and any Third Party pursuant to which Company or its Affiliate has acquired Control of any of the Licensed Technology,
and no Third Party has any right, title or interest in or to, or any license under, any of the Licensed Technology within the Field. All Company In-License Agreements are in full force and effect and have not
been modified or amended. Neither Company nor its Affiliates nor, to the best of its Knowledge, the Third Party licensor in an Company In-License Agreement is in default with respect to a material obligation
under such Company In-License Agreement in connection with this Agreement, and neither such party has claimed or has grounds upon which to claim that the other party is in default with respect to a material
obligation under, any Company In-License Agreement in connection with this Agreement; 
 (o) this
Agreement [***]; 

  
 43 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (p) Company and its Affiliates have [***]; 

(q) no Licensed Technology is subject to any funding agreement with any government or governmental agency; 

(r) to its Knowledge, [***]; 

(s) there are no judgments or settlements against or owed by Company or its Affiliates or, to its Knowledge, pending or threatened claims or
litigation, in either case relating to the Licensed Technology; 
 (t) there is no action, claim, demand, suit, proceeding, arbitration,
grievance, citation, summons, subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the best of its Knowledge, threatened against Company, any of its Affiliates or any Third
Party, in each case in connection with the Licensed Technology or relating to the transactions contemplated by this Agreement; and 
 (u)
Company has not employed (and, to the best of its Knowledge, has not used a contractor or consultant that has employed) any Person debarred by the FDA (or subject to a similar sanction of EMA or foreign equivalent), or any Person that is the subject
of an FDA debarment investigation or proceeding (or similar proceeding of EMA or foreign equivalent), in any capacity in connection with this Agreement. 

7.3. Company Covenants. Company hereby covenants to Vertex that, except as expressly permitted under this Agreement: 

(a) Company will, and will require its Affiliates and Subcontractors to, comply with all Applicable Law in its and their conduct of the
Research Activities, including where appropriate GMP, GCP and GLP (or similar standards); 
 (b) Company will maintain and not breach, and
will cause its Affiliates to maintain and not breach, any Company In-License Agreements in connection with this Agreement; 

(c) Company will promptly notify Vertex in writing of any material breach by Company or its Affiliate or a Third Party of any Company In-License Agreements, and in the event of a breach by Company or its Affiliate, will permit Vertex to cure such breach on Company’s or its Affiliate’s behalf upon Vertex’s request; 

(d) Company will not, and will cause its Affiliates not to, amend, modify or terminate any Company
In-License Agreement in a manner that would adversely affect Vertex’s rights hereunder within the Field without first obtaining Vertex’s written consent, which consent may be withheld in
Vertex’s sole discretion; 
 (e) neither Company nor any of its Affiliates will effect any corporate restructuring or enter into any
new agreement or otherwise obligate itself to any Third Party, or amend an existing agreement with a Third Party, in each case, in a manner that restricts, limits, or encumbers the rights granted to Vertex under this Agreement; 

  
 44 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (f) Company will have, as of the Research Term Effective Date, and will maintain for the
duration of the Term, the requisite resources and expertise to perform its obligations hereunder with respect to the Research Programs; 

(g) Company will not, and will cause its Affiliates not to (i) license, sell, assign or otherwise transfer to any Person any Licensed
Technology (or agree to do any of the foregoing), or (ii) incur or permit to exist, with respect to any Licensed Technology, any lien, encumbrance, charge, security interest, mortgage, liability, grant of license to Third Parties or other
restriction (including in connection with any indebtedness), in each case, that would conflict with, limit, [***] the rights and licenses granted to Vertex hereunder; 

(h) all employees and Subcontractors of Company performing Research Activities hereunder on behalf of Company will be [***], to Company as
the sole owner thereof; 
 (i) in the event of a termination of the Amended and Restated Lonza-MEE
Agreement during the Term, Company will timely request that MEE enter into a direct license with Company in accordance with Section 11.5.6 of the Lonza/MEE 3-Way Agreement; 

(j) Company will not engage directly or indirectly, in any capacity in connection with this Agreement any Person who either has been debarred
by the FDA, is the subject of a conviction described in Section 306 of the FD&C Act or is subject to any such similar sanction; and 

(k) Company will inform Vertex in writing promptly if it or any Person engaged by Company or any of its Affiliates who is performing services
under this Agreement or any ancillary agreements is debarred or is the subject of a conviction described in Section 306 of the FD&C Act, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to
Company’s knowledge, is threatened, relating to the debarment or conviction of Company, any of its Affiliates or any such Person performing services hereunder or thereunder. 

7.4. Disclaimer. 

7.4.1. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY NOR ITS AFFILIATES MAKES ANY REPRESENTATION OR EXTENDS ANY
WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. VERTEX AND COMPANY UNDERSTAND THAT EACH CAPSID AND PRODUCT IS THE SUBJECT OF ONGOING RESEARCH AND DEVELOPMENT AND THAT
NEITHER PARTY CAN ASSURE THE SAFETY, USEFULNESS OR COMMERCIAL OR TECHNICAL VIABILITY OF ANY CAPSID OR PRODUCT. 
 7.4.2. Vertex acknowledges
that the licensed technology in-licensed by company under the Lonza/MEE 3-way agreement is subject to certain disclaimers by Lonza and MEE as set forth in
Section 12.3 of the Lonza/MEE 3-Way Agreement. 

  
 45 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 8. 

INDEMNIFICATION; INSURANCE; LIMITATIONS 

8.1. Indemnification. 

8.1.1. Indemnification by Vertex. Vertex will indemnify Company, its Affiliates, and its and its Affiliates’ employees,
officers and directors (each, a “Company Indemnified Party”) from and against any liability, loss, damage or expense (including reasonable attorneys’ fees and expenses) (collectively, “Liability”) that the
Company Indemnified Party may incur or otherwise be required to pay to one or more Third Parties in connection with any Third Party suit, investigation, claim or demand to the extent attributable to, resulting from or arising out of: 

(a) any claims arising out of the Research, Development, Manufacture, Commercialization or use of any Capsid or Product by, on behalf of, or
under the authority of, Vertex (other than by any Company Indemnified Party) or any of its Affiliates or any of its or their Sublicensees, other than (i) claims by one or more Third Parties relating to Patent infringement arising out of the
practice of the Licensed Patents within the Field in accordance with the license rights as expressly granted under and in accordance with the terms and conditions of this Agreement, or (ii) claims by Third Parties relating to misappropriation
of trade secrets or other intellectual property rights arising out of the practice of the Licensed Know-How within the Field in accordance with the license rights as expressly granted under and in accordance
with the terms and conditions of this Agreement; 
 (b) the material breach by Vertex of any of its representations, warranties or
covenants set forth in this Agreement; or 
 (c) the negligence or intentional acts of Vertex or any Vertex Indemnified Party; 

and except, in each case ((a)-(c)), to the extent such claims fall within the scope of Company’s indemnification obligations under Section 8.1.2.

 8.1.2. Indemnification by Company. Company will indemnify Vertex, its Affiliates and its and its Affiliates’
employees, officers and directors, Sublicensees and Distributors (each, a “Vertex Indemnified Party”) from and against any Liability that the Vertex Indemnified Party may incur or otherwise be required to pay to one or more Third
Parties in connection with any Third Party suit, investigation, claim or demand to the extent attributable to, resulting from or arising out of: 

(a) any claim that [***]; 

(b) any claims of any nature arising out of Company’s practice of the Licensed Technology prior to the Effective Date; 

(c) the material breach by Company of any of its representations, warranties or covenants set forth in this Agreement; or 

(d) the negligence or intentional acts of Company or any Company Indemnified Party; 

  
 46 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 and except, in each case ((a)-(d)), to the extent such claims fall within the scope of Vertex’s
indemnification obligations under Section 8.1.1. 
 8.1.3. Procedure. Each Party will notify the other Party in writing
if it becomes aware of a claim for which such Party may seek indemnification hereunder. If any Procedure is instituted against a Party with respect to which indemnity may be sought pursuant to Section 8.1.1 or 8.1.2, as applicable, such Party
(the “Indemnified Party”) will give prompt written notice of the indemnity claim to the other Party (the “Indemnifying Party”) and provide the Indemnifying Party with a copy of any complaint, summons or other
written notice that the Indemnified Party receives in connection with any such claim. An Indemnified Party’s failure to deliver such written notice will relieve the Indemnifying Party of liability to the Indemnified Party under
Section 8.1.1 or 8.1.2, as applicable, only to the extent such delay is prejudicial to the Indemnifying Party’s ability to defend such claim. Provided that the Indemnifying Party is not contesting the indemnity obligation, the
Indemnified Party will permit the Indemnifying Party to control any litigation relating to such claim and the disposition of such claim by negotiated settlement or otherwise (subject to this Section 8.1) and any failure to contest such
obligation prior to assuming control will be deemed to be an admission of the obligation to indemnify. The Indemnifying Party will act reasonably and in good faith with respect to all matters relating to such claim and will not settle or otherwise
resolve such claim without the Indemnified Party’s prior written consent, which will not be unreasonably withheld, conditioned or delayed; provided that such consent will not be required with respect to any settlement involving only the
payment of monetary awards for which the Indemnifying Party will be fully-responsible. The Indemnified Party will cooperate with the Indemnifying Party in the Indemnifying Party’s defense of any claim for which indemnity is sought under this
Agreement, at the Indemnifying Party’s cost and expense. 
 8.2. Insurance. The Parties hereby acknowledge and agree that
the requirements set forth in Section 12.2 of the Lonza/MEE 3-Way Agreement with respect to insurance coverage and requirements shall apply to the Parties hereunder during the Term for so long as such
Lonza/MEE 3-Way Agreement remains in effect. Further, throughout the Term, each Party will respectively, at its cost, obtain and maintain the insurance coverage listed on Schedule 8.2 from insurance carriers
licensed to do business under the laws of the country, state, commonwealth, province or territory in which such Parry’s obligations are provided, with insurers that carry a rating of [***]. Each Party will furnish to the other Party evidence of
such insurance upon request. Notwithstanding the foregoing, Vertex may self-insure to the extent that it self-insures for its other activities. 

8.3. Limitation of Consequential Damages. Except for (a) claims of a Third Party that are subject to indemnification under
this ARTICLE 8, (b) claims arising out of a Party’s willful misconduct or (c) a Party’s breach of Section 4.7 or ARTICLE 10, neither Party nor any of its Affiliates will be liable to the other Party or its Affiliates for any
incidental, consequential, special, punitive or other indirect damages or lost or imputed profits or royalties, whether liability is asserted in contract, tort (including negligence and strict product liability), indemnity or contribution, and
irrespective of whether that Party or any representative of that Party has been advised of, or otherwise might have anticipated the possibility of, any such loss or damage. 

  
 47 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 9. 

TERM; TERMINATION 
 9.1.
Term; Expiration. Except as expressly set forth herein, this Agreement is effective as of the Effective Date and, unless earlier terminated pursuant to the other provisions of this ARTICLE 9, will expire as follows (such period, the
“Term”): 
 (a) on a country-by-country
and Product-by-Product basis, on the date of expiration of all payment obligations under this Agreement with respect to such Product in such country; and 

(b) in its entirety upon the expiration of all payment obligations under this Agreement with respect to all Products in all countries
pursuant to Section 9.1(a). 
 9.2. Termination of the Agreement. 

9.2.1. Vertex’s Termination for Convenience. Vertex may terminate this Agreement ([***]), for convenience by providing
written notice of its intent to terminate to Company, in which case, such termination will be effective [***] after Company’s receipt of such written notice; except, that if any termination under this Section 9.2.1 applies to
a Product in a country in which Vertex has received Marketing Approval, such termination will be effective [***] after Company’s receipt of such written notice. 

9.2.2. Termination for Material Breach. 

(a) Vertex’s Right to Terminate. If Vertex believes that Company is in material breach of this Agreement, Vertex may deliver
written notice of such material breach to Company. If the breach is curable, Company will have [***] following its receipt of such written notice to cure such breach. If Company fails to cure such breach within such [***] period or the breach is not
subject to cure (a “Company Breach Event”), (i) Vertex may terminate this Agreement by providing written notice to Company, in which case, this Agreement will terminate on the date on which Company receives such written notice or
(ii) Vertex may [***]; provided, however, that if (A) the relevant breach is curable, but not reasonably curable within [***], and (B) Company is making a bona fide effort to cure such breach, Vertex’s right
to terminate this Agreement or elect to exercise the alternate remedy provisions set forth in Section 9.3 on account of such breach will be suspended [***] and if such breach is successfully cured, Vertex will no longer have the right to
terminate this Agreement or elect to exercise the alternate remedy provisions set forth in Section 9.3 on account of such breach. 

(b) Company’s Right to Terminate. If Company believes that Vertex is in material breach of this Agreement (other than a breach of
the confidentiality and non-use obligations set forth in ARTICLE 10), Company may deliver written notice of such material breach to Vertex. If the breach is curable, Vertex will have [***] following its
receipt of such written notice to cure such breach (except to the extent such breach involves the failure to make a payment when due, which breach must be cured within [***] following its receipt of such written notice). If Vertex fails to cure such
breach within the [***] period, as applicable, or the breach is not subject to cure, then, other than for a material breach of the Confidentiality and non-use obligations set forth in ARTICLE 10, Company may
terminate this Agreement by providing written notice to Vertex, in which case, this Agreement will terminate on the date on which Vertex receives such written notice; provided, however, that if (i) the relevant breach
(A) does not involve Vertex’s failure to make a payment when due, and (B) is curable, but not reasonably curable within [***], and (ii) Vertex is making a bona fide effort to cure such breach, Company’s right to
terminate this Agreement on account of such breach will be suspended [***] and if such breach is successfully cured, Company will no longer have the right to terminate this Agreement on account of such breach and provided, further, that if
any such material breach of this Agreement relates to one or more, but not all, Vertex Diseases, then Company shall only have the right to terminate this Agreement in accordance with this 9.2.2(b) with respect to such Vertex Disease(s). 

  
 48 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 9.2.3. Disputes Regarding Material Breach. Notwithstanding the foregoing, if
the Breaching Party in Section 9.2.2 disputes in good faith the existence, materiality, or failure to cure of any breach, and provides written notice to the Non-Breaching Party of such dispute within the
relevant cure period, the Non-Breaching Party will not have the right to terminate this Agreement in accordance with Section 9.2.2, or the right to exercise the alternative remedy provisions of 9.3, as
applicable, unless and until the relevant dispute has been resolved. During the pendency of such dispute, all the terms of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder.

 9.2.4. Termination for Insolvency. If Company makes an assignment for the benefit of creditors, appoints or suffers
appointment of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it that is not discharged within [***] after the filing thereof (each,
an “Insolvency Event”), Vertex may terminate this Agreement in its entirety by providing written notice of its intent to terminate this Agreement to Company, in which case, this Agreement will terminate on the date on which Company
receives such written notice. In addition: 
 (a) All rights and licenses now or hereafter granted by Company to Vertex under or pursuant
to this Agreement are, for all purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined in the U.S. Bankruptcy Code. Upon the occurrence of any Insolvency Event with respect to
Company, Company agrees that Vertex, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. Company will, during the Term, create and maintain current
copies or, if not amenable to copying, detailed descriptions or other appropriate embodiments, to the extent feasible, of all intellectual property licensed under this Agreement. Each Party acknowledges and agrees that “embodiments” of
intellectual property within the meaning of Section 365(n) include laboratory notebooks, cell lines, product samples and inventory, research studies and data, all Regulatory Approvals (and all applications for Regulatory Approval) and rights of
reference therein, the Licensed Technology and all information related to the Licensed Technology. If (x) a case under the U.S. Bankruptcy Code is commenced by or against Company, (y) this Agreement is rejected as provided in the U.S.
Bankruptcy Code, and (z) Vertex elects to retain its rights hereunder as provided in Section 365(n) of the U.S. Bankruptcy Code, Company (in any capacity, including
debtor-in-possession) and its successors and assigns (including a trustee) will: 

(i) provide Vertex with all such intellectual property (including all embodiments thereof) held by Company and such successors and assigns,
or otherwise available to them, immediately upon Vertex’s written request. Whenever Company or any of its successors or assigns provides to Vertex any of the intellectual property licensed hereunder (or any embodiment thereof) pursuant to this
Section 9.2.4(a)(i), Vertex will have the right to perform Company’s obligations hereunder with respect to such intellectual property, but neither such provision nor such performance by Vertex will release Company from liability resulting
from rejection of the license or the failure to perform such obligations; and 

  
 49 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (ii) not interfere with Vertex’s rights under the Agreement, or any agreement
supplemental hereto, to such intellectual property (including such embodiments), including any right to obtain such intellectual property (or such embodiments) from another entity, to the extent provided in Section 365(n) of the U.S. Bankruptcy
Code. 
 (b) All rights, powers and remedies of Vertex provided herein are in addition to and not in substitution for any other rights,
powers and remedies now or hereafter existing at law or in equity (including the U.S. Bankruptcy Code) in the event of the commencement of a case under the U.S. Bankruptcy Code with respect to Company. The Parties intend the following rights to
extend to the maximum extent permitted by Applicable Law, and to be enforceable under U.S. Bankruptcy Code Section 365(n): 
 (i) the
right of access to any intellectual property rights (including all embodiments thereof) of Company, or any Third Party with whom Company contracts to perform an obligation of Company under this Agreement, and, in the case of any such Third Party,
which is necessary for the Manufacture, use, sale, import or export of Capsids; and 
 (ii) the right to contract directly with any Third
Party to complete the contracted work. 
 9.3. [***]. If a [***] occurs, subject to Section 9.2.3, and if Company disputes in good
faith the existence, materiality, or failure to cure of any breach and such [***] has been finally adjudicated against Company in accordance with Section 11.12, Vertex may [***] by providing written notice of such election to Company, in which
case, this Agreement will continue in full force and effect with the following modifications, each at Vertex’s election: 
 9.3.1.
Company’s [***]; and 
 9.3.2. Solely in the event that the applicable [***] is either the uncured material breach by Company of [***],
then in [***] ((a) through (c)), the [***] and the [***]; provided that, such [***] or that is [***]. 
 9.4. Consequences of
Expiration or Termination of the Agreement. 
 9.4.1. In General. If this Agreement expires or is terminated in whole
or in part with respect to one or more countries or one or more Vertex Diseases by a Party pursuant to this ARTICLE 9, the following terms will apply to this Agreement, either in its entirety or with respect to the terminated Vertex Disease or
country that is the subject of such termination, as the case may be: 
 (a) each Party will take all action required under
Section 10.3; 

  
 50 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (b) termination or expiration of this Agreement for any reason will be without prejudice to
any rights or financial compensation that will have accrued to the benefit of a Party prior to such expiration or termination. Such expiration or termination will not relieve a Party from obligations that are expressly indicated to survive the
termination or expiration of this Agreement; and 
 (c) the following provisions of this Agreement will survive the expiration or
termination of this Agreement: [***]. 
 9.4.2. Early Termination. If this Agreement is terminated in its entirety or in part
by a Party pursuant to Sections 9.2.1, 9.2.2 or 9.2.4, the following terms will apply with respect to any country or Vertex Disease that is the subject of such termination (i.e., all Vertex Diseases or all countries worldwide in the case of
termination of this Agreement in its entirety or the applicable terminated Vertex Diseases or country(ies) in the case of termination of this Agreement in part, as the case may be): 

(a) except as set forth in Section 9.4.2(d), the applicable licenses granted by Company to Vertex with respect to the relevant country
or countries or with respect to the relevant Vertex Diseases under this Agreement will terminate automatically upon the effective date of any such termination; 

(b) except as set forth in this Section 9.4, as of the effective date of any such termination, Vertex will have no further rights and
Company will have no further obligations with respect to the relevant country or countries or the relevant Vertex Diseases; 
 (c) the
Territory will be automatically amended to exclude the relevant country or countries or the Field will be automatically amended to exclude the relevant Vertex Diseases, as applicable, upon the effective date of any such termination; and 

(d) any permitted Sublicense of Vertex will, at the Sublicensee’s option, survive such termination on the condition that the relevant
Sublicensee is not in material breach of any of its obligations under such Sublicense. In order to effect this provision, at the request of the Sublicensee, Company will enter into a direct license with the Sublicensee on terms that are
substantially the same terms as the applicable terms of this Agreement; provided that Company will not be required to undertake obligations in addition to those required by this Agreement, and Company’s rights under such direct license
will be consistent with its rights under this Agreement, taking into account the scope of the license granted under such direct license. 

ARTICLE 10. 

CONFIDENTIALITY 
 10.1.
Confidentiality. During the Term and for [***] thereafter, each Party (the “Receiving Party”) receiving any Confidential Information of the other Party (the “Disclosing Party”) hereunder will:
(a) keep the Disclosing Party’s Confidential Information confidential; (b) not publish, or allow to be published, and will not otherwise disclose, or permit the disclosure of, the Disclosing Party’s Confidential Information; and
(c) not use, or permit to be used, the Disclosing Party’s Confidential Information for any purpose, except, in each case, to the extent expressly permitted under this Agreement or otherwise agreed in writing. Without limiting the
generality of the foregoing, to the extent that either Party provides the other Party any Confidential Information owned by any Third Party, the Receiving Party will handle such Confidential Information in accordance with the terms of this ARTICLE
10 applicable to a Receiving Party. 

  
 51 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 10.2. Authorized Disclosure. Notwithstanding Section 10.1, each Party may
disclose the other Party’s Confidential Information to the extent such disclosure is reasonably necessary to: 
 (a) file or prosecute
patent applications as contemplated by this Agreement; 
 (b) prosecute or defend litigation; 

(c) exercise its rights and perform its obligations hereunder; provided that such disclosure is covered by terms of confidentiality
similar to those set forth herein; 
 (d) subject to the remainder of this Section 10.2, its advisors (including financial advisors,
attorneys and accountants), actual or potential acquisition partners, financing sources or investors and underwriters on a need to know basis; provided that such disclosure is covered by terms of Confidentiality similar to those set forth
herein (which may include professional ethical obligations); or 
 (e) comply with Applicable Law. 

In addition to the foregoing, Vertex may disclose Company’s Confidential Information to Third Parties in connection with the actual or potential
Research, Development, Manufacture or Commercialization of Capsids or Products; provided that such disclosure is covered by terms of Confidentiality similar to those set forth herein. 

If a Party deems it reasonably necessary to disclose Confidential Information belonging to the other Party pursuant to Sections 10.2(b) or 10.2(e), the
Disclosing Party will, to the extent possible, give reasonable advance notice of such disclosure to the other Party and take reasonable measures to ensure confidential treatment of such information. 

Notwithstanding anything to the contrary contained herein, in no event may Company disclose Vertex’s Confidential Information to any Third Party [***]
engaged in [***]. 
 10.3. Expiration or Termination of this Agreement. Following the expiration or termination of this
Agreement, if requested by the Disclosing Party, at the Receiving Party’s election, the Receiving Party will return or destroy, all data, files, records and other materials containing or comprising the Disclosing Party’s Confidential
Information, except to the extent such Confidential Information is necessary or useful to conduct surviving obligations or exercise surviving rights. Notwithstanding the foregoing, (a) the Receiving Party will be permitted to retain one copy of
such data, files, records, and other materials for archival and legal compliance purposes and (b) the Receiving Party will not be required to delete or destroy any electronic back-up tapes or other
electronic back-up files that have been created solely by the Receiving Party’s automatic or routine archiving and back-up procedures, to the extent created and
retained in a manner consistent with its or their standard archiving and back-up procedures. 

  
 52 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 10.4. SEC Filings and Other Disclosures. Either Party may disclose the terms
of this Agreement to the extent required to comply with Applicable Law, including the rules and regulations promulgated by the United States Securities and Exchange Commission or any equivalent governmental agency in any country in the Territory;
provided, that such Party will provide the other Party a reasonable opportunity to review such disclosure and reasonably consider the other Party’s comments regarding confidential treatment sought for such disclosure. 

10.5. [***]. Notwithstanding any provision of this Agreement to the contrary, Confidential Information will [***]. Any use made by the
Receiving Party of [***]. 
 10.6. Public Announcements; Publications. 

10.6.1. Announcements. On a date to be determined by the mutual agreement of the Parties (which date shall not be earlier than
[***]), the Parties will jointly issue a press release regarding the signing of this Agreement in a form to be mutually agreed to by the Parties. Except (a) as set forth in the preceding sentence and (b) as required to comply with
Applicable Law (including the rules and regulations promulgated by the United States Securities and Exchange Commission or any equivalent governmental agency in any country in the Territory in accordance with Section 10.4), neither Party will
make any public announcement regarding this Agreement without the prior written approval of the other Party. Notwithstanding the foregoing, subject to Section 10.6.2, Vertex may make scientific publications or public announcements concerning
its Research, Development, Manufacture or Commercialization activities with respect to any Capsid or Product being Researched, Developed or Commercialized for DMD and DM1 and, following exercise of the Option with respect to Cystic Fibrosis or
[***], with respect to any Capsid or Product being Researched, Developed or Commercialized for Cystic Fibrosis or [***], as applicable, without Company’s prior written approval. 

10.6.2. Publications. 

(a) By Vertex. During the Term, Vertex and its Affiliates will submit to Company for review any proposed academic, scientific
and medical publication or academic, scientific and medical public presentation related to the use of any Capsid or Product within the Field or any activities conducted pursuant to this Agreement. Company will review such publication or presentation
for purposes of determining whether any portion of the proposed publication or presentation contains Company’s Confidential Information. Vertex and its Affiliates will submit written copies of such proposed publication or presentation to
Company no later than [***] before submission for publication or presentation (or [***] in advance in the case of an abstract). Company will provide its comments with respect to such publications and presentations within [***] after its receipt of
such written copy (or [***] in the case of an abstract). If requested by Company, Vertex and its Affiliates will (i) redact Company’s Confidential Information from any such proposed publication or presentation or (ii) delay the
proposed publication for a period of up to an additional [***] to enable Company to file a Patent with respect to the subject matter to be made public in such publication or presentation for which Company has the applicable intellectual property
rights. Vertex and its Affiliates will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication. Notwithstanding the foregoing, Vertex’s and its
Affiliates’ obligation to submit any publication to Company for review and approval under this Section 10.6.2 will not apply to any publication that does not contain Company’s Confidential Information. 

  
 53 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (b) By Company. (i) During the Research Term, Company and its
Affiliates will submit to Vertex for review any proposed academic, scientific and medical publication or academic, scientific and medical public presentation related to any Capsid that is reasonably likely to be useful in the Field, or any
activities conducted pursuant to this Agreement, provided that, if any such publication or presentation is related to any Product being Researched, Developed or Commercialized by Vertex in the Field or to the Field itself, then Company and
its Affiliates will not make such publication or presentation without Vertex’s prior written consent. Company and its Affiliates will submit written copies of all such proposed publication or presentation to Vertex no later than [***] before
submission for publication or presentation (or [***] in advance in the case of an abstract). Vertex will provide its comments (or consent (or notice of non-consent), as applicable) with respect to such
publications and presentations within [***] after its receipt of such written copy (or [***] in the case of an abstract). If requested by Vertex, Company and its Affiliates will (A) redact Vertex’s Confidential Information from any such
proposed publication or presentation, or (B) delay the proposed publication for a period of up to an additional [***] to enable Vertex to file a Patent with respect to the subject matter to be made public in such publication or presentation for
which Vertex has the applicable intellectual property rights. (ii) Following the conclusion of the Research Term, the review and comment rights set forth in the foregoing clause (i) shall continue to apply with respect to any proposed
publication or presentation by Company or its Affiliates that relates to the Research, Development or Commercialization of a Capsid within the Field for which Vertex is conducting Research, Development, Manufacturing or Commercialization activities
at the time of such proposed publication or presentation, regardless of whether such publication or presentation contains the Confidential Information of Vertex. In addition, Company and its Affiliates will not make any publication or presentation
related to any Product being Researched, Developed or Commercialized in the Field by Vertex or to the Field itself without Vertex’s prior written consent. At all times during the Term, Company and its Affiliates will comply with standard
academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication. 

10.7. Vertex Information Rights. 

10.7.1. If Vertex determines in good faith that Company is an entity that is subject to financial consolidation with Vertex for the purposes
of its quarterly and annual financial statements (or otherwise requires such information in order to comply with GAAP), Company will make available to Vertex: 

(a) as soon as practicable, but in any event within [***] after the end of each Calendar Quarter [***]; 

(b) as soon as practicable, but in any event within [***] after the end of each Calendar Year [***]; 

(c) on or prior to December 31 of each Calendar Year, Company will perform [***] as prepared by an independent valuation expert; and

  
 54 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (d) any other information or agreements requested by Vertex and reasonably necessary for
the purposes of its quarterly and annual financial statements. 
 ARTICLE 11. 

MISCELLANEOUS 
 11.1.
Assignment. This Agreement will not be assignable by any Party to any Third Party without the prior written consent of the non-assigning Party. Notwithstanding the foregoing, either Party may assign
this Agreement or its rights and obligations under this Agreement in whole, and with respect to Vertex, in part on a Vertex Disease-by-Vertex Disease basis, without any
requirement to obtain the consent of the other Party, to an Affiliate or to a Third Party that acquires all or substantially all of the business or assets of such Party to which this Agreement relates (and with respect to a partial assignment by
Vertex for a Vertex Disease, all of the business or assets of Vertex related to such Vertex Disease) (whether by merger, reorganization, acquisition, sale or otherwise), and agrees in writing to be bound by the terms of this Agreement. This
Agreement will be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry
out the intent of this Agreement. Any assignment not in accordance with this Section 11.1 will be void. 
 11.2. Change of
Control of Company; Notification. Company will notify Vertex in writing promptly (and in any event within [***]) following the extension of a definitive agreement by Company, its Affiliates or its equity holders that could reasonably be
expected to result in a Change of Control of Company. 
 11.3. Force Majeure. Each Party will be excused from the performance
of its obligations under this Agreement to the extent that such performance is prevented by Force Majeure and the nonperforming Party promptly provides written notice of the Force Majeure to the other Party. Such excuse will continue for so long as
the condition constituting a Force Majeure continues, on the condition that the nonperforming Party continues to use Commercially Reasonable Efforts to resume performance of its obligations under this Agreement. 

11.4. Representation by Legal Counsel. Each Party hereto represents that it has been represented by legal counsel in connection
with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, no presumption will exist or be implied against the Party that drafted such terms and
provisions. 

  
 55 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 11.5. Notices. All notices which are required or permitted hereunder will be
in writing and sufficient if delivered personally or sent by nationally-recognized overnight courier, or through email to the applicable email address, addressed as follows: 

If to Vertex: 
 Vertex
Pharmaceuticals Incorporated 
 Attn: Business Development 

50 Northern Avenue Boston, Massachusetts 02210 

[***] 
 with a copy to: 

Vertex Pharmaceuticals Incorporated 

Attn: Corporate Legal 
 50
Northern Avenue 
 Boston, Massachusetts 02210 

[***] and legal_notice@vrtx.com 

and 
 Ropes & Gray LLP

 Attn: Marc Rubenstein 
 800
Boylston Street 
 Boston, Massachusetts 02119 

marc.rubenstein@ropesgray.com 

and if to Company: 
 Affinia
Therapeutics Inc. 
 Attn: Robert Aboud, Chief Legal Officer 

100 Beaver Street, Suite 304 

Waltham, MA 02453 
 [***] 

or to such other address as the Party to whom written notice is to be given may have furnished to the other Party in writing in accordance
herewith. In addition, each Party will deliver a courtesy copy to the other Party’s Alliance Manager concurrently with such notice. Any such written notice will be deemed to have been given and received by the other Party: (a) when
delivered if personally delivered; or (b) on receipt if sent by overnight courier or email. 
 11.6. Amendment. No
amendment, modification or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each of Vertex and Company. 

11.7. Waiver. No provision of this Agreement will be waived by any act, omission or knowledge of a Party or its agents or
employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver by either Party of any breach of any provision hereof by the other Party will not be construed to
be a waiver of any succeeding breach of such provision or a waiver of the provision itself. 

  
 56 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 11.8. Severability. If any clause or portion thereof in this Agreement is for
any reason held to be invalid, illegal or unenforceable, the same will not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement will be construed in such fashion as to maintain its existence, validity
and enforceability to the greatest extent possible. In any such event, this Agreement will be construed as if such clause of portion thereof had never been contained in this Agreement, and there will be deemed substituted therefor such provision as
will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law. 

11.9. Descriptive Headings. The descriptive headings of this Agreement are for convenience only and will be of no force or
effect in construing or interpreting any of the provisions of this Agreement. 
 11.10. Export Control. This Agreement is made
subject to any restrictions concerning the export of products or technical information from the United States of America or other countries that may be imposed upon or related to Company or Vertex from time to time. Each Party agrees that it will
not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or
other governmental approval, without first obtaining the written consent to do so from the appropriate Governmental Authority. 

11.11. Governing Law. This Agreement, and all claims arising under or in connection therewith, will be governed by and
interpreted in accordance with the substantive laws of [***], without regard to conflict of law principles thereof. 
 11.12. Dispute
Resolution. Subject to Section 11.12.3 regarding the resolution of certain Patent-related disputes, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in
connection herewith (a “Dispute”), it will be resolved pursuant to Sections 11.12.1 and 11.12.2. 
 11.12.1.
Escalation to Executive Officers. Either Party may refer any Dispute to the Executive Officers of the Parties (or their designees having sufficient authority to resolve such Dispute), who will confer in good faith on the resolution of the
issue, by delivering written notice to the other Party. 
 11.12.2. Arbitration. If the Executive Officers are unable to agree
on the resolution of any such Dispute within [***](or such other period of time as mutually agreed by the Executive Officers) after such Dispute was first referred to them, then within [***] after the end of such [***] period or such other
mutually-agreed period of time, either Party may, by written notice to the other Party, elect to initiate an arbitration proceeding pursuant to the procedures set forth in this Section 11.12.2 for purposes of having the matter settled (the
“Arbitration Notice”) in accordance with the rules and regulations established and administered by the American Arbitration Association (“AAA”). 

 

  
 57 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (a) Binding Arbitration. Within [***] following a Party’s receipt of the
Arbitration Notice, the Parties will submit such Dispute to, and such Dispute will be finally resolved by, binding arbitration in accordance with the Commercial Arbitration Rules (the “Rules”) of the AAA by an arbitral tribunal
composed of three impartial arbitrators bound by The Code of Ethics for Arbitrators in Commercial Disputes, all of whom will have relevant experience in the pharmaceutical industry ([***]), one appointed by each of the Parties within [***] after the
Arbitration Notice, and the third who will chair the arbitral tribunal appointed by the Party-appointed arbitrators within [***] after the appointment of the second arbitrator, or, failing agreement by the Party-appointed arbitrators, by the AAA in
accordance with the Rules. If, at the time of the arbitration, the Parties agree in writing to submit the Dispute to a single arbitrator, said single arbitrator will (i) have relevant experience in the pharmaceutical industry ([***]) and
(ii) be appointed by agreement of the Parties within [***] after the Arbitration Notice, or, failing such agreement, by the AAA in accordance with the Rules. In no case shall any arbitrator have participated in a prior mediation involving
either Party unless explicitly agreed to by the Parties. Unless otherwise agreed by the Parties hereto, all such arbitration proceedings will be held in [***] All arbitration proceedings will be conducted in the English language. 

(b) Limited Discovery. Documentary discovery may be conducted at the discretion of the arbitrator(s), provided that any such
discovery will (i) be limited to documents directly relating to the Dispute, (ii) be conducted pursuant to document discovery procedures as set forth under the laws of the International Bar Association Rules of Evidence, and (iii) be
conducted subject to the schedule stipulated by the Parties, or in the absence of stipulation, the schedule ordered by the arbitrator(s). At the request of a Party, the arbitrator(s) may at their discretion order the deposition of witnesses.
Depositions shall be limited to a maximum of three depositions per Party, each of a maximum of four hours duration, unless the arbitrator(s) otherwise determine. Notwithstanding any provision of this Section 11.12.2 to the contrary, all
discovery must be completed within [***] after the appointment of the arbitrator(s). 
 (c) Awards and Fees. The
arbitrator(s) may only issue awards of direct monetary damages and will not under any circumstances have the authority or power to grant (i) equitable relief, (ii) orders for specific performance, (iii) punitive damages or
(iv) to the extent set forth in Section 8.3, consequential damages. The allocation of expenses of the arbitration, including reasonable attorney’s fees, will be determined by the arbitrator(s), or, in the absence of such
determination, each Party will pay its own expenses, including attorney’s fees. 
 (d) Rulings. All arbitration
proceedings must be completed within [***] after the Arbitration Notice. The Parties hereby agree that, subject to the provisions of this Section 11.12.2, the arbitrator(s) has authority to issue rulings and orders regarding all procedural and
evidentiary matters that the arbitrator(s) deem reasonable and necessary with or without petition therefor by the Parties as well as the final award. The final award will be issued no more than [***] after the final submissions of the Parties, or as
soon thereafter as practicable. All rulings by the arbitrator(s) will be final and binding on the Parties. The arbitrator(s) shall issue a reasoned decision that accompanies the final award. 

(e) Enforcement of Rulings by Courts of Competent Jurisdiction. Any ruling issued by the arbitrator(s) pursuant to
Section 11.12.2(d) may be enforced, to the extent that such ruling complies with the provisions of Section 11.12.2(c), in any court having jurisdiction over any of the Parties or any of their respective assets. 

  
 58 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (f) Confidentiality. All activities undertaken by the arbitrator(s) or the
Parties pursuant to this Section 11.12.2 will be conducted subject to obligations of confidentiality no less restrictive than those set forth in ARTICLE 10. Further, the Parties acknowledge and agree that their respective conduct during the
course of the arbitration, their respective statements and all information exchanged in connection with the arbitration, and the conduct of the arbitration and any information produced thereunder is Confidential Information under this Agreement and
subject to the provisions of ARTICLE 10. 
 11.12.3. Patent Disputes. Notwithstanding the foregoing in this
Section 11.12, if a dispute arises between the Parties under this Agreement with respect to the interpretation, scope, validity, enforceability, applicability or term of any Patent, then such dispute shall not be resolved pursuant to Sections
11.12.1 and 11.12.2, but instead may be brought by either Party in the federal courts of Massachusetts. 
 11.12.4. Equitable
Relief. Notwithstanding the foregoing in this Section 11.12, nothing contained in this Agreement will in any way limit or preclude a Party from, at any time, seeking or obtaining equitable relief hereunder, whether preliminary or
permanent, including a temporary or permanent restraining order, preliminary or permanent injunction, specific performance or any other form of equitable relief, from any United States court of competent jurisdiction if necessary to protect the
interests of such Party. Each Party agrees that its unauthorized release of the other Party’s Confidential Information or its breach of Section 4.7 of this Agreement will cause irreparable damage to other Party for which recovery of
damages would be inadequate, and that such other Party will be entitled to obtain timely injunctive relief with respect to such breach, without the need to show irreparable harm or the inadequacy of monetary damages as a remedy, and without the
requirement of having to post bond or other security, as well as any further relief that may be granted by a court of competent jurisdiction. 

11.13. Entire Agreement. This Agreement, together with the MTA, constitutes and contains the complete, final and exclusive
understanding and agreement of the Parties and cancels and supersedes all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof, including the CDA, which
is hereby superseded and replaced in its entirety as of the Effective Date. For the avoidance of doubt, the MTA shall survive the Effective Date of this Agreement in accordance with the terms and conditions thereof. 

11.14. Independent Contractors. Both Parties are independent contractors under this Agreement. Nothing contained herein will be
deemed to create an employment, agency, joint venture or partnership relationship between the Parties or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the
other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. 

11.15. Use of Name. Neither Company nor Vertex shall use the name of Lonza or MEE or of any trustee, director, officer, staff
member, employee, student or agent of MEE or Lonza, or any logo, trade name or trademark of MEE or Lonza or any adaptation thereof in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or
financing without the prior written approval of MEE or Lonza (as applicable). 

  
 59 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 11.16. Inerpretation. Except where the context expressly requires otherwise,
(a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b) the words “include,” “includes” and
“including” will be deemed to be followed by the phrase “without limitation,” (c) the word “will” will be construed to have the same meaning and effect as the word “shall,” (d) any definition of or reference
to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments,
supplements or modifications set forth herein), (e) any reference herein to any Person will be construed to include the Person’s successors and assigns, (f) the words “herein,” “hereof” and “hereunder,” and
words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections, Schedules or Exhibits will be construed to refer to Sections, Schedules or
Exhibits of this Agreement, and references to this Agreement include all Schedules and Exhibits hereto, (h) provisions that require that a Party, the Parties or any committee hereunder “agree,” “consent” or
“approve” or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and
instant messaging), (i) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof,
(j) any action or occurrence deemed to be effective as of a particular date will be deemed to be effective as of 11:59 PM ET on such date and (k) the term “or” will be interpreted in the inclusive sense commonly associated with
the term “and/or.” 
 11.17. Intended Third Party Beneficiaries. Except as expressly provided in this
Section 11.17, no provision of this Agreement will be deemed or construed in any way to result in the creation of any rights or obligations in any Person not a Party to this Agreement. Vertex acknowledges and agrees that for so long as any
Licensed Technology is in-licensed by Company under the MEE/Lonza 3-Way Agreement, MEE and Lonza shall each be an intended Third Party beneficiary of this Agreement for
purposes of enforcing any provision of this Agreement that may be reasonably construed in good faith as being necessary to enforce any right that is expressly granted to MEE or Lonza under the MEE/Lonza 3-Way
Agreement or any obligation of Company or any of its sublicensees to MEE or Lonza under the MEE/Lonza 3-Way Agreement. 

11.18. Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other
acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 11.19.
Counterparts. This Agreement may be executed in two counterparts, each of which will be an original and both of which will constitute together the same document. Counterparts may be signed and delivered by digital transmission
(e.g., .pdf), each of which will be binding when received by the applicable Party. 
 [Signature Page Follows] 

  
 60 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
representatives thereunto duly authorized as of the Effective Date. 
  

									
	 VERTEX PHARMACEUTICALS INCORPORATED
	 		 	 AFFINIA THERAPEUTICS INC.

					
	By:	 	/s/ [***]	 		 	By:	 	/s/ [***]
	 Name: [***]
 Title: President and
Chief Executive Officer
	 		 	 Name: [***]
 Title: Chief Executive
Officer

 [Signature Page to Strategic Collaboration and License Agreement] 

 Schedule 1.39 

[***] 

 Schedule 1.42 

[***] 
 {2 pages omitted} 

 Schedule 1.94 

[***] 
 {2 pages omitted} 

 Schedule 2.1.3 

[***] 

 Schedule 2.1.4 

[***] 

 Schedule 4.2.2 

[***] 

 Schedule 5.2.1 

[***] 
 {4 pages omitted} 

 Schedule 8.2 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]